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Abstract
Design and Synthesis of Small Molecules for Speciﬁc Targeting of Proteins
by Non-Covalent Interactions
Avid Hassanpour, Ph.D.
Concordia University, 2014
Hepatitis C virus (HCV) is a small, enveloped virus with a positive stranded
RNA genome that encodes a polyprotein of approximately 3000 amino acids. HCV
polyprotein requires two distinct proteases for viral replication, the NS2 and the NS3.
HCV NS2/3 protease is a cysteine protease that features a highly unusual active site
where NS2 forms a dimer with the active site cysteine on one monomer and histidine
and glutamate on the other. Initial in vitro studies for identiﬁcation of site-derived
cleavage products as inhibitors of NS2 protease showed that the decapeptide from the
N-terminal cleavage inhibits the cleavage between NS2 and NS3 with an IC50 of 90 μM
thus providing a useful starting point for the development of other inhibitors in the
current studies.1 Our approach involves the synthesis of truncated NS2 site-derived
peptide cleavage products in order to evaluate the importance of hydrogen bonding
interactions that are essential for host recognition and to aid in the reduction of
the size of the polypeptide chain. Therefore, a number of truncated peptides were
synthesized through solid-phase peptide synthesis. Furthermore, immunoblotting and
UPLC-MS/MS methods were used for characterization of the NS2/3 protease and
quantiﬁcation of the peptide inhibitors. Our results demonstrate that a hexapeptide
iii
has encouraging potency towards inactivation of the NS2/3 auto-cleavage process.
The second project involves synthesis of islet amyloid polypeptide (IAPP) helical
mimetics. Misfolding and aggregation of islet amyloid ﬁbrils lead to the conversion
of their secondary structure into cytotoxic β-sheet aggregates. Deposition of islet
amyloid ﬁbrils is related to the development and progression of type II diabetes, since
their aggregation causes the impairment and death of the pancreatic beta cells.2 In
order to prevent the formation of amyloid ﬁbrils, we have designed aryl-substituted
heteroaromatic core scaﬀolds to direct the secondary structure of pro-amyloidogenic
peptides into non-amyloidogenic conformers to mimic and induce/stabilize the IAPP
helical state. A range of 2,5-diarylated thiophenes were synthesized as small molecule
mimetics of the α-helix to modulate the amyloidogenesis and cytotoxic eﬀect of islet
amyloid polypeptide. 3-Substituted thiophene-2-carboxylic acids were used as key
intermediates and functionalized by palladium decarboxylative cross-coupling and
direct CH activation successively with overall yields ranging from 23 to 95%. The
eﬀect of the ligands on IAPP amyloid ﬁbril formation was evaluated with the thioﬂavin
T (ThT) ﬂuorescence-based assay. Furthermore, the capacity of these compounds to
inhibit the cytotoxic eﬀect of IAPP was assessed using β-pancreatic cells.
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Chapter 1
General Introduction
1.1 Small Molecule Inhibitors of Proteins
Many drugs act by modulating the misregulation of a receptor/enzyme either by
decreasing or increasing the activity of their target. Small molecule drugs (SMDs)
as antagonists against the aberrant function of proteins are a major subset of drug
molecules. SMDs are of great interest to the pharmaceutical industry and many
advances have been developed in drug discovery in order to design and synthesize
selective small-molecule inhibitors of a desired target with orally bioavailable properties.
For example, compounds that target speciﬁc polo-like kinase (PLK1) activity (a)4
or MDM2-p53 protein-protein interaction (b)5,6 for cancer treatment, inhibit HIV-1
enzyme (c)7–9 for the treatment of AIDS, and disrupt protein aggregation for the
treatment of Alzheimer disease (d)10 are shown in Figure 1.1.
Several guidelines exist to estimate the key parameters of developing drugs with
proper solubility, permeation and absorption. For example in the well-known Lipinski’s
rule11 a molecule with less than 5 hydrogen bond donors and 10 hydrogen bond
acceptors, Log P less than 5 and a molecular weight of less than 500 is likely to be
considered as a bioavailable drug.
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Figure 1.1: Examples of small-molecule inhibitors of enzyme activity and protein-
protein interactions
In order to inhibit the irregular functionality of their target, small-molecule in-
hibitors are further divided into reversible and irreversible inhibitors. Irreversible
inhibition usually results from covalent binding of the inhibitor to the active or al-
losteric site of the enzyme/receptor. The early examples of irreversible inhibitors
possess reactive functional groups such as α-halo ketones, diazomethyl ketones and
epoxides, which can covalently modify the target. The starting strategy in designing
these inhibitors is often to attach such "warheads" to the natural substrate-based
peptides in order to selectively deliver the electrophilic "warhead" of the inhibitor to
the target protein. A substantial number of relatively safe and successful covalently
bound inhibitors have been marketed as eﬀective medicines12–18 (Figure 1.2). Despite
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their elevated potency, usually such "warhead"s lack speciﬁcity, possibly resulting in
binding to diverse proteins and DNA which, can cause side eﬀects. For example, pep-
tidic halomethyl ketones bind to both serine and cysteine proteases through alkylating
the active site of the enzyme similar to the alkylation observed by iodoacetamide.
Therefore, the use of covalent inhibitors is usually limited to study the mechanism
of a speciﬁc target’s action or for acute diseases when a low concentration of drug can
be used for a short period of time.
O OH
O
O
Aspirin Vigabatrin
N
TazobactamAfatinib
(c) (d)
(a) (b)
S
H
O
O O
N N
N
O
OH
N
H
O
N
NO
O
HN
Cl
F
NH2
O
OH
Figure 1.2: Covalent, small-molecule irreversible inhibitors. Target enzyme: (a, Afatinib):
Epidermal growth factor receptor (EGFR) kinases and human epidermal growth factor receptor-2 (HER-2),15 (b,
Tazobactam): β-Lactamase;17 (c, Aspirin): Cyclooxygenases COX-1 and COX-212 (d, Vigabatrin): GABA transam-
inase.18 The S-enantiomer is active
Reversible inhibitors have overcome some of the issues of irreversible inhibitors.
Reversible inhibitors generally bind to the enzyme/receptor via non-covalent interac-
tions, including van der Waals forces, hydrophobic interactions and ionic and hydrogen
bonds (Figure 1.3 a and b). However, some reversible inhibitors may also operate
through a labile covalent but reversible bond with the target protein. Molecules
with an aldehyde, nitrile and α-ketoamide "warhead" are examples of this group of
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inhibitors (Figure 1.3 c and d).
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Figure 1.3: Covalent and non-covalent small-molecule reversible inhibitors. Target:
(a, Entacapone): Catechol-O-methyltransferase (COMT) in treatment of Parkinson’s disease;19,20 (b, Boceprevir):
NS3/4A serine protease in treatment of hepatitis C;21,22 (c, Boceprevir): HIV protease in treatment of HIV;23,24 (d,
Donepezil): Acetyl cholinesterase in treatment of Azheimer disease25,26
Many parameters are involved in designing a small-molecule inhibitor with drug-like
properties, so designing such a molecule demands a lot of time, eﬀort, investment
and the engagement of scientists in several areas. Small molecule inhibitors for a
given target can be designed by several approaches. One traditional method is to
screen libraries of compounds against a target to ﬁnd a relatively potent inhibitor as
a starting point, and then modify the selected compounds towards improved potency,
selectivity, and ADMET properties (absorption, distribution, metabolism, excretion
and toxicology). This method has been mostly used in pharmaceutical companies
when libraries of thousands of compounds are accessible.
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1.2 Thesis Perspective
Towards the design and synthesis of non-covalent small-molecule inhibitors, we have
investigated mechanistically and structurally diverse targets: the NS2/3 protease of
hepatitis C virus (HCV) and the α-helix of islet amyloid polypeptide.
The ﬁrst project involves the study of the NS2/3 enzyme that is one of the two
non-structural proteases of the hepatitis C virus. HCV NS2/3 protease is a cysteine
protease that features a highly unusual active site where NS2 forms a dimer with
the active site Cys on one monomer and the His and the Glu on the other. NS2/3
protease participates in the intramolecular cleavage of the enzyme such that replication
of the virus occurs. Although NS2/3 protease processes a single cleavage between
NS2 and NS3, it also has a signiﬁcant role in viral assembly and RNA replication.
This was shown by infection of chimpanzees with HCV containing a mutated NS2/3
protease.27 Synthesis of small-molecule inhibitors of NS2/3 protease activity was
initiated using the substrate-based peptide synthesis approach. However, the auto-
cleavage activity of the NS2/3 protease hinders the ability of the inhibitors to compete
with the substrate since commonly an intramolecular reaction is kinetically favored
compared to an intermolecular reaction. The focus of this project was on the assay
optimization for the NS2/3 auto-cleavage reaction by means of LC-MS and western
blot techniques. Moreover, the synthesis and evaluation of some substrate-based
peptides were investigated.
The second project involves synthesizing small molecules to target speciﬁc confor-
mational states of islet amyloid polypeptide (IAPP) through non-covalent interactions.
IAPP is an aggregation-prone peptide hormone that can undergo a secondary struc-
tural conversion into partially folded β-sheet intermediates, en route to the formation
of amyloid ﬁbrils. The misfolding and aggregation of IAPP in the pancreas lead
to degeneration of the islets of Langerhans.28 The strategy of this research was to
target and trap the pro-amyloidogenic peptides and direct their secondary structure
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into non-aggregating isomers through the development of small molecules capable
of interacting (mainly hydrogen bond and π-π stacking interactions) with one side
of the transient helical conformer of IAPP. By targeting this speciﬁc conformational
state with small molecules, the equilibrium will be shifted from the pathogenic to the
functional folded non-aggregating isoform. The other main focus of this project was
to develop an eﬃcient and modular synthetic pathway to allow for rapid synthesis of
small molecules for exploring their structure-activity relationships to optimize various
parameters including potency. Through the application of two palladium-catalyzed
cross-coupling reactions, namely palladium-catalyzed decarboxylative cross-coupling
and C–H activation reactions, this second goal was achieved. Finally, the results of
evaluated compounds in the bio-assays are presented.
1.3 Contribution of the Author and Thesis
Organization
Chapter 1 presents a general introduction related to both projects by introducing
small-molecule inhibitors of proteins and considerations in design and development of
small-molecule inhibitors.
Chapter 2 presents the introduction of the ﬁrst project about the HCV NS2/3
protease. It introduces the background in HCV genome, life cycle, translation, and
catalytic triad of the NS2/3 protease. It further introduces the two virally proteases
and advances in development of inhibitors of these two proteases.
Chapter 3 discusses the results of the HCV NS2/3 project towards assay opti-
mization, preliminary kinetic studies of NS2/3 proteases activity, site-derived peptide
synthesis, and evaluation of the peptides. The discussion of this research is included
in context.
In this project, the synthesis of all peptides, their puriﬁcation and characterization
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by mass spectrometry were performed solely by the author. Gel electrophoresis and
western blot optimization and analysis were conducted by the author solely. Mass
spectrometry experiments by Q-TOF were conducted at Concordia University by Jean-
Pierre Falgueyret at Centre for Biological Applications of Mass Spectrometry (CBAMS).
UHPLC-MS/MS experiments were conducted at Université du Québec à Montréal
(UQÀM) in collaboration with Dr. Lekha Sleno’s research group. Author participated
in trypsin digestion experiments. Sample preparations were either conducted by the
author solely or with Makan Golizeh and Dr. Lekha Sleno at UQÀM.
Chapter 4 presents the detail experimental of the NS2/3 protease project. The
methodology, material and instruments employed in the ﬁrst project is explained in
detail.
Chapter 5 introduces the background of the second project about amyloid ﬁbril
formation and protein-protein interaction. The chemistry background of the project
is followed by introducing palladium coupling, decarboxylative and C–H arylation
reactions. In this project, the synthesis of all compounds was conducted by the author
solely. The biological assays of this project such as thioﬂavine T and cytotoxicity assays
were performed at Université du Québec à Montréal (UQÀM) through collaboration
with Dr. Steve Bourgault and Carole Anne De Carufel. The X-ray crystallography
of one compound was performed under supervision of Dr. Xavier Ottenwaelder by
Dylan Mclaughlin and Mohammad Sharif Askari.
Chapter 6 presents the synthesis of 2,5-diaryl substituted thiophenes for modulation
of islet amyloid polypeptide (IAPP) amyloid ﬁbril formation and cytotoxicity. The
discussion of the research is included in the context. The work resulted in publication
of "Synthesis of 2,5-Diaryl Substituted Thiophenes as Helical Mimetics: Towards
the Modulation of Islet Amyloid Polypeptide (IAPP) Amyloid Fibril Formation and
Cytotoxicity" in Chemistry - A European Journal.29
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Chapter 2
HCV NS2/3 Protease
2.1 HCV Epidemiology
Hepatitis C virus (HCV) infection is the major cause of chronic liver disease that can
lead to hepatic ﬁbrosis, liver cirrhosis and hepatocellular carcinoma (HCC).30 Based
on the World Health Organization’s estimation, more than 170 million people (3% of
the world population) have been chronically infected by this virus worldwide and this
number is annually increasing by 3-4 million.31–34 Hepatitis C is a blood-borne disease
and is mainly transmitted through contaminated blood transfusion and drug injection
or injury with unsterilized syringes or needles.35–37 Various surveys reveal that Africa
(mainly Egypt and Cameroon) and the Middle East have the highest prevalence of
HCV infection while Western Europe, Northern Europe and North America have the
lowest (Figure 2.1).38–40
2.2 Therapy and Challenges
The prevailing therapy for chronic HCV infection is a combination of Peginterferon
alpha (PEG-IFN-α) and ribavirin;41–46 however, not only is this treatment highly
genotype-, and age-dependent,47,48 but it is also only eﬀective in 50% of the patient
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Figure 2.1: Worldwide HCV prevalence and genotype distribution. (Figure from reference40)
population. Moreover, this medication suﬀers from many side eﬀects such as exhaustion,
depression, neutropenia, hemolytic anemia, anorexia and weight loss, dermatitis,
pruritus, insomnia and ﬂue-like symptoms that cause many patients to terminate
the therapy.49–52 As a result many attempts have been devoted to developing new
therapies in recent years, and a number of compounds targeting NS3/4A protease,
NS5A protein and NS5B polymerase (RNA-dependent RNA polymerase) have reached
clinical trials.53–60 For instance Boceprevir21,22 (Victrelis®, Figure 1.3, b, Schering-
Plough) and Telaprevir56 (Incivek®, Figure 2.9, d, Vertex Pharmaceuticals) have
been approved by the FDA for the inhibition of NS3/4A protease in 2011. In 2013
Sofosbuvir61 (Gilead Sciences, Figure 2.2, a) was licensed by the FDA for inhibition
of HCV NS5B polymerase. The drug is administrated with other antiviral drugs
such as PEG-IFN-α and ribavirin. Other recently developed drugs for inhibition of
NS5A protein include Ledipasvir62 (Gilead Sciences, Figure 2.2, b) and Daclatasvir63
(Bristol-Myers Squibb). These drugs are also used with standard PEG-IFN-α and
ribavirin antiviral drugs as well as inhibitors of NS5B polymerase such as Sofosbuvir.
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This highlights that more eﬃcient approach for the battle against HCV disease relies
on a combinational therapy where a patient is subjected to more than one drug
simultaneously.
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Figure 2.2: Inhibitors of NS5B polymerase and NS5A protein for the treatment of
HCV. (a): Sofosbuvir was marketed by Gilead Sciences as inhibitor of NS5B polymerase; (a): Ledipasvir was
developed by Gilead Sciences as inhibitor of NS5A protein
HCV has 6 general genotypes with each being classiﬁed into one or several sub-
types.40,47,64–66 The genotype distribution is very geographically dependent; for instance
genotypes 1a, 1b, 2a and 2b are more prevalent in North America and Europe whereas
genotypes 4 and 5 are more frequent in Africa. Variability between the genotypes is
an issue since diﬀerent genotypes contain varying genetic sequences and one speciﬁc
inhibitor may not be eﬀective for every genotype. Most pharmaceutical eﬀorts have
been focused on the most widespread genotypes (1a, 1b, 2b) in the western countries
while other genotypes such as 4, 5, and 6 found exclusively in the third world countries
have not been explored yet.
10
2.3 HCV Genome and Life Cycle
HCV is a positive, single stranded RNA virus. HCV is a member of hepacivirus
Flaviviridae family similar to GB virus B (GBV-B) and tamarin virus.67,68 The HCV
IRES (internal ribosome entry site) at the 5’ non-translated region (5’ NTR) acts as
one of the essential elements by which polyprotein translation initiates. The 3’ non-
translated region (3’ NTR) contains essential factors for the viral genome replication69
(Figure 2.3).
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Figure 2.3: HCV genome translation and processing by host and viral proteases. (Figure
from reference70)
The polyprotein encompassing an open reading frame of approximately 3000 amino
acids (9.6-kb) is processed into structural and non-structural proteins by cellular and
viral proteins respectively.71,72 Host cell signal peptide peptidase (SPP) releases the
structural proteins (core, E1, E2, p7), whereas viral NS2/3 and NS3/4A proteases
release the non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A, NS5B) (Figure
2.3).
The HCV life cycle involves several steps depicted in Figure 2.4. After attachment
of the virus through interaction of enveloped glycoproteins, E1 and E2, to the hepatic
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cell receptors (speciﬁcally CD81,73 SR-BI,74 claudin-175 and occludin76) (Figure 2.4, a)
the virus particle enters the host cell (endocytosis).77 Due to its dependency on the pH
of the cell environment, decapsidation of the viral particle in the cytoplasm takes place
(Figure 2.4, b).78 The released positive and single-stranded RNA functions as m-RNA
and is translated to produce the HCV polyprotein that is then processed by cellular
and viral proteases to structural and non-structural proteins respectively (Figure 2.4,
c). Also the positive-strand RNA makes a negative-strand RNA that subsequently
acts as a template to produce numerous other positive RNAs for translation and
replication (Figure 2.4, d). The mechanism of virion assembly and release is not well
understood mainly because of a lack of proper experimental models. Presumably, the
structural core protein and RNA genome interaction results in the RNA delivery into
the nucleocapsid while with the other viral components the virus assembly takes place
(Figure 2.4, e).77,79–81 Finally the mature viral particles are released from the liver cell
and this cycle is repeated to generate numerous virions (Figure 2.4, f).
Figure 2.4: HCV life cycle. Life cycle process: (a): Viral particles attachment and entry; (b): Decapsidation
and RNA release; (c): RNA translation and polyprotein production; (d): Replication of HCV RNA; (e): Virus
particles maturation and assembly; (f): Virion release. (Figure from reference82)
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2.4 HCV Non-Structural Proteases
2.4.1 NS3/4A Protease
Two virally encoded proteases are responsible for processing non-structural proteins
that are necessary for virus replication. NS3 protease is a 631 amino acid polypeptide
known as a serine protease.83 NS3 protease has been widely studied compared to the
other HCV protease due to its multi functional behavior. The N-terminus one-third
of the NS3 protein together with the NS4A protein form the active chymotrypsin-
like serine protease that mediates the cleavage at the NS3/4A junction and all
three downstream sites (NS4A/NS4B, NS4B/NS5A and NS5A/NS5B). Beside other
functions in the viral life cycle of HCV, NS4A serves as a cofactor that stabilizes and
modulates the activity of NS3.84–87
The catalytic triad of NS3 protease consists of His 57, Asp 81 and Ser 139 in which
the NH’s Ser 195 and Gly 195 in the backbone of residues serve as oxyanion holes88
(numbering based on the sequence of NS3 protein alone). Mutation of any of the
residues involved in the catalytic triad blocks the cleavage of the four sites without any
eﬀect on the processing of other HCV polyprotein positions. NS3/4A protease cleaves
the junction of NS3 and NS4A through a rapid, co-translational and cis mechanism
while the other sites are processed by this enzyme in a slower (except the NS5A/5B
site) and trans manner.89–93
In addition to the proteinase domain, at the C-terminal two-thirds of NS3 protein
is located the NTPase/helicase domain. Helicases are commonly responsible for DNA
helix unwinding; however, because no DNA is involved in the HCV formation process,
the exact role of NS3 helicase has remained controversial. Through hydrolysis of
natural nucleoside triphosphates (NTPs) the required energy is provided for the
helicases to presumably open the duplex HCV RNA.94–97 NS3 helicase is essential in
HCV replication, probably by contribution to the viral assembly process, since its
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mutation stopped the viral replication in chimpanzee models.98
2.4.2 NS2/3 Protease
The NS2 protein is a 23-kDa hydrophobic transmembrane protein (amino acids 810
to 1026) which is a primary viral-translated protein of HCV.99,100 The host enzyme
cleaves the junction between p7 and NS2 which liberates the N-terminus of NS2. The
NS2 protein is not capable of any enzymatic activity without the NS3 protein. In fact,
the C-terminus of the NS2 protein along with one-third of the NS3 protein constitute
the active NS2/3 protease (amino acids 810 to 1206).1,82,100–102 Although the catalytic
active site of NS2/3 protease is located in the NS2 region, a minimum of 180 amino
acids placed in the N-terminus of NS3 is required for the NS2/3 protease activity
(residues 1026 to 1206). The NS3 protein has no role in the catalytic activity of NS2/3
protease, but instead plays an important role in the proper folding of the enzyme which
is essential for the eﬃcacy of NS2/3 processing.83,100,102–104 The very hydrophobic
N-terminus region of the NS2 protein is not essential for the proteinase activity of
this enzyme, and mutation studies demonstrated that this region can be truncated for
better expression and puriﬁcation of the protein. Therefore the minimum sequence
necessary for the activity of the enzyme spans amino acids 907 to 1206 (Figure 2.5).105
In the earlier studies of NS2/3 protease, it was presumed that this enzyme is a
zinc-dependent metalloprotease mainly because of its inhibition by zinc chelators such
as EDTA.103,104,106 However, later investigations demonstrated that this is due to a
zinc-binding residue in the NS3 region that is essential for stabilizing the conformation
and proper folding of the NS3 protein. Consequently, since proper folding of NS3 is
essential for NS2/3 protease activity, zinc is also essential for proper NS2/3 protease
function.88,107–111 A zinc cation coordinates directly to three cysteine residues (1123,
1125, 1171) and, through a molecule of water, to a histidine residue (1175) of the NS3
protein (Figure 2.5).93,112 The critical role of the cysteine residues was demonstrated
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by removing any of the three binding cysteine residues in the NS3 region that abolished
the activity of NS2 and NS3 proteases.93 Consequently, zinc is also essential for binding
to the cysteine residues. Some studies demonstrated that removing zinc from the
protein and replacing other divalent coordinating metals such as cobalt or cadmium
retains the activity of the protein (Figure 2.5).93,112,113
Although the direct role of NS2/3 protease in viral replication has not been deter-
mined, it has been demonstrated that this protein has several eﬀects on the HCV life
cycle. For example, an in vivo study of the HCV genome lacking the NS2 protein abol-
ishes virus replication in chimpanzee models.98 Similar to all non-structural proteins,
the NS2 protein is involved in the assembly and release of viral particles although it is
proposed that its enzymatic activity is not essential for this purpose.114 This could be
a consequence of several interactions between the NS2 protein and other structural
and non-structural proteins and subsequently the roles that each of these proteins
complexes have in the HCV life cycle (NS2:p7-E1-E2 complex,115,116 NS2:NS3,117
NS2:NS4A118). For instance, the liberated N-terminus of the NS3 protein has a direct
eﬀect on HCV replication through production of the replicase; therefore, inhibition of
the junction cleavage between NS2 and NS3 abolishes virus replication.114
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Figure 2.5: Required domain for catalytic activity of NS2/3 protease. Minimum sequence
for NS2/3 processing begins from the C-terminus of NS2 (aa 907) to the N-terminus of the NS3 (aa 1206); H952, E972
and C993 form the NS2/3 protease catalytic triad; Three cysteine residues (C1123, C1125, C1171) and one histidine
residue (H1175) form the NS3 structural zinc binding sites. (Figure from reference83)
Based on the numbering of the full length of the HCV polyprotein, a combination
of the three residues Cys 993, His 952 and Glu 972 creates the catalytic triad of NS2/3
protease, which is discussed in the next section.
2.4.3 Catalytic Triad of NS2/3 Protease
NS2/3 protease has been proposed as a cysteine protease. The function of NS2/3
protease was not completely clear prior to solving its crystal structure.111 In several
studies processing of NS2/3 cleavage was suggested to be through a unimolecular cis
mechanism which is mediated by a second HCV-encoded protease as a viral enzyme
or an unknown host.100 In 2006 the crystal structure of the catalytic domain of the
NS2 protein exposed a highly unusual active site where the three amino acid residues
participating in the activity of this enzyme are not located on a single monomer of
NS2. Rather, NS2 forms a dimer (Figure 2.6, a) with the active site Cys 184 on one
monomer and His 143 and Glu 163 on the other (residue numbering starts from the
C-terminus of the NS2 protein as opposed to the previous section that was based on
the whole polyprotein) (Figure 2.6, b). Interaction of the N-terminus of one monomer
with the C-terminus of the other monomer and vice versa constitutes the dimeric
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active site. The auto-cleavage takes place when these two monomers are at the proper
distance and geometry. This leads to the cleavage of the amide bond in one monomer
by the active cysteine which is located in the same monomer.
Mutation studies on the NS2/3 protein indicate that substitution of residues His
143, Glu 163 and Cys 184 with alanine eliminates the cleavage at the NS2/3 cleavage
site. Other mutations do not have any eﬀect on the enzymatic reaction of NS2/3
protease.100,105,111 In addition to the catalytic triad residues, several other signiﬁcant
amino acids in the NS2 protein aﬀect the assembly and release of the infectious virus
and as a result the overall replication of the virus.114 For example, it has been identiﬁed
that solvent-exposed Ser 168 is necessary for virus production as its mutation to Gly
or Ala abolishes or reduces the production of infectious virus.119 The other notable
residue located in the C-terminus of the NS2 protease is Leu 217 which aﬀects the
virus production through coordination to the side chains of His 143, Cys 184 and
the nitrogen of Cys 184. Both Ser 168 and Leu 217 are solvent-exposed residues
and it is presumed that their mutation could disrupt protein-protein interaction(s)
essential in the viral particles maturation when they are in the process of assembly.119
Furthermore, the dimer is stabilized by Pro 164 in the cis conformation which bends
the backbone of Glu 163 in the catalytic domain of the protein in order to form
the required geometry of that domain. Recognition of such residues helps in the
fundamental understanding of this signiﬁcant protein as well as in designing potential
inhibitors.
As opposed to previous studies, it was determined that since the protease consists
of two monomer units, the NS2/3 cleavage is sensitive to the concentration of the
respective monomers.111 Discovering that dimerization is needed for the NS2/3 cleavage
provides an explanation for the fact that having a certain concentration of NS2 is
necessary for this cleavage. A low concentration of NS2, which would delay the
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Figure 2.6: Catalytic domain of NS2 protease active site. (a): Dimer of the NS2
protease; (b): Catalytic triad of NS2 protease. (Figure from reference111)
dimerization of NS2, may postpone the N-terminal liberation of NS3, which is required
for viral replication.70,120
2.4.4 Mechanism of NS2/3 Proteolysis
The proposed mechanism of the hydrolysis of the viral polyprotein catalyzed by
cysteine protease is shown in Figure 2.7. Initially, polarization of the thiol group in
Cys 184 by His 143, which itself is activated by Glu 163, takes place (1). Accordingly,
the nucleophilic thiolate attacks the carbonyl group of the amide and forms the ﬁrst
tetrahedral intermediate (2). It is postulated that the backbone nitrogen of Cys 184
interacts with the backbone carboxylic acid of Leu 217, which may act as an oxyanion
hole to facilitate the hydrolysis.111 Proton transfer from the acidic imidazolium ion to
the NH of the leaving group forms the corresponding acyl enzyme.
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Figure 2.7: Mechanism of proteolysis of NS2/3 protease
After production of the acyl enzyme a water molecule that is polarized by His 143
through a hydrogen bond attacks the carbonyl group (3) and generates the second
tetrahedral intermediate (4). This intermediate collapses and results in the formation
of free acid as the N-terminal cleavage product and the catalytic triad in its initial
state (5).121,122
2.5 Assay Developments and Characterization of NS2/3
Protease
The auto-cleavage character of NS2/3 protease raises several challenges for scientists in
order to characterize the functionality of this protease and further detect and examine
the inhibitors of this protease. Moreover, the highly hydrophobic N-terminus and
membrane bound nature of the NS2 protein make the expression and puriﬁcation of
the protein challenging and results in the requirement of very speciﬁc assay conditions.
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Some of the early studies of NS2/3 protease were focused on the optimization
of assay conditions in order to increase the eﬃciency of the auto-cleavage reaction.
It has been illustrated that microsomal membrane components are essential in the
activity of NS2/3 protease by providing a hydrophobic ambiance in order to aid proper
folding of the protein.105,123 In the in vitro studies, various detergents were examined
to be substituted by the microsomal membranes by providing artiﬁcial hydrophobic
environment. It was discovered that some detergents such as Triton X-100, Nikkol,
Tween 20, CHAPS and n-dodecyl-β-D-maltoside are able to promote the auto-cleavage
activity of the NS2/3 protease although with lower proﬁciency.1,123
Adding up to 50% glycerol has also been shown to assist the detergent in initiating
the cleavage, presumably by inducing proper folding of the protein.1 Moreover, the
eﬀect of temperature was examined in separate studies and temperatures between 20 -
23 ℃ were found to be optimal, whereas temperatures below 20 ℃ or higher than 30
℃ were detrimental to the process of auto-cleavage.1,123
As explained above, the very speciﬁc assay conditions require high glycerol and
detergent concentrations and these additives hinder the utilization of several analysis
techniques such as mass spectrometry, circular dichroism (CD), UV spectroscopy,
NMR spectroscopy that are available for the characterization of many other proteins.
Nevertheless, through assay optimizations as well as protein mutations and/or modiﬁ-
cations, techniques are available for studying this protein. For example, by removing
the hydrophobic sequence of NS2 at the N-terminus and introducing a solubilizing
agent (ASKKKK) at the C-terminus, ﬂuorescent and mass spectrometry characteriza-
tion of NS2/3 protease has been accomplished.102,124 However, the drawback is the
high dependency of each technique on the protein’s construct and buﬀer conditions.
Further characterization of NS2/3 protease has been done through both in silico
and in vitro experiments. For instance, a recent computational modeling study com-
bined with further in vitro studies explored the essential residues for NS2 dimerization
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through alanine mutation of residues present at the dimer interface.125 By ranking all
calculations of three diﬀerent in silico approaches (DCOMPLEX, EMPIRE, FastCon-
tact) to obtain ΔΔG values, a few residues were revealed to be potentially crucial
for dimer formation of the NS2 protein. (Figure 2.8 demonstrates one example from
FastContact v2.0).
Based on the obtained results ﬁve alanine mutated NS2 constructs (V162A, M170A,
I175A, D186A, I201A, where numbering is based on the NS2 protease crystal structure,
2HD0)111 were subjected to western blot. The results indicate that mutation of these
residues decreases the formation of NS2 dimer (Figure 2.8). Quantiﬁcation of the
western blot reveals that the NS2 monomer to dimer ratio increases for M170A, I175A,
I201A, D186A and V162A to 4.0, 3.2, 3.0, 2.8 and 1.5, respectively, when compared
to the wild type (wt) NS2 protein. Also, the evaluated eﬀect of mutants in the HCV
life cycle using site-directed mutant HCV constructs (pJFH1-Rluc2A) illustrates that
two mutated residues with a high monomer to dimer ratio (M170A, I201A) decrease
the HCV genome replication 100 fold as opposed to I175A and D186A which only
reduces the RNA replication 10 fold.125 Although the mechanism by which NS2 dimer
production, and accordingly HCV genome replication, is decreased through these
mutants is not completely clear, NS2/3 cleavage deﬁciency could be responsible for
hampering RNA replication.
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(a) 
(b) 
Figure 2.8: Evaluation of residues at the NS2 dimer interface. (a) ΔΔG evaluation
of residues at the NS2 dimer interface;125 (b) Reduction in the formation of NS2
dimer by alanine mutation125 (a) The calculation was performed using FastContact v2.0 where ΔΔG =
ΔΔGwt−ΔΔGMut; The protein is labeled with Myc-tag. Monomer to dimer ratio increase for M170A, I175A, I201A,
D186A, V162A: 4.0, 3.2, 3.0, 2.8, 3.0, 1.5 respectively compared to the wildtype(wt)
2.6 General Approaches and Considerations of Syn-
thesizing HCV Protease Inhibitors
Diﬀerent stages of the HCV life cycle are potential targets for the development of
drugs against this infectious virus. For example, the early stage of HCV entry into the
cell is directed by host cell factors such as CD81, SR-B1, claudin 1 and occludin, and
these have been targeted and several inhibitors have been developed. Two examples
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are ITX-506, which inhibits the interaction of HCV E2 glycoprotein and SR-B1,126
and, for previously untreated patients, Alisporivir (Debio-025) used in combination
with PEG-IFN-α-2a, which inhibits cyclophilin.127,128
In addition, many attempts have been made to develop drugs which directly target
protease activity. The goal of designing direct-acting antivirals (DAAs) is to achieve
sustained virological response (SVR) in patients, where infectious HCV RNA is not
observed.54,129 Because of their exclusive function and well characterized role in viral
replication, some of the HCV non-structural proteins provide leads to potential drug
targets. Also, the compelling need for the development of alternatives for pegylated
interferon alpha and ribavirin for the treatment of HCV infections resulted in the
evolution of HCV non-structural protein inhibitors such as NS3/4A protease, NS5A
phosphoprotein130,131 and NS5B polymerase inhibitors.
Various strategies have been employed for the development of protease inhibitors.
Commonly, inhibitor discovery starts with the identiﬁcation of a hit compound. This
can be found by screening natural products or peptide analogs of the natural substrate
to identify compounds that could have some, often non-optimal, potency towards
inactivation of the target. Later, various structural modiﬁcations are applied in order
to improve the ADMET properties as well as to increase the selectivity and potency of
the compounds towards a given target. Structural modiﬁcation of the lead compounds
is less complicated by acquiring information of the protease’s active site. A number of
techniques are available to help a medicinal chemist better understand the mechanism
of the enzyme activity in order to discover an inhibitor, including NMR studies,
X-ray crystallography and molecular modeling. These techniques not only aid in
understanding the overall enzymatic activity itself, but also they provide insight to
the enzyme-inhibitor interactions.108,109,132–134
One of the most essential modiﬁcations involves altering any peptidic nature of
the lead molecules to peptidomimetics or non-peptidic small molecules. This is due
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to the poor drug-like properties of most peptides. Modiﬁcations are applied to the
molecules by replacing/altering some groups in the structure of the lead molecule to
generate new compounds with, hopefully, greater potency, often by taking advantage
of hydrogen bonding or hydrophobic interactions. Another practical modiﬁcation
is the introduction of bioisosteres, which refers to replacing groups with the ones
having similar physical properties, such as size, shape, or polarity in order to improve
ADMET properties of the molecule.135,136
Despite all these eﬀorts to improve the properties of the lead compounds very
few of the new analogs reach clinical application. This is due to the numerous and
sometimes complex parameters that need to be taken into consideration for an inhibitor
to be used as a drug. Interaction of structural properties (reactivity, hydrogen bonds,
pKa, molecular weight, lipophilicity,..) with the protein and environment cause the
biochemical and physicochemical properties, respectively.137 Biochemical properties
include metabolism, binding, target aﬃnity, etc. whereas physicochemical properties
incorporate solubility, chemical stability and permeability. Interaction of both these
properties with the living system determines the pharmacokinetics (PK; bioavailability,
half-life, clearance,..) and toxicity (LD50).137
2.6.1 Advances in Development of NS3/4A Protease Inhibitors
The NS3 protease has been extensively studied in terms of both structure and activity,
and to date several drug candidates that target NS3 protease have reached clinical
trials.138–140 Since NS3/4A protease mediates three cleavages in the HCV polyprotein,
many eﬀorts have focused on designing inhibitors which interfere with the interaction of
NS3 and NS4A.141,142 The ﬁrst generation of NS3/4A inhibitors were substrate-derived
peptides constructed from the N-terminal cleavage products of NS4A/4B, NS4B/5A
and NS5A/5B (Table 2.1).143–147 Some of the natural N-terminus hexapeptide product
of the cleaved sites acted as non-covalent competitive inhibitors since they interacted
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with the same active site as the substrate and thereby decreased the ability of the
substrate to bind with the active site.
Compounda Peptideb IC50 (μM)c
Ki (μM)d
NS4A/4B site-derived peptidese, 145 (IRBM)
1 Ac-DEMEEC-OH 1c
2 Ac-EMEEC-OH 21c
3 Ac-MEEC-OH 150c
4 Ac-DEME-Cha-C-OH 0.35c
5 Ac-DELI-Cha-C-OHf 0.015c
NS4B/5A site-derived peptidese, 146 (IRBM)
6 DCSTPC-OH 180d
7 SGSWLADVWDKK-NH2 >300d
NS5A/5B site-derived peptidese, 143 (BI)
8 DDIVPC-OH 71c
9 Ac-DDIVPC-OH 28c
10 Ac-DDIVPC-OHf 4c
Table 2.1: Substrate based peptide inhibiotors of NS3 protease. aAbbreviations: IRBM:
Instituto di Ricerche di Biologia Moleculare; BI: Boehringer Ingelheim; bAbbreviations: Ac: Acetyl; Cha: β-cyclohexyl-
L-alanine. c,dDeﬁnition: IC50: Concentration of inhibitor required to reduce the target’s activity by 50%; Ki:Binding
aﬃnities of the enzyme-inhibitor; Unlike IC50, Ki is independent of substrate concentration. eNatural N-terminus
cleavage products of NS4A/4B, NS4B-5A, NS5A-5B: DEMEEC, DCSTPC, DDIVPC respectively; f Italic letters
indicate D-amino acids.
Because of their poor pharmacokinetic proﬁle, peptides are not desirable as drugs.
As a result, structural modiﬁcations were made to transform the peptides to pep-
tidomimetics or small, non-peptidic molecules to improve their ADMET properties
and possibly increase the potency and selectivity of the inhibitors towards the target
at the same time. This approach demands structure-activity relationship (SAR) and
structure-property relationship (SPR) studies that evaluate the eﬀects of structure
alterations on the compound’s activity and properties, respectively.
Macrocyclic compounds and α-ketoamides, as linear inhibitors, are two types of
compounds that have been developed as NS3/4A inhibitors. Ciluprevir27,148(BILN
2061, Figure 2.9, a), one of the early examples of NS3/4A protease inhibitors, is a
substrate-based macrocyclic compound that interacts in a non-covalent and reversible
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manner with the substrate.27 Structural modiﬁcations of hexapeptide 8 in Table 2.1
led to the development of this compound.
Since BILN 2061 showed signs of potential cardiotoxicity, additional modiﬁca-
tions were made to its structure to generate improved inhibitors. Examples include
improved macrocyclic inhibitors such as Danoprevir149 (ITMN-191, Figure 2.9, b)
and Vaniprevir150 (MK-7009, Figure 2.9, c) or linear α-ketoamides like Telaprevir56
(VX-950, Figure 2.9, d) and Boceprevir21,22 (SCH-503034, Figure 1.3, b). The last
two compounds are now in the marketplace for the treatment of genotype 1 HCV
infections, still in combination with pegylated interferon-α and ribavirin.151
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Figure 2.9: Examples of small-molecule inhibitors of NS3/4A protease
26
Despite all these therapeutic advances, the development of drug-resistant variants
of the virus to one or more of the existing drugs is another major issue of concern.
Thus, a more eﬀective approach for the battle against HCV will rely on combination
therapy, where patients are subjected to more than one drug simultaneously.
2.6.2 Advances in Development of NS2/3 Protease Inhibitors
To date no small-molecule inhibitors of NS2/3 protease have been reported despite
the fact that it has been conﬁrmed to be essential for viral replication.100,152 In the
often used sequence nomenclature153 ..-P3-P2-P1-P1’-P2’-P3’-.., the bond between P1
and P1’ is deﬁned as the cleavage site between amino acid 1026 and 1027 by cysteine
protease. Initial studies on the function of NS2/3 protease and the inhibitory activity
of peptides on NS2/3 cleavage indicate that the enzyme has a potential to react easily
with speciﬁc peptides.1,152 These peptides encompass the central sequence of NS4A
that is responsible for binding to NS3.93,154 Cleavage of NS2/3 is inﬂuenced by the
NS4A co-factor. This eﬀect is related to the interaction of 12 amino acids of NS4A
with the N-terminus of NS3.88,155,156 As a result, the protein is appropriately folded
and stabilized. Since NS3 is binding to NS2, logically NS4A has the same eﬀect on
NS2 as well.31 The results by Darke et al. in Table 2.2 show that this 12 amino acids
peptide of the NS4A site demonstrates inhibitory activity on NS2/3 protease.152 A
random combination of these 12 amino acids or peptides with less than 12 amino
acid did not illustrate any eﬀect on the processing of NS2/3 (compounds 13 and 14
respectively).
At the time, this inhibition of NS2/3 by NS4A conﬁrmed the hypothesis of the temporal
order of NS protein cleavages in which NS2/3 cleavage takes place before processing
of NS3 to release of NS4A; otherwise, no NS2/3 cleavage occurs.152
In addition to NS4A peptides, the inhibitory ability of site-derived NS2/3 peptides
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Compound Peptidea IC50 (μM) or
% inhibition∗
NS4A site-derived peptidesb
11 KGSVVIVGRIILSGRK 5.7
12 Ac-RGGSVVIVGRIILSGRK 3.4
13 VRLGSISVIGIVRGKK -17∗
14 Ac-RIILSGRK -21∗
15 Ac-KGSVVIV-NH2 8∗
Table 2.2: Inhibition of NS2/3 protease by NS4A site-derived peptides
aAbbreviation: Ac: Acetyl. bNatural 12 amino acids of NS4A inﬂuencing NS3 binding: VVIVGRIILSGR; Compound
11 includes residues 21-34 of NS4A in addition to two lysine residues to increase the solubility; In case of % inhibition
all peptides were used in a ﬁnal concentration of 50 μM .
were examined and several NS2/3 cleavage site derived peptides demonstrated no
eﬀect on the NS2/3 processing (Table 2.3).102,152 The peptides spanned the sequence
of P to P’ (compounds 16-20) and P or P’ only (compounds 21-23). Since the results
were accomplished prior to the determination of the crystal structure of NS2 protease,
common opinion hypothesized an intra-molecular cleavage of the NS2/3 protease since
the competing substrates did not have any eﬀect upon the reaction rate.102,152
Compound Peptidea [C]b(mM) % inhibition
16 DSFGEQGWRRLL∗APITAYSQQTR 0.1 <5
17 EQGWRRLL∗APITAYS 0.1 <5
18 GWRRLL∗APITA 0.1 <5
19 EQGWRLL∗APITAYS 0.62 15
20 GWRLL∗APITA 0.92 20
21 EQGWRLL 1.1 14
22 APITAYS 1.3 -9
23 GRGLRLL 1.2 2
Table 2.3: Inhibition of NS2/3 protease by NS2/3 site-derived peptides (series 1)
aAbbreviation: Peptide sequences are the natural sequence of NS2/3 around the cleavage site; Asterisks indicate the
cleavage site. bAbbreviation: [C] is the ﬁnal concentration of the peptide in the reaction assay.
Despite these results, other in vitro studies for the identiﬁcation of site-derived
cleavage products as inhibitors of NS2/3 protease show that a decapeptide from the
N-terminal cleavage with the sequence of SFEGQGWRLL inhibits the auto-cleavage
reaction of NS2/3 with an IC50 value of 90 μM (Table 2.4).1
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Compound Peptidea IC50 (μM)
24 SFEGQGWRLL∗APITAYSQQT 270
25 KGWRLL∗APITAY 630
26 SFEGQGWRLL 90
27 APITAYSQQT > 1000
28 APITAY > 1000
Table 2.4: Inhibition of NS2/3 protease by NS2/3 site-derived peptides (series 2)
aAbbreviation: Peptide sequences are the natural sequence of NS2/3 around the cleavage site; Asterisks indicate the
cleavage site.
Peptide 26 has been characterized as the most potent NS2/3 substrate-based
inhibitor. These results raised another hypothesis that even though the mechanism of
NS2/3 protease cleavage is known to be an intramolecular reaction, there is potential
for developing inhibitors based on the NS2/3 substrate. Although the mechanism
of NS2/3 enzyme inhibition by these inhibitors has not been studied, it is believed
that they are reversible competitive inhibitors. The rationale is that these types
of inhibitors resemble the substrate in terms of shape and chemical structure, and
therefore compete with the substrate to interact with the same active site. Reversible
competitive inhibitors mimic the features of the substrate; however, the interaction is
not strong enough to sustain the inhibitor in the active site permanently.
2.7 Aims
The overall goals of this research are:
1- Characterization and assay optimization of NS2/3 protease cleavage through
mass spectrometry and western blot techniques and subsequently optimization of these
assays.
2- Synthesis of the natural substrate of NS2/3 protease encompassing the N-terminal
cleavage product of the enzyme.
3- Synthesis, puriﬁcation, and characterization, including evaluation of binding
eﬃciencies, of analogs of the natural substrate to carry out rational studies for the
identiﬁcation of important hydrogen bonds in the binding interaction between the
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inhibitor and the protease.
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Chapter 3
HCV NS2/3 Protease: Results and
Discussion
3.1 NS2/3 Protease Characterization Through Mass
Spectrometry
Mass spectrometry is one of the most well-known and remarkable tools for the
identiﬁcation and quantiﬁcation of proteins. Mass spectrometric analysis is applied for
both qualitative and quantitative purposes. Through this approach the detection and
relative or absolute quantiﬁcation of modiﬁed proteins, such as processed proteins and
posttranslationally modiﬁed proteins, without employing an antibody are possible.157
The accuracy and sensitivity of mass spectrometry techniques explain their high
acceptance compared to many immunological techniques.157
In spite of the broad advantages and apparent simplicity of mass spectrometry
techniques, few studies have been devoted to their implementation for the identiﬁcation
and quantiﬁcation of HCV NS2/3 protease. In one study by Orsatti et al., a quantitative
analysis of the NS2/3 protease through electrospray ionization (ESI) was accomplished,
and the obtained mass of 32869 daltons was in good agreement with the theoretical
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mass of 32871 daltons for the NS2/3 protein.124 Also, the fragmentation pattern of
the ionized peptides illustrated that during regular solubilization of the protein in a
buﬀer containing β-mercaptoethanol, molecular mass of the protein increased by a
molecule of β-mercaptoethanol.124 This residue modiﬁcation was shown to be due to
the reaction of ﬁve out of nine cysteine residues in the NS2/3 protein sequence with
β-mercaptoethanol.
In this research, the NS2/3 protease (904-1206) was obtained from Boehringer
Ingelheim as a puriﬁed protein (the protein sequence diﬀered from the one employed
by Orsatti et al). Therefore, initially it was necessary to characterize and determine
the functionality and enzymatic activity of the protease. The characterization and
eﬃciency evaluation of the puriﬁed NS2/3 protease were performed by means of liquid
chromatography (LC) coupled with an electrospray ionization quadrupole time-of-ﬂight
(Q-TOF) mass spectrometer. This method was applied as a facile and accurate tool
for two purposes: 1) To observe the presence of the correct molecular mass of NS2/3
as the intact protein prior to activation of the protease, 2) To detect the enzymatic
functionality of the protease for a speciﬁc incubation time after which the observation
of the molecular masses corresponding to the cleaved products as well as that of the
intact protein was expected. A detergent (n-dodecyl-β-D-maltoside) was added to
each sample to obtain the enzymatic functionality of the enzyme since some detergents
initiate the enzyme activity through providing a proper folding environment for the
enzyme. To achieve the ﬁrst objective, a 0.54 μM solution of NS2/3 protein in the
cleavage buﬀer (containing 0.5% n-dodecyl-β-D-maltoside as detergent), quenched
with formic acid, was directly injected into the LC-MS. However, in the chromatogram,
no peak representing the intact protein was observed, only a peak corresponding to
the detergent was identiﬁed. Considering that the presence of detergent and salt are
not compatible with mass spectrometric analysis because of the production of intense
ions, it was proposed that the protein’s peak was suppressed by the detergent’s peak.
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To examine this hypothesis, the standard acetone precipitation protocol was applied
in order to remove these interfering components. In this method, only the protein
was precipitated from the solution, leaving the interfering compounds in acetone to
facilitate their removal (Chapter 4). Two iterations of this procedure were generally
suﬃcient for complete removal of the unwanted substances. This acetone precipitation
protocol was applied to a protein sample that had not been initiated for enzymatic
activity (sample had been quenched with formic acid immediately after the addition
of detergent) to generate a "zero time" sample.
Following the protein precipitation and removal of the acetone, samples were
dissolved in 5% acetonitrile/0.1% TFA injected onto a reversed-phase C4 column and
eluted into a Q-TOF Ultima API mass spectrometer. From the sequence provided
by Boehringer Ingelheim, the NS2/3 parent protein has a theoretical mass of 35979
daltons. Analysis of the NS2/3 protease sample by LC-MS provided a peak with a
mass spectrum showing a deconvoluted mass of 36043 daltons. The additional 64
daltons in the experimental mass is due to acetonitrile and sodium adducts (Figure
3.1). The mass spectrum also showed a mass of 36118 daltons which did not match
with the mass of any normally expected fragments. This mass would correspond to a
modiﬁed form of the protein. It would therefore be instructive to further investigate
the components of this peak by separation and collection of these two peaks by HPLC
and performing a tryptic digestion on both proteins. This would provide the peptide
fragments of the unknown protein (36118 daltons) to be compared to the peptide
fragments of the main protein (36043 daltons). The diﬀerences in the amino acid
sequences would provide information of any possible protein modiﬁcation.
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Figure 3.1: Deconvoluted mass of NS2/3 protease at zero time
In pursuit of the second objective of characterization of the enzyme’s functionality,
the NS2/3 protein was incubated for 4 hours in the presence of detergent, followed
by the acetone precipitation protocol. Analysis of this sample by mass spectrometry
provided a mass spectrum showing two masses of 15241 and 20810 daltons. The
masses were compared with the theoretical masses of 15229 and 20767 daltons for
NS2 and NS3 protein fragments respectively (Figure 3.2).
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Figure 3.2: Deconvoluted masses of NS2 and NS3 cleaved products of NS2/3 protease
after 4 hours
Overall, acetone precipitation was implemented as a sample preparation method
to remove the interfering matrix material mainly because it was observed that the
presence of detergent is detrimental to the characterization of the protein by mass
spectrometry. The correct molecular masses of NS2/3 protease and the NS2 and
NS3 fragments were obtained, thus validating that the protein was legitimate and
functional to use. Some diﬀerences between the theoretical and experimental masses
can refer to the instrument’s calibration, however, the protein’s sequence was validated
through a second methodology employing trypsin digestion and LC-MS as will be
explained in the next sections.
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3.2 NS2/3 Protease Characterization Through Trypsin
Digestion and LC-MS
Although acetone precipitation followed by mass spectrometry provided a means to
carry out the initial characterization of the NS2/3 protein, the possibility of protein
denaturation, resulting, in most instances, in diﬃculties with resolubilization of the
protein, is a major drawback of this technique. Moreover, the quantiﬁcation of the
protein is not accurate without standards for measuring the response factor of the
instrument.
To circumvent these issues, protein digestion, which is a key step in sample
preparation prior to analysis by mass spectrometry, was employed. Trypsin protease
is known for speciﬁcally cleaving peptide bonds that are followed by arginine or lysine
residues in the C-terminus of a given polyprotein, except when either of these amino
acids are followed by proline.158
Tryptic digestion followed by mass spectrometry has been used in the charac-
terization and identiﬁcation of the NS2/3 enzyme with cysteines modiﬁed by β-
mercaptoethanol, mentioned above (Section 3.1), in two studies by one group.102,124
However, this technique has been applied in the study of HCV NS3 enzyme several
times.159,160
Protein digestion by trypsin produces diﬀerent size peptide fragments that are
beneﬁcial for the analysis of proteins.158 Since peptides are smaller than proteins their
quantiﬁcation provides higher sensitivity, as well as improved separation through liquid
chromatography. In addition, since small peptides can be synthesized or purchased
conveniently, they can be used as standards in those experiments that demand protein
quantiﬁcation. Due to these advantages, we have incorporated this method prior to
mass spectrometry for quantiﬁcation of enzymatic activity of NS2/3 protease.
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3.2.1 Assay Optimization
External Calibration Curve Development
To generate an accurate and quantitative analysis when employing any analytical
technique such as HPLC or mass spectrometry, it is essential to calibrate the response
of the instrument to the compounds of interest using calibration standards. An
external calibration curve is one of the most widely used calibrations, because of its
simplicity and applicability to various methods. Therefore, in order to develop a
quantitative method for the preliminary kinetics studies of NS2/3 protease, an external
calibration curve was established based on the protease’s cleavage products.
NS2/3 protease cleaves the junction between amino acids 1026 -1027 (Figure 3.3,
a) and produces two cleaved peptide fragments: NS2 and NS3. In the NS2/3 protease
cleavage studies, after a certain incubation time the reaction process was stopped by
treating the samples with formic acid to produce a mixture of NS2 and NS3, with a
substantial amount of intact NS2/3 protein remaining as well (Figure 3.3, b).
Treatment of this protein cocktail (b and c) with trypsin produces several other
peptide fragments from digestion of the NS2, NS3 and NS2/3 polyproteins. In the
NS2/3 parent protein, trypsin cleaves the peptide bonds right after arginine residues
at two diﬀerent sites (Figure 3.3, b) and produces a 13 amino acid peptide referred to
as LLAPI (Figure 3.3, d). Thus, this peptide is the tryptic digestion fragment from
unprocessed parent NS2/3 protease. Trypsin also cleaves the amide bond immediately
after the arginine residue in the NS3 protein produced from cleavage of the NS2/3
enzyme to give an 11 amino acid peptide referred to as API (Figure 3.3, e). These two
tryptic digestion peptides represent the cleaved (NS2, NS3) and un-cleaved proteins
(NS2/3 protease). It is noteworthy to mention that the NS2 protein also gives rise to a
trypsin digest product that has not been demonstrated in Figure 3.3, since monitoring
the API peptide resulted from the NS3 product was suﬃcient. Furthermore, the
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tryptic digestion fragment resulted from the NS2 protein did not interfere with the
product from the NS3 protein.
In order to quantify the enzymatic reaction of the NS2/3 protease, these two
trypsin-digested peptide fragments were monitored at two diﬀerent times: when
the enzyme had not undergone any self-processing (zero time) and after a certain
incubation time, when the enzyme had undergone some self-processing.
	


 
	 	 
 !"#$
%& 	


'(&	%#	!% )	
&
! #	 
	





''(&	%#	!% 
)	
&)
	&#)	
&
 


Figure 3.3: Schematic representation of NS2/3 protease cleavage and tryptic digestion
products
To establish an accurate quantiﬁcation method and to consider the respective
response factors of the two tryptic digestion peptides, an external calibration curve was
developed using synthetic standard samples of API and LLAPI (the 11 and 13 amino
acid tryptic digest peptides, respectively). Hence, a series of API and LLAPI peptide
mixtures with various concentrations were prepared. In these mixtures the quantity
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of LLAPI peptide (represents the un-cleaved peptide or substrate) was kept constant
(1 mg) and the quantity of API peptide (representing the cleaved peptide or product)
varied (Table 3.1). External standards were prepared in the same buﬀer solution
that was used for the NS2/3 protease cleavage. Standard samples were subjected
to reversed-phase ultra high performance liquid chromatography coupled to mass
spectrometry (UHPLC-MS/MS) with a hybrid quadrupole-time-of-ﬂight (Q-TOF) MS
instrument.
API/LLAPI a API/LLAPI API/LLAPI % Cleavage SDb
(mg/mg) (area) (mmol/mmol)
1 0.56 0.85 45.8 2.7× 10−02
0.5 0.3 0.42 29.7 2.3× 10−02
0.2 0.13 0.17 14.5 8.9× 10−03
0.1 0.06 0.08 7.8 3.5× 10−03
0.05 0.03 0.04 4.1 1.9× 10−03
0.02 0.01 0.02 1.7 2.0× 10−03
Table 3.1: External calibration for quantiﬁcation of NS2/3 protease. aAPI/LLAPI: 11-
mer peptide over 13-mer peptide (representative of cleaved over un-cleaved peptide), bSD: Standard deviation of
API/LLAPI (area). (Number of replicates: 3)
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Figure 3.4: External calibration curve using API and LLAPI synthetic peptides.
(Number of replicates: 3)
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From the analysis of each of the API-LLAPI peptide standard mixtures by UHPLC-
MS/MS, a corresponding area ratio of the peaks resulting from each component was
obtained using total ion current (TIC) as the detector response. Since the molar
ratios of the API-LLAPI peptides are known in these standard samples, a calibration
curve could be generated. Figure 3.4 illustrates variations of the area ratio versus
molar ratio of API over LLAPI peptide which resulted in a linear calibration curve for
employment in the NS2/3 protease assay system. The molar ratio of API to LLAPI
can also be related to the percent cleavages of the NS2/3 protease by re-expressing
the quantities as API
(API+LLAPI)
, representing the amount of cleaved (NS3) peptide over
the initial amount of NS2/3 protease.
This calibration curve will permit samples from the NS2/3 protease assays to be
easily quantiﬁed following trypsin digestion.
Solid Phase Extraction Optimization
Several parameters can have a direct eﬀect on LC-MS analysis, of which matrix
composition and analyte concentration are noteworthy. Solid-phase extraction (SPE)
has been an extensively employed approach for sample preparation. With SPE,
the analyte of interest is retained on a solid phase while undesired components are
washed away with an appropriate mobile phase. The analyte is then released from
the solid phase by changing the mobile phase. In this way, components that suppress
electrospray ionization of the target sample or damage/shorten the column and MS
system lifetime can be removed. Moreover, enrichment of analyte concentration
is another advantage of utilizing this method.161,162 The application of SPE in the
characterization and quantiﬁcation of the NS2/3 protease experiments, immediately
after trypsin digestion and prior to mass spectrometry analysis, would be advantageous
in several ways. These advantages included the removal of detergent and glycerol as
well as concentration of the protein sample for better overall sensitivity of the protocol.
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Moreover, via this technique the sample buﬀer could be easily exchanged to solvents
with better compatibility with the LC-MS.
Depending on the analyte of interest and the composition of impurities, various
stationary phases will perform diﬀerently for analyte retention and impurity sepa-
ration.163 Therefore, method optimization studies were started by examining two
diﬀerent types of SPE cartridges: Oasis® HLB, a hydrophilic-lipophilic reversed-phase
cartridge, and Strata™-X, a polymer-based cation exchange cartridge.
The HLB cartridge retains polar analytes and the cation exchange polymer-based
cartridge was expected to retain the target peptides due to the presence of a positively
charged arginine residues in the peptide sequence.
The percent recovery of the representative trypsin-digested cleaved (API) and
uncleaved (LLAPI) peptides was calculated using the synthetic standard peptides as
controls. A solution containing a 1:1 ratio of the standard peptides (API and LLAPI)
was prepared in the buﬀer used for the NS2/3 experiments and samples were applied
on both cartridges. After removing the interfering compounds, such as detergent and
salts, by washing the cartridge with water and methanol, the retained analytes were
recovered from the column, employing single or mixed solvents (Chapter 4). The
recovered peptides were subjected to LC-MS analysis and the percent recovery of each
peptide fragment was measured. The results are shown in Figure 3.5.
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Figure 3.5: Solid-phase extraction of control synthetic peptides. API and LLAPI peptides
were subjected on two diﬀerent columns. Y-axis shows the percentage recovery of each peptide; X-axis represents
the column and solvent conditions; HLB: Hydrophilic-Lipophilic-Balanced reversed-phase sorbent; ACN: Acetonitrile,
IPA: isopropyl alcohol. (Number of replicates: 3)
Methanol, acetonitrile (ACN) and mixtures of isopropyl alcohol (IPA)/ACN were
examined as the eluting solvents for peptide recovery. MS directed quantiﬁcation
of these recoveries demonstrated that a combination of ACN: IPA (60:40) provided
an equal recovery of both peptides from either the Oasis® HLB or the Strata™-X
cartridges, with slightly higher overall recovery from the Oasis® HLB cartridge.
Although with this mixture of solvents elution of the peptides from the cartridge
was incomplete (about half of each analyte was retained in the cartridge), this loss
was inconsequential since the equivalent degree of recovery of each peptide would be
suﬃcient for accurate quantiﬁcation of the API/LLAPI ratio.
From these studies, a sample preparation method was established, based on solid-
phase extraction, to remove the analytical sample incompatible mass spectrometry
42
interferences such as glycerol, detergent and salt present in the NS2/3 protease matrix
buﬀer. After removing the impurities, a 60:40 ACN:IPA solvent mixture was found to
elute the peptides to an equal degree from an Oasis® HLB column.
3.2.2 Time Course Studies of Auto-Cleavage of the NS2/3
Protease
Obtaining kinetic information of a protease reaction is of great interest in order to
understand the mechanism of the enzyme reaction, to generate eﬃcient enzymatic
assays and further to develop inhibitors for such an enzyme.
The productivity and rate of an enzymatic reaction are highly aﬀected by the
protein’s construct as well as the type and concentration of detergent in the case of
membrane-bound, hydrophobic proteins. The NS2/3 protease is even more inﬂuenced
by these parameters because of its intra-molecular, auto-cleavage process. Several
groups have shown the time course study of the auto-cleavage reaction to estimate
the overall rate of reaction.1,102,123,152 Darke et al.152 demonstrated that a 3 hour
incubation of NS2/3 (810-1615, from HCV BK strain) resulted in 60% processing of
the enzyme. Therefore the observed rate constant of the ﬁrst order reaction (kobs)
was estimated as 0.04 min−1. This result was comparable to the reaction rate of the
identical protein construct measured by Pieroni et al.123 under optimized conditions
(detergent and temperature) which revealed 75% cleavage of the enzyme after a 4
hour incubation time. Two later studies showed the time course assay of this protease
with diﬀerent protein constructs. Pallaoro et al.102 obtained a rate constant of kobs=
0.05 min−1 for the truncated NS2/3 protease (907-1206-ASK4) while Thibeault et
al.1 obtained a maximum of 50% cleavage after a 5 hour incubation time for the
truncated NS2/3 protease (904-1206). The latter’s enzyme construct, genotype and
assay conditions are very similar to the ones of the present work. To ensure the
functionality of the NS2/3 protease and further to compare the preliminary kinetics of
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this protease with the available data in the literature, a time course study was carried
out.
The experiment was followed at diﬀerent time intervals with a 0.54 μM ﬁnal
concentration of protein, since this concentration was utilized previously by Thibeault
et al.1 To initiate the reaction, n-dodecyl-β-D-maltoside (DM) was added to each
sample as detergent. Samples were incubated at 23 °C and the enzymatic reaction was
monitored up to four hours. After each time course interval, reactions were quenched
with formic acid and treated with trypsin following the trypsin digestion procedure
(Chapter 4). Subsequently, samples were extracted through solid-phase extraction and
then subjected to UHPLC-MS/MS.
Peptides were identiﬁed based on the MS/MS data using ProteinPilot™ software,
and quantiﬁed through peak integration using MultiQuant™ software (Chapter 4).
Figure 3.6 shows six analyzed chromatograms obtained from UHPLC-MS/MS analysis
where each plot presents the amounts of cleaved (API or product) and un-cleaved
(LLAPI or substrate) peptides versus time. In Figure 3.6 chromatogram 1 shows the
analysis of the control reaction at zero incubation time, in which no cleavage happened.
During the ﬁrst hour of incubation, samples were collected at 30 minute intervals.
Analysis of these samples showed the formation of 4 and 7% cleaved products after
30 and 60 minutes, respectively (chromatograms 2 and 3). After the ﬁrst hour, data
were collected at one hour time intervals until a total of 4 hours had elapsed. The
amount of cleaved product slowly increased during this time, reaching 19% after 4
hours (chromatogram 6).
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Figure 3.6: UHPLC-MS/MS proﬁle of NS2/3 protease time course experiment. Y-axis
shows the total ion current of cleaved or un-cleaved peptides. (Number of replicates: 3)
The external calibration curve (Figure 3.4) was used to convert the peak areas of
the cleaved and un-cleaved peptides in each chromatogram to the molar ratios (Table
3.2). From these molar ratios, the percent cleavage of the enzyme as a function of
time could be calculated (Figure 3.7).
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Incubation time API/LLAPI a API/LLAPI % Cleavage SDb
(min) (area) (molarity)
0 2.0× 10−03 2.9× 10−03 0.3 0.1
15 1.0× 10−02 1.5× 10−02 1.5 0.2
30 2.5× 10−02 3.7× 10−02 3.5 0.5
60 5.1× 10−02 7.5× 10−02 7.0 0.2
90 7.8× 10−02 1.1× 10−01 10.3 1.0
120 9.8× 10−02 1.4× 10−01 12.6 1.0
180 1.4× 10−01 2.1× 10−01 17.6 0.6
240 1.6× 10−01 2.4× 10−01 19.1 0.2
Table 3.2: NS2/3 time course cleavage data. aAPI/LLAPI: Cleaved product over un-cleaved substrate;
bSD: Standard deviation of API/LLAPI (area). (Number of replicates: 3)
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Figure 3.7: NS2/3 time course cleavage by UHPLC-MS/MS. (Number of replicates: 3)
Since the enzymatic reaction of the NS2/3 protease is considered a pseudo-ﬁrst
order reaction, the percentage of substrate remaining over time follows an exponential
rate law described by the following equation,
S
S + P
= e−kobst, (3.1)
46
where S represents the amount of substrate or un-cleaved NS2/3, P is the amount of
cleaved product, kobs is the observed rate constant, and t corresponds to the elapsed
time. The observed rate constant (kobs) based on the 3 replicates of the experiments
was calculated as 1.0× 10−05 s−1 (Figure 3.8). For a similar construct under similar
assay conditions for the NS2/3 protease, Thibeault et al.1 obtained 50% cleavage
after 5 hours enzyme activity using the western blot technique for quantiﬁcation,
corresponding to a kobs of 3.8 × 10−05 s−1. Although the quantiﬁcation techniques
were diﬀerent, this data demonstrates that a slower reaction process was observed in
the case of our protein. Nonetheless, our data obtained from the mass spectrometry
experiments is close to the value from the literature. Overall, these experiments were
important as controls for establishing the baseline activity for auto-cleavage of our
NS2/3 protease construct under our assay conditions in order to eventually measure
the eﬀects of the developed inhibitors.

	











       





	

Figure 3.8: Determination of rate constant of NS2/3 processing from UHPLC-MS/MS
time course data. (Number of replicates: 3)
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In summary, trypsin digestion followed by tandem mass spectrometry was carried
out to obtain an accurate and robust assay for quantiﬁcation of the NS2/3 protease.
This involved characterization of the cleavage reaction over time in order to achieve
initial kinetic information of the protease reaction. Since this method was applied for
quantiﬁcation purpose, sample preparation and calibration curve development were
performed prior to subjecting protein samples to mass spectrometric analysis. For
this reason, samples were treated with trypsin (Chapter 4) followed by their solid-
phase extraction to remove salt and detergent and then subjected onto reversed-phase
UPLC-MS/MS using a hybrid quadrupole-time-of-ﬂight (Q-TOF) MS equipment.
3.2.3 NS2/3 Protease Sequence Alignment
In order to validate the obtained masses of the intact and cleaved NS2/3 protease from
the acetone precipitation followed by mass spectrometry, the referenced theoretical
masses of NS2/3 protease from the literature (provided by Boehringer Ingelheim in
a patent)3 was compared to the peptide fragment sequences obtained from trypsin
digestion and HPLC-MS/MS. The alignment of the two sequences is shown in Figure
3.9 where the highlighted regions identify the peptide sequences from the trypsin
digestion and HPLC-MS/MS that are identical to the sequence according to the
Boehringer Ingelheim patent. The sequence alignment provided a very good sequence
coverage (97% coverage based on the Blast® software) proving that the masses
obtained from the mass spectrometry after acetone precipitation reﬂect the actual
masses of this protease and its cleavage products.
48
MKKKKLEHHHHHHTSAGITKVPYFVRAQGLIRACMLVRKAAGGHYVQMAFMK 
LAALTGTYVYDHLTPLQDWAHAGLRDLAVAVEPVIFSDMEVKIITWGADTAAC 
GDIISGLPVSARRGREILLGPADNFEGQGWRLLAPITAYSQQTRGLLGCIITSLTGR 
DKNQVEGEVQVVSTATQSFLATCVNGVCWTVFHGAGSKTLAGPKGPITQMYTN 
VDQDLVGWQAPPGARSMTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRP 
VSYLKGSSGGPLLCPSGHAVGIFRAAVCTRGVAKAVDFIPVESMETTMRTSSAW 
RHPQFGGKKKK 
Figure 3.9: Sequence alignment of the peptide fragments from trypsin digestion and
UHPLC-MS/MS compared to the literature3
3.2.4 NS2/3 Protease Inhibition by Classical Inhibitors
To better understand the binding sites of proteases, several types of classical protease-
inhibitors have been evaluated. Some classical cysteine, cysteine/serine and metallo-
protease inhibitors are able to inhibit NS2/3 protease processing in vitro as shown
in Table 3.3.1 These results provide important insights into the mechanism of this
enzyme.
For instance, NS2/3 protease inhibition by cysteine/serine protease inhibitors such
as tosyl lysine chloromethyl ketone (TLCK) and tosyl phenylalanyl chloromethyl
ketone (TPCK) conﬁrm the presence of an active site histidine, while the inhibition by
alkylating agents such as iodoacetamide speciﬁes an active site cysteine. The inability
of 1,7-phenanthroline to cause inhibition, taken together with the inhibitory activity
of 1,10-phenanthroline, indicate that the enzyme is inhibited through a chelation
mechanism by this metalloprotease inhibitor (Table 3.3).1
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Compound Inhibitor Inhibition of NS2/3
∗Target Protease Concentration
∗Cysteine protease
N-Ethylmaleimide 0.1 mM 100% inhibition
Iodoacetamide 1 mM 100% inhibition
E64 0.2 mg/mL No inhibition
∗Serine protease
Aprotinin 1 mg/mL No inhibition
Pefabloc 1 mg/mL No inhibition
∗Cysteine/Serine protease
TLCK 0.5 mM 100% inhibition
TPCK 0.5 mM 100% inhibition
Leupeptin 0.1 mg/mL No inhibition
∗Metalloprotease
EDTA 2 mM 100% inhibition
1,10-Phenanthroline 1 mM 80% inhibition
1,7-Phenanthroline 1 mM No inhibition
∗Aspartic acid protease
Pepstatin 0.01 mg/mL No inhibition
Table 3.3: Eﬀect of classical protease inhibitors on NS2/3 protease inhibition.
Table information was adopted from Thibeault et al ;1 0.8 μM of the NS2/3 protease was used in the assays; TLCK:
Tosyl Lysine Chloromethyl Ketone; TPCK: Tosyl Phenylalanyl Chloromethyl Ketone
In addition to the analysis of the enzyme’s activity, we have examined one classi-
cal NS2/3 enzyme inhibitor in order to evaluate the optimized sample preparation
protocol and mass spectrometry assay prior to measuring the biological activity of the
substrate-based inhibitors. Iodoacetamide was selected for evaluation since it is known
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as potent inhibitor of cysteine proteases.1 A dose-response curve was obtained using
eight diﬀerent concentrations of iodoacetamide (Figure 3.10) employing an NS2/3
protease concentration of 0.54 μM and an incubation time of 1 hour.
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Figure 3.10: Dose-response curve of NS2/3 inhibition by iodoacetamide
The percent cleavage of the NS2/3 was quantiﬁed by mass spectrometry, as
previously described at each concentration of inhibitor. Control samples without
inhibitors were quantiﬁed by the same method. Subsequently, the percent inhibition
was obtained based on the following equation,
%Cctl −%Csubt
%Cctl
× 100, (3.2)
where %Cctl is the percent cleavage of the NS2/3 observed in the control samples
without inhibitor and %Csubt is the percent cleavage of the NS2/3 at a particular
concentration of inhibitor. The percent inhibition was plotted as a function of the
inhibitor concentration, generating the typical sigmoidal dose-response curve shown
in Figure 3.10. The result is comparable with the literature values of the percent
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inhibition reported in Table 3.3 for iodoacetamide (95% vs. 100% inhibition at 1 mM
inhibitor concentration respectively).1
Overall, the purpose of accomplishing this experiment was to attain a dose-response
inhibition curve as a proof of concept through our optimized mass spectrometry method,
in which the enzymatic activity of the protease can be followed.
3.3 NS2/3 Protease Characterization Through Im-
munoblotting
Although trypsin digestion followed by mass spectrometry usually provides a very
eﬃcient and accurate analysis of proteins, it was essential to analyze and detect the
protein by a second method to cross-validate the two approaches. Moreover, having
a second technique available provides options, and one of the two techniques may
prove to be better suited for the evaluation of substrate-based inhibitors. Towards
this aim, western blotting (immunoblotting) as a major and practical technique for
the identiﬁcation and quantiﬁcation of the desired protein from a complex mixture
was selected. Most of the NS2/3 protease quantiﬁcation and mechanistic studies
have utilized western blot strategies. Particularly, in the early characterization,
mutation and cleavage studies of this protein several groups took advantage of this
technique.99,100,103,123,164 Because of the complexity of the NS2/3 protease auto-cleavage
mechanism, in which the substrate is part of the enzyme, the application of several
protein identiﬁcation/characterization strategies is challenging. In the western blotting
technique proteins separated by gel electrophoresis are transfered from the sodium
dodecyl sulfate polyacrylamide gel (SDS-PAGE) to the binding supports such as
nitrocellulose or polyvinylidene ﬂuoride (PVDF) membranes. This technique is
particularly practical for the NS2/3 protease, since the antibody for the detection of
the NS2 or NS3 cleaved fragments can be applied. Hence, the individual protein is
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initially detected by this antibody (primary antibody), and thereupon a secondary
antibody detects the primary antibody for further visualization of the protein.
3.3.1 Determination of the Optimal NS2/3 Protease
Concentration
One parameter to be optimized in the NS2/3 cleavage western blot assay was the
acceptable concentration range of protein, in which both the substrate and the product
could be quantiﬁed in a reliable manner. One general rule for obtaining such a reliable
quantiﬁcation method is to avoid the production of over-saturated immunoreactive
bands. This is particularly essential in inhibition assays since saturated bands can
introduce errors to the quantiﬁcation assays and therefore alter the inhibitor’s eﬃciency
results by orders of magnitude. Producing quantiﬁable NS2/3 protein signals is even
more challenging since the substrate is part of the enzyme. This means that starting
with a high concentration of the enzyme can result in saturated substrate bands but
un-saturated, quantiﬁable product bands at certain incubation times. On the other
hand, starting with a low enzyme concentration can produce un-saturated, quantiﬁable
bands of the substrate but weak signals of the product that can not be quantiﬁed.
Both cases are not reliable for quantiﬁcation purposes.
Despite such a wide application of western blotting on the study of NS2/3 protease
activity, few have considered the eﬀect of the protein concentration on their quantiﬁca-
tion techniques and often the assays were carried out within a speciﬁc range of protease
concentrations without specifying the reason of selecting such a concentration.1,102,152
To determine the suitable concentration for the NS2/3 protease western blotting
assays, four protein concentrations, each diﬀering two folds from each other were used.
Previously, for quantiﬁcation of NS2/3 protease inhibitors by western blot, 0.54 and
0.8 μM of ﬁnal protein (904-1206) concentrations were employed in the literature.1
Therefore a concentration range of 0.1 to 1 μM of the protein was employed in this
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work. Samples with these concentrations were subjected to gel electrophoresis and
western blot assays after one and four hours incubation time and the results were
compared to those of the control zero-time incubation sample in each set of reaction.
The blots were visualized on the ﬁlm and quantiﬁed by ImageJ software (Chapter 4).
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Figure 3.11: Evaluation of the eﬀect of enzyme concentration on immunoblotting
assays
In the gels shown in Figure 3.11 the top band is the NS2/3 parent protein (un-
processed or substrate) and the bottom band is the NS2 cleaved product. Quan-
tiﬁcation of 0.1 and 0.2 μM protein concentration samples and plotting the percent
cleavage product over time demonstrated linearity over the time periods used in
these experiments. Increasing the protein concentration to 0.5 and 1.0 μM resulted
in saturation of both the substrate and cleaved product bands. Over-saturation is
more evident from the formation of white spots on the NS2 cleaved product bands.
Although some of these NS2/3 concentrations have been used in literature in the
western blot experiments for quantiﬁcation purposes, the saturation of bands that we
observed at these concentrations could hamper their reliable quantiﬁcation.
After repeating the experiments, some inconsistent results were observed at a
concentration of 0.1 μM NS2/3 protein. Presuming that a concentration of 0.1 μM was
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near the detection limit for quantiﬁcation, 0.2 μM was selected as the concentration
to use with the western blot quantiﬁcation experiments.
3.3.2 Determination of the Optimal NS2/3 Protease
Incubation Time
Evaluation of the enzymatic time course reaction is one of the essential factors in
the optimization of any technique being employed. As demonstrated in the mass
spectrometry approach, NS2/3 protease cleaves itself over time and this cleavage is
initiated by using detergents in vitro.
With the goal of using this assay to aid in designing reversible substrate-based
inhibitors, the objective was to perform the NS2/3 cleavage assay during the time period
when the enzyme kinetics are linear. As in the case with the enzyme concentration,
measuring an inhibitor’s binding eﬃciency out of the linear range can change the
eﬃciency results by orders of magnitude mainly through underestimating the inhibitor’s
activity. This is simply demonstrated in Figure 3.12 where, in the early stage of the
enzyme reaction, the percent cleavage increases linearly over time. In this stage (linear
phase) the forward enzyme-catalyzed reaction convert the substrate to the product.165
Later, as the substrate becomes depleted, the plot of product formation versus time
reaches the plateau phase. Evaluation of the eﬃciency of reversible inhibitors should
be performed in the linear range of protein incubation time. This is because in
the plateau phase the enzyme-inhibitor equilibrium has been reached and therefore
alteration of inhibitors concentrations does not reﬂect their potency.
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Figure 3.12: Schematic representation of product formation over time. Example curve;
percent cleavages and incubation time parameters are not related to any speciﬁc enzyme reaction
Therefore, a time course reaction using a concentration of 0.2 μM of the NS2/3
protein, selected based on the experiments described in the previous section, was
performed. Following incubation times of 15, 30, 60 and 180 minutes, it was observed
that the percent cleavage increased over time (Figure 3.13).
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Figure 3.13: Evaluation of the eﬀect of enzyme incubation time on immunoblotting
assays (Number of replicates: 2)
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The amount of protein in each band was quantiﬁed by comparing to those of the
control zero incubation time and the plot of percent cleavage versus time was obtained
(Figure 3.14). This plot showed that the percent cleavage as a function of time was
linear up to an incubation time of approximately 30 minutes. Since it is important
to stay in this linear phase when using immunoblotting assay to evaluate inhibitors,
an incubation time of 15 minutes, well within this linear phase, was selected as the
protein incubation time.
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Figure 3.14: Plot of cleavage product versus time obtained from time course experiment
immunoblot (Number of replicates: 2)
In addition to determining the linear phase of the cleavage process, some preliminary
information about the enzyme kinetics was obtained from this time course study. Based
on equation 3.1, by plotting the natural logarithm of ratio
(
S
S+P
)
as a function of
time (Figure 3.15), the observed rate constant (kobs) of the pseudo-ﬁrst order NS2/3
cleavage reaction can be extracted from the slope. The experimentally determined
value of kobs of 3.0×10−05 s−1 by western blot assay is comparable with the kobs of
1.0× 10−05 s−1 from our study by mass spectrometry, which demonstrated a 3-fold
diﬀerence. Yet, our data demonstrates a close value of NS2/3 protease rate of reaction
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when compared to the study by Thibeault et al.1 for similar NS2/3 protease construct
and assay condition (3.8× 10−05 s−1).
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Figure 3.15: Plot of natural logarithm of the ratio
(
S
S+P
)
as a function of incubation
time. (Number of replicates: 2)
Overall, a time course study of NS2/3 protease through a western blot assay was
performed in order to determine the linear phase time parameters. Based on two
replicates of the experiments, this linear phase was observed over the ﬁrst 30 minutes
of the enzyme reaction.
3.4 Rational Design of NS2/3 Substrate-Based In-
hibitors
Employing substrate-based inhibitors has been a useful approach towards the devel-
opment of potent inhibitors of various enzymes. Initial studies on the function of
NS2/3 protease demonstrated that a decapeptide from the N-teminus of the substrate
(SFEGQGWRLL, P10-P1) inhibited the enzyme with an IC50 of 90 μM.1 Therefore
this decapeptide provided a starting point for the development of NS2/3 protease
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inhibitors.
Although the natural substrate-based decamer provided some inhibition of the
NS2/3 protease, large peptide inhibitors generally do not have drug-like properties.
Some of the obstacles of large molecules are their poor solubility, metabolism by
proteases, low absorption through membranes and as a result low entry into the circu-
latory system.137 Although large molecules can be administrated through intravenous
injection to overcome some of these deﬁciencies, this is not an ideal route of adminis-
tration for patients compared to oral administration. Determination of the minimum
peptidic sequence that is recognized by the enzyme aids in development of small
molecule inhibitors of this enzyme. Since each residue in the peptide backbone acts as
a potential recognition element for the enzyme; (Figure 3.16) therefore, removing or
substituting each amino acid sequentially provides a means to probe the importance
of various interactions of the peptide backbone and side chains with the enzyme.
P2
CONH COOH
P1
S2
S1
S1'
N-Terminus CONH
Figure 3.16: Substrate nomenclature and inhibitor binding to the active site. The blue
sequence of amino acids represents the designed inhibitor; The cleavage site of protein is between S1 and S1’
As part of the process of designing and synthesizing small molecule inhibitors of
the HCV NS2/3 protease, the potency of each peptide was determined after systematic
removal of each residue (truncation studies) from the N-terminus of the decapeptide.
The backbone and side chains of the amino acids starting from the P1 position of each
peptide (C-terminus) potentially provide more eﬀective interactions with the NS2/3
cysteine protease compared to those that are farther from this position. Therefore,
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each amino acid removal was started from the N-terminus of the peptide to gradually
probe the importance of each amino acid interaction with the enzyme. Further, the
substrate-based decapeptide could be used as a comparative reference for the in vitro
evaluation of the new peptides as NS2/3 protease inhibitors.
3.4.1 Peptide Synthesis
A general synthetic protocol for the preparation of the P10-P1 sequence of the
natural NS2/3 substrate and N-terminus truncated peptides (P9-P1, P8-P1, etc.)
was developed. Peptides were manually synthesized on the Wang resin166 based on
standard Fmoc solid-phase peptide chemistry167,168 (Chapter 4). Solid-phase peptide
synthesis has several advantages over traditional solution-phase peptide synthesis.
Among these are the convenient removal of unreacted reagents in each step, allowing
for the use of excess amounts of reagents in order to drive each step towards completion,
and simpliﬁed isolation/puriﬁcation of the intermediates in each step as a consequence
of their attachment to the resin.168
Fmoc-protected amino acids were attached to the Wang resin (Scheme 3.1) as the
solid support through their carboxyl groups. Reactive groups in the side chains of the
amino acid residues were protected with protecting groups that are stable under basic
conditions. However, the α-amino group was masked with a temporary protecting
group (Fmoc) that was removed under basic condition and before the introduction of
subsequent amino acids (Scheme 3.2). The next Fmoc protected amino acids were
attached to the free amine using coupling reagents such as HBTU and DIC and bases
such as DIPEA and DMAP (Scheme 3.1). Treating the peptides with a mixture of
TFA/H2O/TIS released the peptides from the resin. In addition, all the side-chain
protecting groups were removed under these conditions (Scheme 3.2).
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Scheme 3.1: Chemical structures of resin, coupling reagents and bases employed in
the solid-phase peptide synthesis
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Scheme 3.2: Solid-phase peptide synthesis on the Wang resin employing the Fmoc-
protected amino acids
Based on this procedure, a range of peptides, listed in Table 3.4 were synthesized
and puriﬁed through reversed-phase high performance liquid chromatography (RP-
HPLC). Initially, the Fmoc-protecting group was retained and was not deprotected in
the ﬁnal stage of the synthesis of the substrate-based decapeptide in order to avoid
zwitterion formation and complications in the puriﬁcation. Based on the promising
results of this Fmoc-protected decapeptide (vide infra) compared to the reference
decapeptide from the literature, however, the Fmoc protecting group was maintained
in all ﬁnal peptides synthesized. The purities of the peptides were conﬁrmed by
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analytical RP-HPLC and the molecular masses of all compounds were obtained by
Q-TOF mass spectrometry (Table 3.4).
Peptide Sequence Theoretical [M +H]+ Obtained [M +H]+
Fmoc-S-F-E-G-Q-G-W-R-L-L 1414.67 1414.60
Fmoc-F-E-G-Q-G-W-R-L-L 1327.64 1327.30
Fmoc-E-G-Q-G-W-R-L-L 1180.57 1180.91
Fmoc-G-Q-G-W-R-L-L 1051.53 1051.50
Fmoc-Q-G-W-R-L-L 994.51 994.56
Fmoc-G-W-R-L-L 866.45 866.54
Fmoc-W-R-L-L 809.43 809.47
Fmoc-R-L-L 623.35 623.38
Fmoc-L-L 467.25 467.28
Table 3.4: Synthesized peptides from truncation approach using solid phase peptide
synthesis. Peptides were puriﬁed using semi-preparative HPLC with a C-18 column; Full names of amino acids
available in abbreviations
3.4.2 In Vitro Evaluation of Substrate-Based Peptides
The peptides listed above (Table 3.4) were evaluated for NS2/3 inhibitory activity
by means of the western blot technique. Stock solutions of peptides were prepared
in DMSO to a range of concentrations and pre-incubated with the NS2/3 protease
for 15 minutes. After the pre-incubation period the detergent was added to the
protein-inhibitor mixture and each sample was then incubated for 15 minutes (Chapter
4).
Up to this point, a decapeptide (SFEGQGWRLL) that is the N-terminal cleavage
product of the NS2/3 protease had been identiﬁed as the most potent substrate-
based peptide inhibitor of NS2/3 protease cleavage.1 Initially, the synthesized Fmoc-
decapeptide (Scheme 3.3) was evaluated by the western blot technique to provide a
comparison to the deprotected decapeptide in the literature. Using our optimized con-
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ditions (protein concentration: 0.2 μM, incubation time: 15 minutes) a series of assays
were performed with various concentrations (0.37 to 120 μM) of the Fmoc-decapeptide.
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Scheme 3.3: Structure of Fmoc-decapeptide
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Figure 3.17: Dose-response NS2/3 inhibitory activity of Fmoc-decapeptide by im-
munoblotting
The resulting western blot from this experiment is shown in Figure 3.17. The ﬁrst
band from the left (−ctrl) is the zero time control in which the reaction was stopped
immediately after the addition of detergent. The second band from the left (+ctrl)
is the positive control protein that was performed in the absence of an inhibitor,
and represents the maximum cleavage of the NS2/3 to give NS2 under these assay
conditions. The blot displays a dose-response relationship whereby an increase in the
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concentration of inhibitor results in a decrease in the amount of cleaved NS2 product
formed. Since substantial amounts of the substrate were still present after 15 minutes
incubation time, the changes in substrate concentration were not visually obvious
on the gel; however, quantiﬁcation of the signals by ImageJ software provided data
that could be used to generate an IC50 value. The IC50 indicates the concentration of
the inhibitor or drug at which the target’s activity is 50% inhibited. The IC50 was
determined from the dose-response curve (Figure 3.18), generated by plotting the
percent inhibition against the common logarithm of the concentration of the inhibitor
for the series of assays conducted. Origin software was used to ﬁt a curve to the data.
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Figure 3.18: Dose-response curve of Fmoc-decapeptide. Standard deviation: 0.58 (Two experi-
ments)
The half maximal inhibitory concentration of the NS2/3 protease by Fmoc-
decapeptide was determined to be 18 μM. This value shows that the Fmoc-decapeptide
is ﬁve-fold more potent than the deprotected decapeptide (without the Fmoc protecting
group) which has an IC50 value of 90 μM. This increase in potency suggests that this
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protecting group may be involved in some additional interactions with the enzyme that
stabilize the inactive conformer and thereby decrease the cleavage activity. Regardless,
the results suggested that maintaining the Fmoc protecting group in the structure of
the other synthesized site-derived peptides may be beneﬁcial for inhibitory activity.
In vitro evaluation of the 9- and 8-mer peptides was hindered due to solubility
issues. Therefore the 7-mer peptide (Scheme 3.4) was evaluated next for NS2/3
inhibition through the same procedure used for the decapeptide.
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Scheme 3.4: Structure of Fmoc-heptapeptide
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Figure 3.19: Dose-response NS2/3 inhibitory activity of Fmoc-heptapeptide by im-
munoblotting
The removal of an amino acid may lead to the loss of some enzyme-inhibitor
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interactions since each residue in the peptide backbone functions as a potential
recognition element for the enzyme. Thus, as a general principle, it was expected that
truncation of residues from the C-terminus of the decapeptide would result in some
loss of potency if the residues were involved in important binding interactions.
The western blot for the Fmoc-heptapeptide is shown in Figure 3.19, and the
resulting dose-response curve is shown in Figure 3.20. From the dose-response curve,
the IC50 value of the Fmoc-heptapeptide was measured as 32 μM, which corresponds
to about a two-fold loss in potency compared to the Fmoc-decapeptide. This amount
of diﬀerence can be attributed to errors in the reaction assays/quantiﬁcation methods,
and should not necessarily lead to the conclusion that the heptapeptide is less potent
than the decapeptide.
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Figure 3.20: Dose-response curve of Fmoc-heptapeptide. Standard deviation: 0.30 (Two
experiments)
Finally, Fmoc-hexapeptide (Scheme 3.5) was subjected to the western blot assay.
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For the same reasons outlined previously, a higher or equal value of the IC50 was
expected for this peptide in comparison to the Fmoc-heptapeptide. The potency of
Fmoc-hexapeptide to inactivate the NS2/3 protease was evaluated using the same
procedure described for the other truncated peptides, except that a maximum concen-
tration of 60 μM was used due to solubility issues.
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Scheme 3.5: Structure of Fmoc-hexapeptide
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Figure 3.21: Dose-response NS2/3 inhibitory activity of Fmoc-hexapeptide by im-
munoblotting
The western blot for the Fmoc-hexapeptide is shown in Figure 3.21, and the
resulting dose-response curve is shown in Figure 3.22. Interestingly, from the dose-
response curve, an IC50 value of 4.8 μM was measured for the Fmoc-hexapeptide.
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Thus, removal of amino acid residues in this case resulted in 6- and 4-fold gains in
potency compared to the Fmoc-heptapeptide and Fmoc-decapeptide, respectively.
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Figure 3.22: Dose-response curve of Fmoc-hexapeptide. Standard deviation: 0.63 (Two experi-
ments)
Other NS2/3 site-derived peptides containing a similar hexapeptide sequences have
been previously evaluated by other groups.1,102 As illustrated in Table 3.5, compound
(18) encompassing a hexapeptide in the P site and a pentapeptide in the P’ site
did not have any inhibitory eﬀect on the enzyme activity, whereas compound (25),
which diﬀers in possessing a hexapeptide in the P’ site, inhibited the enzyme with the
IC50 value of 630 μM. Employing the N-terminus acetylated hexapeptide aldehyde
as well as the acetylated hexapeptide hydroxamate did not improve the potency for
inactivation of the NS2/3 protease.
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Compound Peptide [C]a(mM) IC50 (μM) or
% inhibition∗
NS2/3 site-derived peptides
18102 (Table 2.3) GWRRLL∗APITA 0.1 <5∗
251 (Table 2.4) KGWRLL∗APITAY - 630
29102 Ac-GWRRLL-CHO 0.1 <5∗
30102 Ac-GWRRLL-CONHOH 0.1 <5∗
Table 3.5: Eﬀect of various hexapeptides as part of a larger peptide sequence on NS2/3
protease inhibition
aAbbreviation: [C] is the ﬁnal concentration of the peptide in the reaction assay; Ac: Acetyl
While some studies examining these types of site-derived peptides as NS2/3 protease
inhibitors have been reported in the literature, none have examined the simple P-site
derived hexapeptide (P6-P1) as we did in this study. This Fmoc-hexapeptide has
been the most potent NS2/3 site-derived peptide inhibitor reported so far. These
results strengthen the hypothesis that the Fmoc protecting group is able to interact
speciﬁcally with the enzyme, presumably through π− π stacking interactions with the
aromatic residues of the enzyme. Moreover, it is likely that removing the amino acids
alleviates some steric interactions between the inhibitor and the enzyme, and therefore
allows for improved potency. In the absence of an enzyme-inhibitor crystal structure,
NMR studies or a molecular modeling studies to provide supporting evidence, however,
this explanation remains conjecture at this point. Overall, the encouraging results
obtained from the Fmoc-hexapeptide would open the research area for developing
small molecule inhibitors of the NS2/3 protease based on this peptide.
69
3.5 Future Directions
In order to prepare the NS2/3 protease inhibitors, diﬀerent strategies and synthetic
approaches can be investigated. In our study, the Fmoc-hexapeptide was demonstrated
to be the most potent site-derived peptide reported against the inhibition of the NS2/3
protease so far. Truncation of amino acids enables the determination of the important
interactions of the inhibitor’s backbone and side chain residues with the enzyme.
Another approach in the development of protease inhibitors involves the identiﬁca-
tion of important interactions of the inhibitor’s side chains solely, with the enzyme
through alanine scanning. Following the determination of the critical interactions,
modiﬁcation of site-derived peptides at P1 position will be explored to prepare potent
cysteine protease traps. The following approaches will be taken to increase the binding
eﬃciency of the synthesized peptides.
3.5.1 Evaluation of the Side-Chain Binding Aﬃnity
The importance of the binding aﬃnity of each amino acid residue (such as hydrogen
binding), which is a key interaction in the recognition of natural substrate, will be
explored. Therefore, systematic replacement of each amino acid in the N-terminus
cleavage product of the enzyme with the amino acid alanine has been employed
(Scheme 3.6).
NH
HN OH
O
P1O
P2OHN
Fmoc
P
n
Scheme 3.6: Evaluation of hydrogen bonding by alanine scanning. Arrows show the position
that alanine will be replaced
Alanine has a small, hydrophobic moiety and its backbone conformation and
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ﬂexibility resemble the replaced residues. By this approach functional information
of each amino acid and its importance in the recognition by the active site will be
achieved. In our study, Fmoc-hexapeptide was subjected to these replacements to
identify the essential amino acids required for recognition by the enzyme. Each
replacement will then be evaluated with in vitro assays such as western blot and mass
spectrometry.
3.5.2 Increasing the Electrophilicity of P1 Anchor
Most inhibitors of the cysteine proteases have exploited the mechanism of amide bond
hydrolysis and contained an electrophilic functionality that reacts with the active site
cysteine residue. Thereby, the minimum fragments of the peptides that have shown
enzymatic activity will be coupled to better cysteine electrophiles. Both reversible
and irreversible inhibitors of cysteine targets will be employed at the P1 position.
Therefore, we expect to have high-aﬃnity active-site ligands in this phase of the
project by employing Michael acceptors (Scheme 3.7, b) and aziridines as irreversible
inhibitors of the NS2/3 protease since they will bind to the enzyme covalently.
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Scheme 3.7: Increasing the electrophilicity of potential peptide inhibitors. a: A peptide
aldehyde as reversible inhibitor of cysteine protease; b: A peptide Michael acceptor as irreversible inhibitor of cysteine
protease
Alternatively, reversible inhibitors bind to the active site of the enzyme non-
covalently through hydrogen bonds, ionic bonds or van der Waals interactions. However
our approach is to synthesize two classes of reversible inhibitors which bind to the
enzyme covalently. Such P1 cysteine protease traps are typically aldehydes (Scheme
3.7, a) and nitriles that we will enhance the design of future generations of the
reversible NS2/3 protease inhibitors.
3.6 Conclusion
NS2/3 protease has been one of the most challenging HCV proteins to study. This is
evident by the number of marketed dugs to inhibit NS3/4A protease, NS5A protein and
NS5B polymerase but non for the inhibition of the NS2/3 protease. To date neither a
small-molecule inhibitor nor an eﬀective drug target of NS2 protease has been reported.
Despite the fact that designing inhibitors for an enzyme with intra-molecular enzymatic
reaction appears as an obstacle, a rational design assisted by various methods such as
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molecular modeling, mass spectrometry and NMR studies can provide such molecules.
In this work, tryptic digestion followed by tandem mass spectrometry were carried
out to obtain initial enzymatic information of the NS2/3 protease. Tandem mass
spectrometry was established as a precise method for the kinetics studies of the
enzyme, however, it would be a starting point to employ this method for evaluation of
potential inhibitors. Furthermore, gel electrophoresis and western blot techniques were
optimized for this enzyme and the obtained kinetics data were compared to similar
studies. Rational design of the NS2/3 protease inhibitors initiated with systematic
truncation of the NS2/3 protease site-derived peptides implicating peptide synthesis.
An Fmoc-hexapeptide was discovered as the most potent peptidic inhibitor of this
enzyme. This would be a starting point to modify and develop more potent and
smaller molecule inhibitors towards inhibition of the NS2/3 protease.
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Chapter 4
Experimental
4.1 NS2/3 Protease
In the present work the puriﬁed NS2/3 protein was kindly provided by Boehringer
Ingelheim (Laval, Canada, Ltd.). The NS2/3 protein (904-1206) contained four lysine
residues, followed by a histidine tag at its N-terminus and another four lysines at the
C-terminus. After puriﬁcation by a chelating column containing Ni+2, the inactive
NS2/3 protein was stored in the refolding buﬀer containing 50 mM Tris pH 8.0, 0.5
M arginine HCl, 5 mM TCEP, 1% LDAO.1 The stock aliquots of the protein were
stored at -80 °C until their activation for auto-cleavage.
4.1.1 Materials
n-dodecyl-β-D-maltoside, HEPES, Tween® 20, Tris HCl and glycerol were obtained
from BioShop® in biotechnology grades. TCEP was purchased from Thermo Fisher
Scientiﬁc.
Materials for western blot assay: Amersham ECL western blotting reagent from
GE Healthcare Life Sciences or Pierce ECL western blotting reagent from Thermo
Fisher Scientiﬁc were purchased. Protein bands were visualized on Carestream®
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Kodak® BioMax® MS ﬁlms (20×25 cm) using a radiography instrument. A rabbit
polyclonal anti-NS2 antibody raised against NS2 (residues 904-1026) for probing NS2
protein in western blot experiments. The NS2 antibody was donated by the McGill
cancer center (Dr. Arnim Pause laboratory). Goat polyclonal secondary antibody to
rabbit (horseradish peroxidase conjugated secondary antibody) was purchased from
Abcam®. Nitrocellulose membranes (pore size 0.2 μm) and prestained protein ladder
(all blue, 10-250 kDa) were obtained from Bio-Rad.
4.1.2 Enzyme Auto-Cleavage Activity
Based on the procedure reported by Thibeault et al.1 the "cleavage buﬀer" including
50 mM Hepes pH 7.0, 50% glycerol (w/v), 1 mM TCEP and n-dodecyl-β-D-maltoside
(DM) was employed. The concentration of detergent varied depending on the 0.5%
ﬁnal detergent concentration for the 0.54 μM protein concentration, however it never
exceeded 0.5% in the ﬁnal reaction mixture. All samples contained a 2-5% ﬁnal
concentration of DMSO depending on the experiment. Also the concentration of
DMSO did not exceed 5% in the ﬁnal reaction mixture.
Protein samples were prepared for the enzymatic reaction in the following manner
(protein concentration varied in some experiments): To the cleavage buﬀer were added
the inhibitor or the same volume of DMSO as the vehicle control. Protein was added
and the mixture was pre-incubated for 15 minutes at 23 °C (mixtures were stirred at
400 rpm in the mass spectrometry experiments). n-Dodecyl-β-D-maltoside was added
to initiate the cleavage reaction and the incubation time was measured from this
time point. The reaction was stopped by addition of SDS (sodium dodecyl sulfate),
Laemmli buﬀer in the western blot assays and by addition of formic acid in the mass
spectrometry experiments. These were added to the samples right after the addition
of the detergent (DM) in case of zero incubation time.
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4.2 Acetone Precipitation
The procedure provided by Thermo Scientiﬁc169 was followed for acetone precipitation
with slight modiﬁcations. To the mixture of the NS2/3 protein, cleavage buﬀer and 2%
DMSO was added 0.5% of n-dodecyl-β-D-maltoside when the ﬁnal concentration of
the protein was 0.54 μM. After speciﬁc incubation time, pre-cooled acetone at -20 °C
was added to the four times volume of this reaction mixture. The sample was mixed
well and incubated overnight at -20 °C. The sample was centrifuged at 13000-15000 xg
for 10 minutes at room temperature and the supernatant was carefully disposed. This
cycle was repeated twice. Subsequently, residual acetone in the sample was evaporated
at room temperature and the sample was prepared for the mass spectrometry analysis.
4.3 Mass Spectrometry Measurement
Following the acetone precipitation, protein pellets were dissolved in 5% acetoni-
trile/0.1% TFA. Samples were injected onto a reversed-phase VYDAC® column (5μ,
100 mm) that was equilibrated with 5% aqueous acetonitrile/0.1% formic acid using
an Agilent 1100 HPLC. A ﬂow rate of 0.2 ml/min was used. Solvent gradients were
as the following: 5-95% acetonitrile in 5 minutes, constant acetonitrile in 95% for 3
minutes and 95-5% acetonitrile in 3 minutes. Samples were eluted into the electrospray
(ESI) source of a Q-TOF Ultima API Mass Spectrometer (Waters). Mass calibration
was applied by employing horse heart myoglobin as a standard (average mass =
16951.49 u, C769H1212N210O218S2). Other employed mass spectrometry parameters
were as the following: source temperature 80 °C and desolvation temperature 300 °C.
Capillary voltage 3.5 kV and cone voltage 35 V. MaxEnt1 algorithm was employed for
deconvolution of protein envelopes.
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4.4 Trypsin Digestion and Sample Preparation
For the ﬁnal volume of 150 μL reaction mixture, the NS2/3 protease (0.54 μM) was
added to the cleavage buﬀer (100 μL) containing 5% DMSO and the mixture was pre-
incubated at 23 °C for 20 minutes with shaking at 750 rpm. n-Dodecyl-β-D-maltoside
(0.5%) was added and protein samples were incubated at speciﬁc time intervals. The
enzymatic reaction was quenched by addition of 1% formic acid (30 μL). 100 mM
ammonium bicarbonate pH 8.5 was added subsequently. The sample was incubated
with 50 mM dithiothreitol (DTT) for 10 minutes at 25 °C to reduce the disulﬁde
bonds (750 rpm) and was incubated with 50 mM iodoacetamide (IAM) in the dark
for 30 minutes at 37 °C (750 rpm) to alkylate the reduced bonds. 2.4 μg trypsin were
added to the sample and it was incubated for 18 hours at 37 °C (750 rpm). After
digestion process, 500 μL water was added to the sample and it was loaded onto an
OASIS® HLB column (30 mg) which was pre-washed with 1 mL methanol and 1 mL
water. The sample tube was washed with another 500 μL water and loaded onto
the column and 1 mL water was added to the column too. Sample on the column
was washed with optimized organic solvent mixture, ACN/IPA 60:40 for two times
(500 μL). Through this mixture of solvent, sample was collected from the column
and was dried under vacuum (Thermo Fisher Scientiﬁc Universal Vacuum System,
Asheville, NC) for 3 hours. 10% ACN (100 μL) was added to the protein sample for
the LC-MS/MS analysis.
4.5 Reverse-Phase UHPLC-MS/MS
NS2/3 protein samples in 10% ACN or synthetic standard peptides in NS2/3 cleavage
buﬀer were loaded (20 μL) onto a 2.1 × 100 mm Kinetex® XB-C18 column with
1.7 μm, 100 Å, solid core particles (Phenomenex, Torrance, CA), by employing a
Nexera® UHPLC (Shimadzu, Columbia, MD). The column was equilibrated with 5%
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aqueous acetonitrile-0.1% formic acid (B). As it is illustrated in Figure 4.1, the column
was maintained at 5% (B) at a ﬂow rate of 300 μL/min and a gradient from 5-24%
acetonitrile over 9 minutes, 24-80% acetonitrile over 30 seconds, 80% acetonitrile over
4.5 minutes, 80-5% acetonitrile in 17 minutes and 5% acetonitrile over 8 minutes was
applied.
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Figure 4.1: Solvent gradient in UHPLC-MS/MS
A Rheodyne switch valve (IDEX Health and Science, Oak Harbor, WA) was
employed to avoid the entering of any salt into the ion source. Therefore, elution
between 0-2 minutes and 17.5-25 minutes were sent to the waste.
A high-resolution hybrid quadrupole-time-of-ﬂight (Q-TOF) TripleTOF® 5600mass
spectrometer (AB Sciex, Concord, ON, Canada) combined with a DuoSpray™ ion
source (positive ion mode) was used and the total ion current (TIC), MS and MS/MS
data were visualized by PeakView® software version 1.2. The peptides were identiﬁed
based on the MS/MS data by ProteinPilot™ software version 4.1. Quantiﬁcation of
peptides and peak integration were performed by MultiQuant™ software version 2.1.
4.6 SDS-PAGE and Western Blot
Following the addition of SDS Laemmli buﬀer, protein samples were boiled at 95 °C
for 5 minutes. In case of using 0.21 μM of protein concentration, which was employed
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in most of the experiments, 52 μg of the protein was loaded on a 15% sodium dodecyl
sulfate (SDS) polyacrylamide gel electrophoresis applying the voltage of 100-130. The
separated proteins were transferred to the supported nitrocellulose membrane using
transfer buﬀer (5.8 g tris base, 2.9 g glycine, 0.37 g SDS, 200 mL MeOH, 800 mL
dH2O) by applying 80 voltage for 80 minutes. The membrane was blocked for one
hour in 5% w/v dried milk dissolved in TBS (tris-buﬀered saline) with 0.5% tween®
20. The membrane was blocked with 1:5000 dilution of anti-NS2 antibody in TBS
buﬀer for one hour. After 4 times wash, the membrane was blocked in a 1:10000
dilution of horseradish peroxidase (HRP) conjugated secondary antibody (anti-rabbit).
After 7 times washing steps, the membrane was incubated in the ECL reagent and
the protein signals were detected on a Kodak ﬁlm using a radiography instrument.
Protein densitometry was carried out using ImageJ analysis software.
4.7 Peptide Synthesis
4.7.1 Materials
All Fmoc-L-amino acids, Wang resin (1.0-1.5 mmol/g OH loading, 1% cross-linked with
divinylbenzene, 70-90 mesh), O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hex-
aﬂuorophosphate (HBTU), N,N’-Diisopropylcarbodiimide (DIC), 4-Dimethylaminopyridine
(DMAP), pyridine, triﬂuoroacetic acid (TFA), triisopropylsilane (TIS) were purchased
from Sigma-Aldrich. DMF was dried and stored over activated 3 Å molecular sieves in
a ﬂame-dried Schlenk ﬂask. Peptides were synthesized in a cylindrical reaction vessel
equipped with fritted disc (coarse porosity) and two valves for introducing inert gas
and vacuum. Peptide identiﬁcation was performed on an Agilent 1200 reversed-phase
HPLC. The preparative RP-HPLC was performed on semi-preparative C-18 column
(Waters, 19×50 mm) or C-18 (ACE 5, 250×10 mm). The analytical RP-HPLC was
carried out on a C-18 column (Agilent, Elipse XDB, 4.6×150 mm).
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4.7.2 Fmoc-Solid Phase Peptide Synthesis
Peptides were manually synthesized on the Wang resin. Initially resin (1 equiv) was
soaked in DMF for 30 minutes to swell. To a ﬂame dried ﬂask was added the ﬁrst
Fmoc amino acid (6.6 equiv) dissolved in DMF (2 mL). DIC (7 equiv) was added and
the mixture was stirred at 0 °C for 20 minutes. DMAP (0.1 equiv) was added and
after a few minutes stirring, the solution was added to the resin in a fritted reaction
cylinder and agitated under argon for 1 hour. This step was repeated 2 more times.
Beads were washed 5 times with DMF in order to remove the excess reagents and
the Fmoc was removed by treating the beads with 20% solution of piperidine/DMF
for 10 minutes (3 times). After more washing steps (5 times with DMF) the next
couplings of the Fmoc amino acids (3 equiv) were performed with HBTU (3 equiv) as
the coupling reagent and DIPEA (3 equiv) as the base in DMF for 1 hour. Ninhydrin
(Kaiser test) was used for the identiﬁcation of residual free amine in each step. Several
coupling and deprotection steps were performed until the desired length of peptide
sequence was obtained. Finally beads were washed 3 times with DMF, DCM and
methanol separately. In the last step, a solution of TFA/TIS/H2O (95:2.5:2.5 v/v)
was added to the resin to cleave the peptide from the resin and to deprotect the side
chain protecting groups from the peptide. TFA was removed from the samples by
rotary evaporation and samples were lyophilized to obtain the crude peptide.
Mass spectrometry and HPLC were performed on the crude samples and later
semi-preparative HPLC was carried out to purify the samples. The solvent system
for both analytical and semi-preparative HPLC were water-0.05% TFA (A) and
acetonitrile-0.05% TFA (B). Analytical HPLC was carried out using a linear gradient
of 5-95% solvent B over 16 minutes with the ﬂow rate of 1 ml/min. A linear gradient
of 30-95% B was used for peptides puriﬁcation over 30 minutes with the ﬂow rate of 5
ml/min. Fractions were characterized by a Q-TOF Ultima API Mass Spectrometer
(Waters) and analytical HPLC was performed to ensure the purity of collected fractions.
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Combined fractions were dissolved in water/acetonitrile and lyophilized.
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Chapter 5
Synthesis of 2,5-Diaryl Substituted
Thiophenes as Helical Mimetics
5.1 Protein Structures
A great part of protein properties is governed by their dynamic characteristics including
their folding, conformational and structural features. Four levels of protein structures
are deﬁned for the structural organization of proteins;170 the primary structure of
proteins is the linear arrangement of amino acids connected through covalent bonds
to make the polypeptide chains (Figure 5.1, a). Secondary structure results from
the backbone hydrogen bond interactions within a segment of a polypeptide chain.
Two main motifs of secondary structure are α-helices (Figure 5.1, b) and β-sheets
(β-pleated sheets, Figure 5.1, c). α-Helices are formed by the hydrogen bonds between
the oxygen atom of a carbonyl group in the backbone (i) with the hydrogen atom of
the amide group four residues further (i+4). The repetition of these hydrogen bonds
establishes a right-handed coil motif engaging up to 40 amino acids. Each complete
α-helix turn consists of 3.6 amino acids and spans a length of 5.4 Å.170 β-Sheets
are the parallel or anti-parallel shapes of the polypeptide segment resulting from the
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hydrogen bonds between the NH of the amino acid in one chain and the oxygen atom
of the carbonyl group in the adjacent chain. The tertiary structure of the protein
refers to the three dimensional shape of the whole polypeptide chain that is formed
as a consequence of hydrogen bonds, hydrophobic interactions and disulﬁde bonds.
The tertiary structure demonstrates the folding of all secondary structures (α-helices
and β-sheets) into a globular polyprotein. Proteins associated with more than one
polypeptide chain can be stabilized by interactions similar to those found in tertiary
structures and form quaternary structures (Figure 5.1, e).170 Not every protein has a
quaternary structure. Hemoglobin is an example of a protein possessing a quaternary
structure.
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Figure 5.1: Levels of protein structures. (a) Primary structure; (b) α-Helix of the secondary structure;
(c) β-Sheet of the secondary structure; (d) Tertiary structure; (e) Quaternary structure
83
5.2 Protein Misfolding
Protein folding refers to the proper distribution and unique arrangement of α-helices, β-
sheets and random coils to establish the tertiary structure of the protein in its functional
and native form. The aberrant folding of a speciﬁc protein or the failure to adopt
and/or maintain its native conformation is attributed to protein misfolding.28 Several
pathological conditions arising from protein misfolding are speciﬁed as conformational
or misfolding diseases.171 Molecular chaperones are responsible for directing the proper
and eﬃcient folding of proteins and therefore also preventing their aggregation.172,173
Ineﬀective or low levels of chaperone proteins that can result from aging leads to
protein misfolding. Environmental factors including pH, temperature, oxidation, and
glycation can promote misfolding of the proteins as well.174 Moreover, genetic factors
that can aﬀect amino acid composition and gene mutations also inﬂuence protein
misfolding.175,176
The accumulation of misfolded proteins leads to the formation of protein aggre-
gates. These aggregates can be cytotoxic to various types of cells through the loss
of the functional structure of the native protein and/or their interaction with other
components in the cell. The generation of these aggregates can lead to the production
of either disordered amorphous aggregates or highly organized ﬁbrils.174 The highly
ordered and insoluble ﬁbrils are referred to as amyloid ﬁbrils or plaques28 when they
accumulate in the extracellular space, as opposed to their intracellular counterparts
which are referred to as intracellular inclusions.177
Figure 5.2 illustrates a general proposed mechanism of amyloid formation.178
Assisted by folding enzymes and molecular chaperones, the synthesized protein folds in
the lumen of the endoplasmic reticulum (ER). The properly folded protein is liberated
from the cell into the extracellular space. The functional and native protein (N) is
converted to a partially folded intermediate (I) or completely unfolded (U) protein.178
During this process several α-helical structures unfold and β-sheets accumulate. The
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formation of unfolded protein from the native protein is not thermodynamically favored
and this intermediate has a high propensity to aggregate. Protein oligomerization
through the intermolecular interaction of β-sheets is a step towards the formation of
aggregates.174
Figure 5.2: General representation of protein misfolding and aggregation. Abbreviations:
ER: endoplasmic reticulum; N: native protein; I: partially folded intermediate; U: unfolded protein; QC: quality
control factors which hinder protein misfolding (Figure from reference178)
Since under denaturing conditions several non-disease related proteins are able to
form the amyloids in vitro, it is known that amyloid ﬁbril formation is an intrinsic
property of many proteins;179–181 however several genetic and environmental factors,
such as those outlined earlier, as well as the protein’s charge and hydrophobicity, which
is aﬀected by the identity of the side chain residues, promote the formation of amyloid
ﬁbrils. Amyloid ﬁbril formation is related to about 20 progressively degenerative
diseases.182 Although all amyloid ﬁbrils are similar in their characteristic cross-β-
sheet structures, the speciﬁc protein misfolding/aggregation disorders caused depend
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on the identity of the misassembling protein and the tissue subjected to protein
deposition and cellular degeneration.183,184 For example, the ﬁbrils in Alzheimer’s
disease, Parkinson’s disease, spongiform encephalopathy disease (mad cow disease),
systemic amyloidosis and Huntington’s disease are generated from problems with the
folding of amyloid β-peptide (Aβ), α-synuclein, prion protein (PrP), lysozyme or
transthyretin and huntingtin, respectively.182,185,186 Diabetes mellitus type 2 (DM-2
or type II diabetes) is the target of this study and involves islet amyloid polyeptide
(IAPP) for the formation of ﬁbril aggregates.
5.2.1 Islet Amyloid Polypeptide (IAPP)
IAPP, also known as amylin, is a 37-amino acid, C-terminally α-amidated peptide that
is co-secreted with insulin by the pancreatic β-cells. IAPP is an unusual aggregation-
prone peptidic hormone that readily forms amyloid ﬁbrils.187 The IAPP amyloidogenic
process observed in the pancreas is believed to accelerate type II diabetes pathogenesis
by exacerbating β-cell degeneration, ultimately compromising insulin secretion. In
patients aﬄicted by type II diabetes, the islet amyloid polypeptide (IAPP) deposits
in the pancreas, leading to the degeneration of the islets of Langerhans.187
Previous studies have proposed a model for the formation of the ﬁbrillar ag-
gregates.188–191 The model relies on the nucleation polymerization mechanism and
contains two phases. The initial phase is the lag phase with the formation of unfolded
peptides from the soluble monomeric peptides as illustrated schematically in Figure
5.3. A fragment of the unfolded peptide aggregate acts as a nucleation site to provide
a template for the formation of other oligomeric ﬁbrillar intermediates (protoﬁbrils).
The lag phase is followed by the elongation phase that leads to the rapid growth of
the protoﬁbril species. Subsequently the mature and insoluble ﬁbrils are formed as
the plateau phase is reached.
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Figure 5.3: General representation of amyloid aggregate formation. (Figure from reference188)
5.2.2 General Therapeutic Approaches to Prevent Protein
Aggregation
Similar to many other disease targets, the formation of amyloid ﬁbril aggregates can
be prevented at several stages. These approaches have been presented by Soto et
al.171 and are illustrated in Figure 5.4. The ﬁrst step towards protein aggregation
is protein unfolding and misfolding, making it one of the essential target stages to
be inhibited. This can be achieved through stabilization of the protein conformation
in the native state (Figure 5.4, a). The application of synthetic small molecules
in Alzheimer’s disease192 or protein mutation in transthyretin amyloidosis193 are
examples of stabilizing the native conformation of protein in order to prevent protein
misfolding.
The second strategy is the employment of compounds, mainly small peptides, in
order to inhibit unfolding of and/or re-constitute the native form of protein (Figure
5.4, b). Peptides that speciﬁcally interact with the protein and either stabilize the
native conformation or destabilize the unfolded protein were shown to inhibit the
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aggregation of the prion protein and amyloid beta.194–196
Inhibitors can also be used to compete with the protein-protein interactions involved
in the misfolding process. These competitive inhibitors discourage protein aggregation
through the interaction with either protein monomers or oligomers (Figure 5.4, c, d).
These inhibitors can be small molecules that interact with the nuclei to prevent their
growth towards the formation of oligomeric ﬁbrils. These compounds also can interact
with the already formed oligomers and interfere with the intermolecular forces, either
to other oligomers or to other proteins, that favor the formation of aggregates. An
example involves blocking a key protein (protein X) for prion protein propagation to
prevent its interaction with the prion protein.197,198
Finally, several approaches have been proposed to enhance the removal of amyloid
aggregates or misfolded proteins. For example, elimination of the interaction of
some accessory components with the amyloid aggregates decreases the stability of
the plaques and their further accumulation and insolubility. Anionic sulphates or
sulphonates have been demonstrated to prevent the stabilization and improve the
clearance of amyloid aggregates in Alzheimer’s disease.198,199
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Figure 5.4: General representation of therapeutic approaches towards preventing
protein misfolding and aggregate formation. (Figure from reference171)
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5.2.3 Approaches Towards Inhibition of Islet Amyloid Fibril
Formation
Peptides as IAPP Receptor Agonists and IAPP Fibril Formation Inhibitors
Since IAPP is co-secreted with insulin and its deﬁciency is related to the emergence
of type II diabetes, theoretically it is expected that the employment of synthesized
IAPP peptide would compensate the deﬁciency of natural IAPP hormone in body.
However, the high propensity of IAPP to aggregate limits its use in the treatment
of type II diabetes. Therefore other analogs with low or no aggregation properties
have been developed as IAPP receptor agonists. Pramlintide (Symlin) has been
approved as a drug for both diabetes type I and II as an IAPP replacement for
IAPP hormone deﬁciency (Figure 5.5, b).200 Replacement of the residues of the IAPP
sequence involved in the cross β-sheet structure of aggregates with proline provides a
non-aggregating and soluble polypeptide hormone with similar properties to the IAPP
hormone. The replacement of the three amino acid residues at positions 25, 28 and
29 of human IAPP with proline residues was inspired by the primary sequence of rat
IAPP, which does not aggregate like human IAPP.
Over the last two decades, several compounds have been reported to inhibit IAPP
aggregation in vitro by interfering with the later stages of ﬁbrillogenesis through
destabilization of the ordered cross β-sheet quaternary structure of the amyloid
ﬁbrils.201,202 One example of these compounds is generated from modiﬁcation of the
natural sequence of IAPP through N-methylation of the two residues at positions
24 and 26 (Figure 5.5, c).202 This polypeptide has improved solubility and lowered
cytotoxicity compared to the IAPP as a result of these residue modiﬁcations.
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Figure 5.5: (a): Primary structure of IAPP (amylin); (b): An IAPP receptor ago-
nist;200 (c): An IAPP aggregation inhibitor202
Small-Molecule Inhibitors of IAPP Fibril Formation
Some of the obstacles of using peptide molecules as therapeutic drugs are poor
bioavailability, low absorption through membranes and low stability in the biological
circulatory system.137 Although large molecules can be dosed through intravenous
injection, oral dosing still remains the preferred route of administration for patients.
To overcome the drawback of peptides as therapeutic agents, small-molecule in-
hibitors have emerged. However, despite advances in the development of small-molecule
inhibitors of ﬁbril formation of the relevant proteins for some neurodegenerative dis-
eases, the development of small-molecule inhibitors of islet amyloid ﬁbril formation
has seen less progress. The observed inhibition of amyloid ﬁbril formation by small
molecules such as the dye Congo red initiated the prospect of developing small-molecule
inhibitors for IAPP ﬁbrils.203–205 For example, the co-crystallization of Congo red
and insulin demonstrated an interaction between aromatic residues of Congo red and
phenylalanine 24 of insulin that inhibited the formation of insulin ﬁbrils.206,207 Based
on this observation, several natural and synthetic polyphenols were evaluated for the
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inhibition of IAPP ﬁbril formation and a synthesized phenolsulfonphthalein exhibited
an IC50 of 1μM.208 In a separate study some substituted rhodanine heterocyclics that
were characterized as tau aggregation inhibitors209 were evaluated against IAPP ﬁbril
inhibition. Two derivatives of this class of compounds inhibited IAPP ﬁbril formation
(Figure 5.6, a, b).210 Although the exact mechanism of this inhibition is not clear,
π-stacking interactions of the aromatic compounds with the monomer or oligomer
of IAPP, preventing the formation of the aggregated ﬁbrils, constitutes a reasonable
proposal.210
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Figure 5.6: Chemical structure of rhodanine heterocyclic core scaﬀolds. IC50 values for
compounds (a) and (b) were obtained as 1.23 and 0.45 μM respectively210
Interfering with the later stages of ﬁbrillogenesis does not prevent the formation
of the preﬁbrillar oligomers that were recently recognized as the most cytotoxic
proteospecies of the amyloidogenic cascade,211–214 suggesting a potential drawback to
many of these therapeutic approaches.
5.2.4 Small-Molecule Mimetics of the α-Helices
As the most encountered secondary structure of proteins (∼40%), α-helices are in-
volved in several biological functions of proteins. α-Helices mediate protein-protein
interactions (PPIs) that are important in cellular processes and regulatory pathways
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and their aberrant function leads to the development of many diseases. Examples
are PPIs involved in HIV fusion215 or the mis-regulation of anti-apoptosis proteins
such as Bcl-2 (B-cell lymphoma 2) that leads to tumor induction and several cancer
diseases.216 Consequently, targeting α-helices is arising as an attractive strategy in the
development of therapeutic approaches and drug discovery. Developing the ligands
that can chemically and spatially interact with the partial α-helix state in order to
prevent some protein-protein interactions or to restrict the conformational ensemble of
a speciﬁc protein into non-aggregating helical conformations has become a promising
alternative strategy.217,218
Stabilizing α-helices of proteins has been accomplished through various approaches
such as covalent linkages (disulﬁde, lactam, oleﬁn, azobenzene)219–222 and non-covalent
interactions (π-π interactions, salt bridges, cation-π interactions, metal chelates,)223–226
using peptidic molecules (Figure 5.7).
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Figure 5.7: Approaches towards stabilization of helical state of proteins. Covalent linkages:
disulﬁde, lactam, oleﬁn, azobenzene; Non-covalent linkages: π-π interaction, salt bridge, cation-π interaction;218
Helical ribbon structure was obtained from http://en.citizendium.org/wiki/Protein_structure
Although designing non-peptidic small molecules to interact with the large and
usually buried interface area of proteins227 is challenging, strategies have been de-
veloped to mimic the structural and conformational characters of protein secondary
structures. Trisubstituted indanes (Figure 5.8) were one of the early achievements
in mimicking partial areas (i -1, i, i+1 residues) of the α-helix as a proof of concept
for interacting with neuropeptide receptors (tachykinin receptors)228,229 to inhibit
protein-protein interactions. In later attempts, small molecules capable of interacting
with and stabilizing larger areas of the α-helices were designed. Functionalized ter-
phenyls217,230,231 (Figure 5.8) represent one such scaﬀold with a reported application
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as a mimic of the i, i+4 and i+7 positions of the α-helix side chain of smooth muscle
myosin light chain kinase (smMLCK) to disrupt its interaction with calmodulin (CaM)
and consequently to prevent the hydrolysis of 3’-5’-cyclic nucleotide phosphodiesterase
(PDE) enzyme.232
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Figure 5.8: Early examples of small-molecule mimetics of α-helices
Alternatively, other synthetic templates have been shown to be attractive scaﬀolds
for interacting/stabilizing the α-helical region of proteins. Some drawbacks of the
terphenyl compounds such as long synthetic pathways and low aqueous solubility (high
log P, the octanol/water partition coeﬃcient) were improved by substituting the phenyl
rings with heterocyclic scaﬀolds. Terpyridine233 and pyridazine234 α-helix mimetics
were developed through substitution of the phenyl rings with the heterocyclic scaﬀolds.
These compounds showed improved solubility compared to the terphenyl scaﬀolds,
but were not as potent for inhibiting the interaction of Bcl-xL (B-cell lymphoma-extra
large) and Bak peptides (Figure 5.9, a and b). A series of imidazole-phenyl-thiazole
compounds demonstrated improved solubility compared to the terphenyl compounds,
and were used for inhibition of the interaction between Dbs (a guanine nucleotide ex-
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change factor) and Cdc42 (cell division cycle 42) proteins. The compound shown below
in Figure 5.9, c, inhibits the Dbs/Cdc42 interaction with an IC50 value of 67 μM.235
The Miranker and Hamilton groups recently developed small molecules targeting the
transient helical state of IAPP in order to inhibit lipid-catalyzed aggregation.236,237
These polycarboxylate ligands were developed on pyridyl (Figure 5.9, d), quinoline or
peptoid scaﬀolds and were shown to inhibit lipid-induced IAPP aggregation, but to
strongly accelerate IAPP ﬁbrillogenesis under lipid-free conditions.
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Figure 5.9: Small-molecule mimetics of the α-helices. (a): Functionalized terpyridine to mimic
Val74, Leu78, Ile81 and Ile85 of the α-helix of Bak protein;233 (b): Oxazole-pyridazine-piperazine scaﬀold to mimic
Val74, Leu78, Ile81, and Ile85 of the α-helix of Bak protein;234 (c): Imidazole-phenyl-thiazole scaﬀold to mimic
Gln770, Lys774 and Leu777 of Dbs protein;235 (d) Pentapyridyl scaﬀold to inhibit lipid-catalyzed aggregation of
IAPP236,237
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5.3 Palladium-Catalyzed Cross-Coupling Reactions
Small-molecule mimetics of α-helices have been synthesized through various approaches.
During the pioneering work in the development of α-helix mimetics, the main objective
was obtaining an active compound capable of interacting with the α-helix of the target
protein, with less consideration given to the modularity of the synthetic pathways. As
the ﬁeld has matured and the amount of research with α-helix mimetics has grown, the
synthetic accessibility of these mimetic compounds has gained importance to allow for
their rapid synthesis for exploring structure-activity relationships to optimize various
parameters, including potency.
Among chemical transformations, carbon-carbon bond formation through tran-
sition metal-catalyzed reactions stands out as one of the most valuable synthetic
transformations. In a survey of 1039 transformations used for the synthesis of 128
potential drug molecules in 2006, 11% of the total reactions performed by three
companies (AstraZeneca, GlaxoSmithKline, Pﬁzer) were carbon-carbon bond forming
reactions.238 Palladium-catalyzed coupling reactions emerged as a versatile method for
the formation of C–C bonds, accounting for 22% of these carbon-carbon bond forming
reactions.238 Similar ﬁndings were presented in another study, which stated that of
7315 reactions reported in 139 articles in three journals, 11.5% were carbon-carbon
bond forming reactions, and 62.3% of these were catalyzed by palladium.239
5.3.1 Classical Palladium Catalyzed Cross-Coupling Reactions
Generally palladium-catalyzed coupling reactions are classiﬁed into two types: classical
and modern palladium cross-coupling reactions. Palladium-mediated coupling reactions
between oleﬁns and aryl- or alkylmercuric halides were pioneered by Heck in 1968
using stoichiometric amounts of palladium catalyst.240,241 Improved protocols were
later developed by Heck, Mizoroki and Fitton through a key discovery of replacing
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organomercury compound by an aryl halide as well as altering this reaction into a
catalytic process.242–247 The traditional Suzuki and Negishi coupling reactions employ
arylboronic acids/esters and organozincs respectively and a wide range of aryl halides
and, along with the Heck reaction, earned the 2010 Nobel Prize in Chemistry for their
discoveries (Figure 5.10).248
Other useful classical palladium-mediated reactions employ organotins (Stille),
organosilanes (Hiyama) and Grignard reagents (Kumada) (Figure 5.10). The Sono-
gashira coupling is a mild palladium-catalyzed reaction for the formation of sp-sp2
carbon-carbon bond between alkynes and aryl halides, but also requires a copper
co-catalyst. Finally, in the Tsuji-Trost coupling, carbon-carbon bond formation takes
place between nucleophiles and compounds bearing an allylic leaving group (Figure
5.10).
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Figure 5.10: Most utilized traditional palladium-catalyzed cross-coupling reactions
The general catalytic cycle of cross-coupling reactions is illustrated in Scheme 5.1.
The ﬁrst step of the catalytic cycle involves the oxidative addition of a palladium(0)
complex to the aryl halide (6) to provide an aryl-substituted palladium(II) complex
(7). The transmetallation of the organometallic coupling partner (8) with its aryl
group with the Pd(II) species (7) forms the bisarylated palladium complex (9) and
the metal salt byproduct. In the last step reductive elimination of biaryl (10) from
complex (9) furnishes the ﬁnal product and regenerates the Pd(0) catalyst (Figure
5.1). In this catalytic cycle Pd(II) pre-catalyst sources can also be used, however, they
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need to be reduced to Pd(0) in situ using a number of diﬀerent methods. Ligands
such as phosphine ligands, solvents or various reagents can reduce Pd(II) to Pd(0).249,250
Oxidative 
addition
Ar-X
Ar-PdLn-Ar
Ar-M
M-X
Ar-Ar
Reductive 
elimination
Transmetallation
6
7
8
9
10
PdLn (0)
ArPdLnX
Scheme 5.1: General catalytic cycle of cross-coupling reactions
Although these traditional cross-coupling reactions are robust and well-established
methods for the formation of carbon-carbon bonds in medicinal chemistry, materials sci-
ence, total synthesis and industrial chemistry, they suﬀer from several drawbacks. For
example some of the organometallic reagents require special precautions since they are
either toxic (organotin reagents)251 and/or sensitive to air (organotin, organozinc and
Grignard reagents). Also, the generation of stoichiometric amounts of byproducts such
as metal salts results in poor atom-economy. Moreover, to prepare the organometallic
coupling reagents and functionalize them, several synthetic steps are required which
is not favorable in terms of cost, energy consumption and waste production. Lastly,
many organometallic coupling reagents can no be carried through other synthetic
steps, or are not compatible with a number of other functional groups. To overcome
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these limitations, methods have been developed to circumvent the requirement of
stoichiometric amounts of an organometallic coupling partner while maintaining the
eﬃciency and selectivity of the conventional coupling reactions.
5.3.2 C–H Arylations
Direct C–H arylation coupling reactions were developed to address the previously
outlined issues with conventional cross-coupling reactions. This transformation can
take place through the reaction of an unactivated C–H bond via direct oxidative
arylation employing organometallic (Scheme 5.2, a) or simple (hetero)arene coupling
partners (Scheme 5.2, b) or a via direct arylation reaction using aryl (pseudo)halide
coupling reagents (Scheme 5.2, c).252–254
R1 H
cat. [TM]
oxidant
R2M
R1 H
cat. [TM] R1 R2
oxidant
R2H
cat. [TM]
M = organometallic reagent
X = (pseudo)halides
(a)
(b)
(c)
R1 H R2X R1 R2
R1 R2
Scheme 5.2: Classiﬁcation of transition metal-catalyzed direct arylations of (het-
ero)arenes. R1 and R2: (hetero)arenes; TM: transition-metal catalyst
The oxidative arylation reaction with stoichiometric amounts of organometallic
reagents was developed using various additives, and molecular oxygen, solvents or
metal salts have served as oxidants in these reactions.255 This method can be consid-
ered as an improved halogen-free version of conventional coupling reactions for the
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formation of C–C bonds.256–258 An example of a direct arylation of benzoic acids (11)
with aryl boronates (12) developed by Yu et al. is shown in Scheme 5.3, (a).259,260
A substantially improved oxidative arylation of a broad range of (hetero)arenes with
aryl boronic acids (15) was accomplished under considerably milder conditions using
oxygen as an oxidant instead of metal salts (Scheme 5.3, b).261
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Scheme 5.3: Oxidative direct arylation of arenes and heteroarenes with organoboronic
coupling partners
Subsequently, cross-coupling reactions have been developed employing other
organometallic compounds such as organotin262 and organomercury reagents. Although
more advanced methods use less toxic coupling reagents such as organosilanes,263,264
the main drawbacks of these methods remain the need for pre-activation of the coupling
partners, the sensitivity of the organometallic reagents, which often can not be carried
through synthetic steps, and the production of stoichiometric amounts of metallic
waste.
Dehydrogenative arylations also utilize oxidants for the formation of C–C bonds
via C–H functionalization; however, they take advantage of the reaction of two distinct
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C–H bonds and eliminate the need for an organometallic coupling partner. This
method was pioneered by Moritani and Fujiwara265–267 for the direct arylation of
oleﬁns (Scheme 5.4, a). This method has also been expanded to intramolecular
oxidative arylations of biphenyl compounds, which were particularly advantageous
for the preparation of key intermediates towards the synthesis of naturally occurring
compounds268,269 (Scheme 5.4, b). The challenges of cross-coupling two simple arenes
include the issues of regioselectivity (because of the presence of several non-symmetry
related unactivated C–H bonds), chemoselectivity (both simple arenes can react with
the catalyst at various parts of the catalytic cycle to generate homocoupled products
as well as the cross-coupled product) and ﬁnally reactivity (both C-H bonds have
relatively inert electronic properties).270 A route to homocoupled products via a
dehydrogenative arylation of functionalized (hetero)arenes has also been developed,
with improved regioselectivity achieved through the installation of directing groups;
however, stoichiometric amounts of oxidants were needed in these reactions.271–274
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Scheme 5.4: Inter- (a) and intramolecular (b) dehydrogenative arylation reactions
The ﬁrst example of a direct arylation reaction using aryl halide coupling reagents
was disclosed by Ames et al.275–277 During an attempt to perform a Heck reaction
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between aryl bromide (22) and alkene (23), product (24), resulting from the in-
tramolecular cyclization of aryl bromide (22) via a direct arylation reaction, was
obtained (Scheme 5.5). Further experiments revealed that alkene (23) was not involved
in the reaction. The conditions were further optimized, and a new route to several
related heterocycles was developed.
X
N
NBr OEt
O
Pd(OAc)2 (5.0 mol%)
Et3N (5.0 equiv)
MeCN, 150 °C, 5 h
X = O, NH
X
N
N
X = O    15% yield
X = NH  55% yield
22
23
24
Scheme 5.5: An intramolecular direct arylation of simple arenes and aryl bromides by
Ames et al.275–277
The intramolecular reaction of arene C–H bonds with aryl halides was greatly
studied by Fagnou et al. and an early example involved an intramolecular direct
arylation of the C–H bond of substituted benzenes (25) with aryl bromides/chlorides
to form tricyclic biaryls (26) (Scheme 5.6).278,279
  Pd(OAc)2 (5 mol%)
K2CO3 (2 equiv)
DMA, 145 °C, 14 h
O
Br
H
PhDave-Phos (10 mol%)
O
R
R
R= Me, OMe, CF3, 
      F, Cl, Br, H
92 - 98%
25 26
Scheme 5.6: An intramolecular synthesis of biaryls via direct arylation by Fagnou et
al.278
Commonly, C–H palladation is more favored with electron-rich (hetero)arenes and
although debated, the proposed mechanism for many of these reactions involves elec-
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trophilic aromatic substitution (SEAr). For instance ﬁve membered heteroaromatics
(27) undergo a C–H palladation reaction due to their high nucleophilicity (Scheme
5.7).
Y H
Ar PdII X
Y H
PdII
HX
Y ArY PdII
Pd(0)
27 28 29 30 31
X
Ar
Ar
Scheme 5.7: General electrophilic aromatic substitution (SEAr) for direct arylation
mechanism of heteroarenes
Electrondeﬁcient or electron-neutral aromatics are not prone to undergo direct
arylation through the above electrophilic substitution mechanism.280 Fagnou et al.
established a complementary catalytic system for these compounds. In these reac-
tions polyﬂuorinated biaryl compounds were synthesized through the arylation of
polyﬂuoroaromatic compounds with various aryl halides employing a Pd(OAc)2 and
S-Phos ligand ligand catalyst system with K2CO3 as a base.281 Kinetic isotope eﬀect
studies supported the postulate that these reactions proceed through a concerted
metallation deprotonation (CMD) mechanism in which carbon-metal bond formation
and carbon-hydrogen bond breakage take place simultaneously282 (Scheme 5.8).
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Scheme 5.8: General concerted metallation deprotonation (CMD) mechanism
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Fagnou et al. also described the intermolecular direct arylation of electron-neutral
benzene (17), used in excess, by aryl bromides (35) with a catalyst system consisting
of Pd(OAc)2, the DavePhos ligand and pivalic acid as an additive and K2CO3 as a
base. The broad scope of this reaction was demonstrated by the successful reaction
of a variety of aryl bromides with diverse electronic and steric properties to generate
high yields of the biaryl products (36); however, the reaction was not eﬃcient with
aryl chloride and aryl iodide substrates.283 Pivalic acid was shown to operate as a
proton shuttle in the catalytic cycle.283
H Br
R R
Pd(OAc)2 (2 mol%)
DavePhos (2 mol%)
PivOH (30 mol%)
K2CO3 (2.5 equiv)
DMA, 120 °C
(30 equiv) 63-85%
17 35 36
Scheme 5.9: Intermolecular direct arylation of unactivated benzene
The onset of the catalytic cycle is the oxidative addition of the palladium(0)
complex to the aryl bromide (37) to provide the aryl-substituted Pd(II) species (38)
(Scheme 5.10). Deprotonation of pivalic acid (39) by the carbonate base forms the
pivalate anion (40) that can undergo ligand exchange on complex (38) to generate KBr
and species (41). Coordination of the benzene ring (17) and concerted proton transfer
from the benzene and metallation occurs in the next step (transition state 42).284,285
Dissociation of the pivalic acid from (43) generates (44), followed by reductive
elimination to form the biaryl product (34) and regenerate the Pd(0) catalyst.
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Scheme 5.10: Catalytic cycle of palladium-catalyzed direct arylation of benzene
Despite many advances in C–H activation reactions, chemo- and regioselectivity
continue to be a hurdle. For instance the C–H activation of substituted, unsymmetrical
arenes is challenging because of the presence of non-equivalent hydrogen atoms in the
molecule. Although these hydrogen atoms will have diﬀerent acidities and reactivities,
unless a reaction can be done exclusively with only one of them, mixtures of products
will result. Likewise, similar considerations apply for unsymmetrically substituted
heteroaromatics. For example, for 3-methylthiophene (45), while there is a suﬃcient
diﬀerence in reactivity so that none of the C4 arylated product is formed, the reactivity
of the protons at the C2 and C5 positions is similar enough that a mixture of
regioisomers (46 and 47) is produced in the direct arylation reaction with aryl
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bromide substrates286 (Scheme 5.11).
S HH 25 SHS HPd(P(t-Bu)3]2
Ph-Br
n-Bu4NBr
μW, 170 °C
8 min, DMF, 39%45 46 47
3.3 1
Scheme 5.11: Regioselectivity in C–H arylation of 3-methylthiophene
Various strategies have been employed to overcome these hurdles and provide some
control over the regio- and chemoselectivity. The utilization of blocking groups at the
position with competitive reactivity or the employment of steric bulk at one position
have resulted in improved regioselectivity in direct arylation reactions. For example
blocking one of the α-positions of a thiophene (C2 of 48) with a methyl group results
in the formation of only one regioisomer (50) in a direct arylation reaction with aryl
halides287 (Scheme 5.12). Other functional groups, such as acetyl, nitrile, n-butyl
and sulfonyls at the C2 position of thiophenes and furans can be used for the same
purpose and have been reported by Doucet et al.287,288
S H
DMA, KOAc
20 h, 150 °C
48 49 50
X
SPd(OAc)2
X = I, Br
R
R
R = CN, CHO, OMe 41-92%
Scheme 5.12: Regioselectivity in C–H arylation of 2-methylthiophene
An example of the use of steric bulk to control regioselectivity is shown in Scheme
5.13. In these reactions, a direct arylation reaction with 3-thiophenecarboxaldehyde
(51) produced a mixture of regioisomers (53) and (54), with a 4:1 preference for C2
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arylation. When the C3 aldehyde was converted to the bulkier diethyl acetal group in
compound (52), direct arylation at the less sterically encumbered C5 position was
favored, giving a 1:3 ratio of products (53):(54) following deprotection of the acetal.289
51 53 54
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Scheme 5.13: The eﬀect of steric bulk on the C–H arylation of 3-substituted thiophene
Although advances have been made in controlling the regio- and chemoselectivity
of direct arylation reactions, examples with complete control are somewhat rare. These
limitations highlight the need for alternative methods that show better selectivity yet
still do not rely on organometallic coupling partners.
5.3.3 Decarboxylative Cross-Coupling Reactions
In light of the regioselectivity and chemoselectivity limitations of direct arylation reac-
tions and the issues stemming from the need for organometallic coupling partners in
classical palladium-catalyzed cross-coupling reactions, decarboxylative cross-coupling
reactions are an attractive alternative. Decarboxylative cross-coupling reactions were
developed based on the substitution of carboxylic acids for either the organometallic
reagents of traditional cross-coupling reactions or the aryl halides of Heck-type cou-
plings. Carboxylic acids and their related salts are stable to storage, readily available,
and easy to handle, unlike some of their organometallic counterparts. The byproduct
from a decarboxylative cross-coupling reaction is carbon dioxide gas, rather than the
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metal salt byproducts formed from traditional cross-coupling reactions.
The ﬁrst example of a decarboxylative coupling reaction was established by Nilsson
et al. in 1966 with a super-stoichiometric copper-catalyzed reaction of iodoarenes
and nitrobenzoic acids in low yield and limited substrate scope.290 These reactions
remained unstudied for about 30 years until Steglich et al. reported an intramolecular
decarboxylative coupling towards the synthesis of the alkaloid heterocycle Lamellarin
G291 and later with higher yield and reduced reaction time for the synthesis of Lamel-
larin L292 (Scheme 5.14, 56). Although the reaction did not require a metal additive
as a co-catalyst, a stoichiometric amount of palladium was employed.
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Scheme 5.14: An early example of palladium-catalyzed decarboxylative cross-coupling
reaction
A breakthrough towards palladium-catalyzed decarboxylative cross-couplings was
reported by Myers et al. in a Heck-type reaction.293 Decarboxylative coupling occurred
between ortho-substituted carboxylic acids (57) and acrylates/styrenes (58) utilizing
a stoichiometric amount of silver carbonate that served both as an oxidant and
base. Heteroaromatic and electron-poor and -rich aromatic acids were tolerated in
the reactions. The oleﬁn substrate scope was expanded by the same group to 5-7
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membered cyclic α,β-unsaturated ketones and ortho-substituted benzoic acids that
are more challenging in traditional Heck-coupling reactions.294
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R2
57 58
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Ag2CO3 (3.0 equiv)
DMF:DMSO (95:5)
120 °C, 0.5 - 3 h
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59
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Scheme 5.15: Intermolecular decarboxylative coupling of ortho-substituted benzoic
acids and oleﬁns by Myers et al.
There are several successful protocols for decarboxylative cross-couplings diﬀering
in the substrate scope and utilization of mono- or bimetallic catalytic systems.
Gooßen et al. established the ﬁrst intermolecular decarboxylative cross-coupling
reaction of a range of ortho-substituted benzoic acids and aryl halides using a Pd/Cu
catalytic system for the formation of biaryls.295 The method was envisioned based on
the limitations of Nilsson’s protocol where super-stoichiometric amounts of copper were
required and limited substrates were applicable.290 The early example employed a sto-
ichiometric amounts of copper (1.5 equiv) and catalytic palladium(II) acetylacetonate
(2 mol%) for the decarboxylative coupling of ortho-nitrobenzoic acids with a range of
aryl bromides at a reaction temperature of 120 °C.295 Gooßen’s group also developed
modiﬁed reaction conditions that employed catalytic amounts of both palladium and
copper (a more stable and less active copper complex) at temperatures295 as shown in
Scheme 5.16. The requirement for ortho-substituted benzoic acids still remained the
limitation of this method. Further optimization expanded the reaction scope to other
aryl coupling partners such as aryl chorides,296 tosylates297 and triﬂates.298 The use
of aryl triﬂate coupling partners circumvents the need for ortho-substitution of the
benzoic acids.298,299
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Scheme 5.16: Decarboxylative cross-coupling using copper co-catalyst by Gooßen et
al.
The mechanism proposed by Gooßen for the bimetallic reactions discussed above is
illustrated in Scheme 5.17. Initially copper carboxylate (63) is formed through anion
exchange between copper salt (61) and carboxylate anion (62). This leads to the
extrusion of CO2 and the generation of organocuprate species (64). The other part of
the catalytic cycle involves a typical palladium-catalyzed process where the oxidative
addition of a Pd(0) complex into the aryl halide (7) forms intermediate (65). Through
the coordination of the two catalytic cycles, transmetallation of the organocuprate
species (64) with the aryl-substituted Pd(II) intermediate (65) generates the biarylated
palladium(II) species (66). In the last step, reductive elimination of intermediate
(66) results in the formation of cross-coupled biaryl product (67) and regenerates the
Pd(0) catalyst.
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Scheme 5.17: Mechanism of co-catalyzed decarboxylative cross-coupling proposed by
Gooßen
Another useful protocol was developed by Becht et al. where no copper catalyst was
used but instead silver carbonates were applied. The decarboxylative cross-coupling
occurred between electron-rich ortho-arene carboxylic acids and aryl iodides300 or
diaryliodonium salts.301 Similar to Gooßen’s original protocol, this method also
required stoichiometric amounts of silver carbonate. It was proposed that the silver
salt serves as a base and possibly as a co-catalyst through coordination to the carboxylic
acid. Similar reactions were developed by Wu et al. through the use of a PdCl2 catalyst
and the BINAP ligand and stoichiometric amounts of silver carbonate.302
In the same year that Gooßen disclosed the bimetallic decarboxylative cross-
coupling, Forgione et al. revealed a decarboxylative cross-coupling of aryl bromides
and heteroaromatics while attempting direct arylations of heterocycles utilizing car-
boxylic acids as blocking groups at the C2 position of heteroaromatics.286 The reaction
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diﬀered from previous decarboxylative cross-couplings in several aspects; only pal-
ladium was employed as the catalyst and tetrabutylammonium chloride was used
presumably as a phase-transfer catalyst. One great advantage of this methodology
involved the short reaction time (8 minutes) through microwave irradiation (Scheme
5.18). In a follow-up study by the same group, the substrate scope was expanded to
aryl chlorides, iodides and triﬂates.303
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Scheme 5.18: Decarboxylative cross-coupling of heteroaromatics using mono catalyst
The proposed mechanism (Scheme 5.19) starts with the typical oxidative addition
of the palladium(0) complex into the aryl halide to provide the aryl palladium(II)
intermediate (71). A ligand exchange forms intermediate (73) through displacement
of the halide with heteroaryl carboxylate (72). Three mechanistic pathways were
postulated from this step. In path A direct decarboxylation and extrusion of CO2
result in generating C2 palladated species (74). This intermediate would undergo
reductive elimination to form the desired heteroaryl product (75). Benzoic acids or
heteroaromatic-3-carboxylic acids failed to cross-couple under these conditions and
therefore path A would not be a plausible mechanism. Instead, the electron richness
of the heteroaromatic and the carboxylate as the directing group in path B assist
the electrophilic palladation of the heteroaromatic to form intermediate (76). To
re-obtain the aromaticity of the heteroaromatic ring, CO2 extrusion occurs to provide
bisarylated palladium species (74) that can undergo reductive elimination to form the
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desired product (75). The formation of trace amounts of C3 palladation by-product,
if C3 of the heteroaromatic is hydrogen, suggested path C as a possible mechanism.
Path C still utilizes the π-nucleophilicity of the heteroaromatic in which intermediate
(77) is formed through C3 electrophilic palladation. A C3 to C2 migration forms
the more stable intermediate (76) that goes through the same CO2 extrusion and
reductive elimination such as path A. In case, where R is hydrogen, a deprotonation
at C3 provides the rearomatized complex (78) that undergoes reductive elimination
to generate (79). This intermediate can re-renter the catalytic cycle to form the
2,3-biarylated compound. Several parameters such as base and catalyst were evaluated
and the condition demonstrated on scheme 5.18 were utilized as the optimized reaction
condition. In addition both electron-poor and -rich aryl halides were found to be
tolerated.
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Scheme 5.19: Mechanism of decarboxylative cross-coupling proposed by Forgione,
Bilodeau et al.
Decarboxylative cross-coupling reactions were established as convenient and alter-
native methods for the formation of carbon-carbon bonds. Decarboxylative coupling
circumvent the regioselectivity issues arised from some direct arylation reactions and
take advantage of easily available carboxylic acids. However, these methods require
extend optimizations to overcome their own limitations such as proto-decarboxylation.
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Chapter 6
Synthesis of IAPP α-Helix Mimetics:
Results and Discussion
6.1 Project Perspective
IAPP exhibits a conformational ensemble mainly populated by the disordered confor-
mations in the non-aggregated soluble state, although it diverges from an absolute
random coil by the presence of local and transient ordered structure.304 Recent mecha-
nistic studies have suggested that the pro-amyloidogenic peptide undergoes a random
coil to α-helix conformational conversion during the initial phase of self-assembly
where the helical intermediates could be on-pathway to amyloid formation.304,305
According to this model, α-helix formation and self-association of helical segments are
linked and accelerate self-assembly,305 with similar driving forces to those of coiled
coil motif formation. Consequently, the accelerated self-assembly generates a high
local concentration of the amyloidogenic domain of IAPP (segment 20-29, Figure
6.1), which has a high propensity to adopt a β-structure, favoring the formation of
cross-β-sheet assemblies en route to amyloid formation. Consistently, IAPP was shown
to adopt a helical structure spanning approximately residues 8 to 19 (Figure 6.1) when
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the peptide was bound to model membranes306,307 or glycosaminoglycans (GAGs),308
and the interactions accelerated the rate of IAPP amyloid ﬁbril formation.
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Figure 6.1: The primary sequence of IAPP representing the helix region and random
coils
According to the helical intermediates hypothesis described above, an alternative
strategy to control the formation of IAPP amyloid ﬁbrils would be to design molecules
that target and stabilize the transient helical segment 8-19 of IAPP, modulating
the helix-assembly process. This approach could inhibit the formation of oligomeric
and ﬁbrillar aggregates by over-stabilizing the helical intermediates, not allowing the
propagation of the β-sheet conformation from the 20-29 domain of IAPP. Recent
studies using membrane models have shown that, indeed, IAPP can be trapped in a
non-amyloid prone helical conformation.305,307,309 Alternatively, as reported for lipids
and GAGs, helical targeting ligands could potently accelerate the self-assembly of IAPP
into β-sheet-rich amyloid ﬁbrils by initially shifting the conformational equilibrium
towards the α-helix, without overly stabilizing the helical motif. Considering that
oligomers are the most potent cytotoxic proteospecies,213 both pathways will decrease
the toxicity induced by the amyloidogenic process of IAPP, either by blocking the
formation of pre-ﬁbrillar assemblies (α-helix over-stabilization) or by accelerating the
structural conversion of oligomers into less cytotoxic amyloid ﬁbrils.
In the present work, small molecules that are chemically and spatially paired with
the residue side chains conﬁned to one side of the helical conformer of IAPP have been
developed. Consequently, the helical motif of IAPP can be stabilized or the conversion
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of toxic oligomers into less toxic amyloid ﬁbrils can be accelerated. Eventually, the
synthesized scaﬀolds can be densely substituted with a wide range of functional groups
through modular synthetic routes. In the current work, the molecules produced by
our synthetic approach were tested as modulators of the formation of IAPP ﬁbrils as a
proof-of-concept. However, the general synthetic route can be used for the preparation
of molecules tailored with diﬀerent side-chain residues to stabilize and/or interact
with the α-helix of other proteins for various applications.
6.2 Design of the Small-Molecule Mimetics
The synthesis of α-helical templates of proteins was established and widely applied
by Hamilton et al. and has proven to be an attractive approach towards interact-
ing/stabilizing the α-helices of proteins. Functionalized terphenyls217,230,231 represent
one such scaﬀold with a reported application as a mimic of the α-helix side chain of
smooth muscle myosin light chain kinase (smMLCK) to disrupt its interaction with
calmodulin (CaM) (Figure 6.2, b).310
Binding of ligands to the helical motif largely results from the interaction of the
ligand with the amino acid side chains projecting on one face of the α-helix and spaced
three or four residues away from each other, referred to as i, i+4 and i+7. In the
transient helical conformation of IAPP comprising residues 8-19, residues Arg 11, Phe
15 and His 18 are oriented on one face of the α-helix306 and represent the key motif
that will be targeted to stabilize the transient α-helix of IAPP (Figure 6.2, a). As
hypothesized from coiled coil motifs formation, the presence of hydrophilic side chains
(Arg, His) will provide the speciﬁcity of the interaction whereas the hydrophobic
residue Phe will contribute to the thermodynamic stability of the interaction by
hydrophobic core packing.
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R1
X
R3
R2
i
i + 4
i + 7
Arg
Phe
His
(a) (b)
X = C, N
Figure 6.2: Representation of the side chain helical motifs. (a): Ribbon representation of IAPP
α-helix (PDB ID: 2KB8);311 (b): 3,2’,2”-Tris-substituted terphenyl template
Although used as starting points for the synthesis of small-molecule mimetics of
α-helices, terphenyls and several of their analogs suﬀer from long synthetic pathways
(10 sequential and 7 linear steps for the synthesis of 3,2’,2”-tris-substituted terphenyl
templates).310 Facile modiﬁcations of the side-chain R groups are crucial in order to
optimize the peptide-ligand interactions in an eﬃcient manner. To avoid the long
synthetic routes required to prepare the terphenyls yet to take advantage of the ability
of such templates to interact with the side chain α-helix of IAPP, we attempted to
design a new template that would be amenable to a ﬂexible synthetic approach to
quickly construct the ligands in an eﬃcient and modular manner.
Bioisosterism is a strategy that has been widely applied in medicinal chemistry for
the rational design of potential drugs. This strategy involves the substitution of atoms
or groups in a molecule with others possessing similar physicochemical properties
to give new molecules with similar or improved biological properties. Bioisosteric
replacement allows for modiﬁcations to improve a compound’s solubility, potency,
bioavailability and safety. Parameters such as size, electronic distribution, shape,
functional group reactivity, and lipid and water solubility play a role in the group’s or
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atom’s ability to function as a bioisostere.135,136 Ring equivalents are one of the classes
of bioisosteres with the most extensive use in drug discovery and development. Under
this classiﬁcation, various heterocycles often function as bioisosteres for benzene rings
or other heterocycles. Examples of ring bioisosterism in various anti-inﬂammatory
drugs are illustrated in Scheme 6.1.135
N
N
H3C S
CF3
O O
NH2
N
O
S
O O
NH2
CH3
N
S
O O
N
Cl
CH3
H3C
Celecoxib Valdecoxib Etoricoxib
Scheme 6.1: Ring equivalent bioisosterism in three classes of anti-inﬂammatory drugs.
Same colored squares indicate ring equivalents135
Relying on the bioisosterism of thiophene and benzene,135,312 a template molecule
related to the terphenyl scaﬀold was designed by maintaining the two terminal benzene
rings and replacing the central benzene ring with a thiophene (Figure 6.3, b).
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Figure 6.3: Representation of the proposed thiophene template helical mimetics. (a):
Ribbon representation of IAPP α-helix (PDB ID: 2KB8);311 (b): 2,5- Diaryl substituted thiophene template
The replacement of benzene with thiophene allows for several signiﬁcant synthetic
advantages. A ﬁve-membered heteroaromatic core scaﬀold (Figure 6.3, b) aﬀords
a ﬂexible synthetic approach in which substituent modiﬁcations can be made in
a modular manner while avoiding the long synthetic routes that have been used
previously for the synthesis of terphenyls.310 The presence of the heteroatom introduces
changes in reactivity that allow convenient chemo- and regioselective pathways that
are unavailable in the synthesis of the terphenyl compounds.
6.2.1 Synthesis of the Key Intermediate
Ideally, the side chain positions of the synthetic scaﬀolds would interact with the
amino acid side chains of i, i+4 and i+7 in order to stabilize the α-helix of the
protein. The i+4 position of the IAPP is occupied with a phenylalanine residue. To
increase the versatility of the synthesized molecules, two commercially available 3-
substituted thiophenes, 3-methyl-2-thiophenecarboxylic acid (85) and methyl 3-amino-
2-thiophenecarboxylate (86), were employed. The methyl group at the C3 position
of thiophene carboxylic acid (85) would provide hydrophobic interactions with the
phenylalanine residue of the IAPP, while the amino group of the thiophenecarboxylate
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(86) could be further functionalized to examine the interaction of bulkier groups at
this position as well as other possible interactions such as hydrogen bonding.
S
OH
O
S
O
O
NH2
85 86
HH
Scheme 6.2: Two commercially available substituted thiophenes
From a synthetic aspect, these commercially available thiophenes provide readily
accessible starting materials from which highly regioselective synthetic routes can be
established. Moreover, thiophene is more electron-rich than a typical benzene ring
and therefore by using properly designed reaction conditions, a regioselective synthesis
would be achieved. Functionalization of the amino group at the C3 position of methyl
3-amino-2-thiophenecarboxylate (86) provides one of the key intermediates for the
synthesis of diaryl substituted thiophenes and serves as a protecting group to allow
further cross-coupling reactions to be carried out.
The primary amine of the thiophene carboxylate (86) was initially functionalized
with a mesyl group. Previous attempts in our group to functionalize the primary
amine of the same thiophene with a tosyl group using strong bases such as sodium
hydride (1 equiv) generated a mixture of products due to decomposition of the starting
material. Therefore, an excess of pyridine, which also served as the base, was used
as the reaction solvent along with an optimized 1.5 equivalents of mesyl chloride to
obtain the mesylated amine (87) in 90% yield (Scheme 6.3). The reaction could also
be performed on a multi-gram scale and the product was puriﬁed via recrystallization.
Methylation of the secondary sulfonamide (87) was then performed based on the
protocol reported by Taddei et al.313 The methylated sulfonamide (88) obtained from
this method, which employs Cs2CO3 as the base and methyl iodide, did not require
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any chromatographic puriﬁcation and was produced in excellent yield (95%) (Scheme
6.3).
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NH2
O
OMe
S
Cl
O O
S
NH
O
OMe
SO
O90%
pyridine (0.8 M)
(1.5 equiv)
50 °C, 1 h
S
N
O
OMe
SO
O
MeI (2.5 equiv)
Cs2CO3 (1 equiv)
DMF, 40 °C, 24 h
95%
86 87 88
Scheme 6.3: Mesylation and methylation of methyl 3-amino-2-thiophenecarboxylate
6.2.2 Synthesis of 2,5-Diaryl Substituted Thiophenes
The synthesis of diaryl substituted heteroaromatics has been previously accomplished
through various palladium-catalyzed cross-coupling reactions. The predominant strate-
gies involve the utilization of organometallic precursors and/or result in the formation
of symmetrically substituted heteroaromatics.272,312,314–317 For example, palladium-
catalyzed C–H activation reactions have emerged as attractive methods for the forma-
tion of carbon-carbon bonds between heteroarenes and aryl halides without the use of
organometallic derivatives.318–335
S
R
HH 25 S
R
ArH S
R
HArAr-X
89 9190
[Pd]
base
MinorMajorR = Cl, Br, Alkyl, OMe,
       CHO, CH2OH
Scheme 6.4: Regioselectivity in the C–H activation reaction of 3-substituted thio-
phenes286,289,336
However, the main limitation of the C–H functionalization of 3-substituted thio-
phenes is the formation of mixed arylated products at the C2 and C5 positions (Scheme
6.4).286,336
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To avoid this limitation yet still take advantage of the C–H arylation strategy while
controlling the regioselectivity of the products, the previously outlined commercially
available 3-substituted thiophene 2-carboxylic acids have been used in combination
with a decarboxylative cross-coupling reaction (Scheme 6.5). Decarboxylative cross-
coupling reactions have been developed as a powerful method for the formation of
carbon-carbon bonds between aliphatic and aromatic carboxylic acids and aryl or vinyl
substrates.337–342 Decarboxylative arylation processes circumvent the requirement of
organometallic building blocks343–345oﬀering readily available, inexpensive and easy to
use coupling partners. In this view, we performed palladium-catalyzed decarboxylative
cross-coupling reactions of thiophene carboxylic acids and various aryl bromides.29,286
S CO2R
R1
H
decarboxylative 
cross-coupling
Pd (0)
Br R2
S
R1
H
R2
C-H arylation
Pd (0)
R3
Br
S CO2R
R1
R3
92 9394
R = Me R = H
Scheme 6.5: Two methods of palladium-catalyzed cross-coupling reactions286,346
The combination of both the C–H arylation and decarboxylative cross-coupling
reactions allow for a short and modular synthetic pathway through which a large
library of α-helix mimetic compounds can be readily synthesized.
6.2.3 Synthetic Pathways
Two pathways have been envisaged for the preparation of 2,5-diarylated thiophenes
(99), diﬀering only in the order of the two diﬀerent coupling reactions.
As illustrated in Scheme 6.6, route A utilizes C5-arylation of the substituted
thiophene methyl ester (88) resulting in aryl-thiophene intermediate (95) followed
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by saponiﬁcation to provide carboxylic acid (96). Decarboxylative cross-coupling of
acid (96) results in the formation of the desired 2,5-diaryl substituted thiophene (99).
Alternatively, initial saponiﬁcation of ester (86) in pathway B provides the thiophene
carboxylic acid intermediate (97) that can undergo decarboxylative cross-coupling to
aﬀord aryl-thiophene (98). This is followed by C5-arylation to provide the desired
2,5-diaryl substituted thiophene (99).
Initially, in order to compare the eﬃciency of each pathway, both routes were
carried out using the same substituted arylbromides (2- and 3-bromobenzonitrile).
Interestingly, both the C5-arylation and decarboxylative cross-coupling steps in route
A resulted in lower yields compared to route B, giving overall yields of 2,5-diaryl
substituted thiophene (99a) of 12 and 42% (R1=CN, R3=CN), respectively. In order
to examine whether the superior eﬃciency of route B was general, other functionalized
aryl halides were also employed in both pathways. Scheme 6.6 shows one other
example using 2-bromobenzaldehyde and 3-bromoanisole in which, once again, a
higher overall yield was observed with route B compared to route A (59 vs. 29%,
respectively, R1=OMe, R3=CHO). Route B was therefore chosen for the preparation
of the remaining analogues.
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Scheme 6.6: Comparison of the two synthetic pathways
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6.2.4 Decarboxylative Cross-Coupling Reaction of Thiophene
Forgione et al. have reported optimized conditions for the decarboxylative cross-
coupling of various heteroaromatics.286,303 The reaction optimization was developed
using N -substituted pyrrole carboxylic acids and altering various parameters such
as base, solvent, catalyst, aryl substrate and heating system (thermal vs. microwave
heating). The optimized reaction conditions employ microwave heating with a reaction
time of only 8 minutes and oﬀers a strong control of regioselectivity. Some examples
of the molecules generated with this methodology are illustrated in Scheme 6.7.
N
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74%
O
86%
S
63%
N O
88% 41%
N
S
23%
X
Y
OH
O
Z
X
Y
Z
Br
Pd[P(t-Bu)3]2 (5 mol%)
n-Bu4NCl  H2O (1 equiv)
Cs2CO3 (1.5 equiv)
DMF, μW, 170 °C, 8 min
RR
2 equiv
Scheme 6.7: Examples of decarboxylative cross-coupling reaction products by Forgione
et al.286,303
These optimized conditions for decarboxylative cross-coupling reactions were
employed to generate the intermediates towards the synthesis of 2,5-diaryl substituted
thiophenes. The required thiophene carboxylic acids underwent decarboxylative
cross-coupling with a variety of aryl-bromides to produce the corresponding arylated
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thiophenes (Table 6.1).
The reaction of both 3-methyl-2-thiophenecarboxylic acid (85) and 3-(N -methyl
methylsulfonamido)thiophene-2-carboxylic acid (97) with electron-poor and -rich aryl
bromides were performed and the results illustrate that both types of aryl bromide
substituents are well tolerated in the reaction.
S
OH
O
R2
S
R2
R1
R1
Br
98a - f100
Pd[P(t-Bu)3]2
n-Bu4N+Cl-
Cs2CO3, DMF
μW, 170 °C, 8 min
R2 = Me            85
R2 = N-MeMs   97
Entry R2 R1 Product Yield (%)[a]
1 N -MeMs CN 98a 58
2 N -MeMs OMe 98b 68
3 N -MeMs CO2Et 98c 66
4 Me CN 98d 69
5 Me OMe 98e 75
6 Me CO2Et 98f 61
Table 6.1: Synthesis of monoaryl substituted thiophenes. [a]Isolated yields. Condition: thiophene
carboxylic acid (2 equiv), aryl bromide (1 equiv), Pd[P(t-Bu)3]2 (0.05 equiv), n-Bu4N+Cl− (1 equiv), Cs2CO3 (1.5
equiv), anhydrous DMF, 8 min microwave irradiation at 170 °C
These intermediate scaﬀolds provide one terminal and the central part of the ﬁnal
desired scaﬀolds mimicking i and i+4. The variety of R1 substituents would help
probe the requirements for eﬀective interaction with the i position of the α-helix of
IAPP while the R2 functional groups provide potential hydrophobic or hydrogen bond
interactions with the i+4 position of the target peptide.
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6.2.5 C–H Activation Reaction of Aryl Thiophenes
To obtain the desired 2,5-diaryl substituted thiophene templates, the C5 positions
of the intermediate compounds resulting from the decarboxylative cross-coupling
reactions (98a-f) were subjected to a C–H arylation reaction. Although the C5
position of these intermediates is more reactive than the C4 position due to the higher
acidity of the proton on C5, complete regioselectivity can not be attained without an
appropriate choice of reaction conditions. A survey of the literature revealed that a
direct arylation reaction reported by Fagnou et al. would meet our requirements.
Fagnou and co-workers have developed C–H activation reaction conditions utilizing
a wide range of heteroaromatics and aryl bromides.346 The reaction was speciﬁcally
eﬀective when the C2 position of the heteroaromatic was blocked, providing regiose-
lective products. Some examples produced from this methodology are illustrated in
Scheme 6.8.
S
EtO2C
63%
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63%
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29%
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52%
CHO
Me MOM
YH Y
Br
  Pd(OAc)2 (2 mol%)
PCy3 HBF4 (4 mol%)
PivOH (30 mol%)
K2CO3 (1.5 equiv)
DMA, 100 °C
R
R
1 equiv
Scheme 6.8: Examples of the C–H activation reaction reported by Fagnou et al.346
Direct arylation reactions previously reported from our group utilized Fagnou’s
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conditions with slight modiﬁcations for the eﬃcient synthesis of thienoisoquinolines.347
The modiﬁed conditions involved a higher loading of the palladium source and ligand
(5 mol% and 10 mol%, respectively). The products from the decarboxylative cross-
coupling reaction were subjected to the optimized C–H activation conditions to eﬀect a
regioselective C–H activation at the C5 position of the 2-arylthiophene to generate 2,5-
diaryl substituted thiophenes. A diverse range of products was generated using both
the 3-sulfonamide-2-arylthiophenes and 3-methyl-2-arylthiophenes. The results of reac-
tions of 3-methyl-2-arylthiophenes with a range of arylbromides are shown in Table 6.2.
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S
R1
98d - f
S
R1
R3R3
Br
99c - m
  Pd(OAc)2
PCy3 HBF4
PivOH, K2CO3
DMA, 16 h
101
H
99x
Entry R3 R1 Product Yield (%)[a]
7 CN OMe 99c 23
8 CHO OMe 99d 79
9 CF3 OMe 99e 81
10 CO2Et OMe 99f 73
11 CO2Et CO2Et 99g 94
12 CN CO2Et 99h 81
13 CF3 CO2Et 99i 72
14 CHO CO2Et 99j 65
15 CF3 CN 99k 47
16 CN CN 99l 50
17 H CN 99m 62
18 OMe CO2Et 99x 9
Table 6.2: Synthesis of 2,5-diaryl substituted thiophenes (Series 1) [a]Isolated yields.
Conditions: 2-aryl thiophene (1 equiv), aryl bromide (2 equiv), Pd(OAc)2 (0.05 equiv), PCy3.HBF4 (0.1 equiv),
PivOH (0.3 equiv), K2CO3 (1.5 equiv), anhydrous DMA, 16 h thermal heating at 100 °C
From these results, it became apparent that the reaction worked well with electron-
deﬁcient aryl bromides. However, electron-rich aryl bromide partners exhibited
diminished or no reactivity. For example, the above reaction provided 9% yield with
2-bromoanisole (99x). These results diﬀer from those observed in Fagnou’s work
since they observed decreased reactivity for electron-deﬁcient aryl bromides with
some coupling partners.346 More investigation is required to rationalize this change in
reactivity.
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The results from the reactions of 3-sulfonamide-2-arylthiophenes with a range of
aryl bromides under the same reaction conditions are summarized in Table 6.3.
98a - c
S
N
R1X
R3
X
R3
Br
99a, b
  Pd(OAc)2
PCy3 HBF4
PivOH, K2CO3
DMA, 16 h
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SH
N
SO
O
R1
S
O
O
99n - w
Entry X R3 R1 Product Yield (%)[a]
19 C CHO OMe 99b 87
20 C CN OMe 99n 75
21 C CF3 OMe 99o 78
22 C CO2Et CN 99p 77
23 C CHO CN 99q 64
24 C CF3 CN 99r 95
25 C CN CN 99a 72
26 C CHO CO2Et 99s 65
27 C CF3 CO2Et 99t 75
28 C CN CO2Et 99u 93
29 N - CO2Et 99v 10
30 C OMe CO2Et 99w 14
Table 6.3: Synthesis of 2,5-diaryl substituted thiophenes (Series 2) [a]Isolated yields;
Conditions: 2-aryl thiophene (1 equiv), aryl bromide (2 equiv), Pd(OAc)2 (0.05 equiv), PCy3.HBF4 (0.1 equiv),
PivOH (0.3 equiv), K2CO3 (1.5 equiv), anhydrous DMA, 16 h thermal heating at 100 °C
Once again the electron-rich aryl bromides provided lower yields than electron-poor
ones. Examples are the reaction of 3-sulfonamide-2-arylthiophene with 2-bromopyrdine
and 2-bromoanisole, which generated products (99v) and (99w) in only 10% and 14%
yield respectively.
The results from the above reactions demonstrated that the electron density of the
133
existing 2-aryl group on the thiophene did not aﬀect the yields of the C5 arylation
reaction. However, the identity of the C3 substituent of the thiophene had a small
eﬀect on the yields, giving slightly higher yields for the 3-sulfonamide-2-arylthiophene
products.
All products were characterized by NMR and high resolution mass spectrometry.
For additional conﬁrmation of the regioselectivity of the C–H activation reaction,
X-ray crystallography was performed on product (99n). The X-ray crystal structure
provided clear evidence that the decarboxylative cross-coupling reaction had occurred
at the C2 position and the C–H arylation reaction at the C5 position of the thiophene
(Figure 6.4).
99n
S
N
SO
O
OCN
Figure 6.4: X-ray crystal structure of a 2,5-diaryl substituted thiophene
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6.3 Evaluation of Islet Amyloid Polypeptide Modu-
lation and Cytotoxicity
6.3.1 ThT Fluorescence Assay
All synthesized 2,5-diaryl substituted thiophenes were initially investigated for their
capacity of modulating IAPP amyloid ﬁbril formation by means of the Thioﬂavin
T (ThT) ﬂuorescence assay. Thioﬂavin T is a dye containing both hydrophobic and
polar segments that forms micelles in aqueous media348 (Figure 6.5, a).
S
N
N
CH3
CH3
CH3Cl-
H3C
6.1 Å
15.2 Å


Figure 6.5: Chemical structure of Thioﬂavin T and β-sheet diagram a: Structure and
dimensions of Thioﬂavin T; b: Schematic representation of the β-sheet, R represents the side chain residue and Cα,
C and N represent the backbone of the β-sheet. Hydrogen bonds are not shown349
Among several proposed mechanisms for the binding of ThT to the ﬁbrils, Krebs
et al.349 introduced the β-sheet of the proteins responsible for the formation of the
binding channels (6.5 to 6.9 Å) where ThT (6.1 Å short axis, 4.3 Å thick) can bind
perpendicularly through its short axis (Figure 6.5, b). ThT-ﬁbril interactions maintain
the ThT structure in a ﬂat and excited conformation. Therefore, ThT dye ﬂuoresces
upon binding to protein aggregates with a cross β-sheet structure, mostly ﬁbrillar in
morphology.350
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IAPP amyloidogenesis is a nucleation-dependent polymerization process that is
characterized by a ThT-negative phase (lag-phase; around 6 h), in which the high-
energy nucleus is formed, followed by a thermodynamically favorable elongation phase
that is characterized by the rapid growth of ThT-positive ﬁbrils (Figure 5.3). Accord-
ing to the described helical intermediates, the random coil α-helix conformational
conversion occurred during the initial stage of the lag phase. Analysis of the aggrega-
tion kinetics obtained by ThT ﬂuorescence gave us early mechanistic insights about
the eﬀects of these substituted thiophenes on IAPP amyloidogenic pathway.
6.3.2 ThT Assay Results
IAPP was synthesized by solid phase peptide synthesis on a Rink amide polystyrene
resin based on Fmoc chemistry and was puriﬁed by preparative scale reversed-phase
high performance liquid chromatography (RP-HPLC) (Appendix). The ThT ﬂuores-
cence assay was performed using aliquots of IAPP dissolved in hexaﬂuoro-2-propanol
(HFIP). Following several steps including ﬁltering the solution, lyophilizing the peptide
and dissolving it in the assay buﬀer, ThT ﬂuorescence was measured after addition of
each substituted thiophene, and the results were compared to a control sample run
without the substituted thiophene. Measurements were obtained every 10 minutes over
the course of 25 hours with excitation at 440 nm and emission at 485 nm (Appendix).
Several 2,5-diaryl substituted thiophenes tested by the ThT assay had little or no
eﬀect on the kinetics of IAPP amyloid formation (Figure 6.6). Also, several of these
compounds (99i, 99j, 99n, 99o, 99p and 99t) increased the ﬁnal ThT ﬂuorescence
without aﬀecting the lag phase or the rate of amyloid ﬁbrils formation (Appendix).
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Figure 6.6: Eﬀects of 2,5-diaryl substituted thiophenes on IAPP kinetics of amyloid
ﬁbril formation monitored by ThT ﬂuorescence (Series 1). IAPP (12.5 μM) was incubated
in 20 mM Tris, pH 7.4, at 25 °C without agitation in the absence (diamond, blue) or in the presence of 12.5 μM
of compound (square, red). ThT ﬂuorescence (40 μM) was measured every 10 min over the course of 25 h, with
excitation at 440 nm and emission at 485 nm.
Among all the compounds prepared in the course of this study, only compound (99l)
(Table 6.3, entry 16) slowed the formation of ThT-positive aggregates, as observed by
the increase of the lag phase period (Figure 6.7, A) when the compound was used at an
equimolar ratio to IAPP. Moreover, compound (99l) showed concentration-dependent
inhibition of the formation of IAPP ThT-positive aggregates, with a lag phase of 15 h
at 8 molar equivalents (100 μM; Figure 6.7, B).
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Figure 6.7: Eﬀects of 2,5-diaryl substituted thiophenes on IAPP kinetics of amyloid
ﬁbril formation monitored by ThT ﬂuorescence (Series 2). IAPP (12.5 μM) was incubated in 20
mM Tris, pH 7.4, at 25 °C without agitation in the absence (A and B; circle, blue) or in the presence of 12.5 μM of
compound (99d) (A; square, red), μM compound 99l (A; triangle, green), increasing molar equivalents of compound
99l (B). ThT ﬂuorescence (40 μM) was measured every 10 min over the course of 25 h, with excitation at 440 nm
and emission at 485 nm.
At 50 and 100 μM (4 and 8 equivalents, respectively) compound (99l) also decreased
the ﬁnal ThT ﬂuorescence, suggesting that a lower amount of IAPP amyloid ﬁbrils were
formed and/or that these aggregates showed a less deﬁned cross-β-sheets quaternary
structure. We also varied the concentration of ThT ﬂuorescent dye to conﬁrm that
this inhibitory eﬀect was not the result of a displacement of ThT binding to ﬁbrillar
aggregates by compound (99l). Our results showed that in the presence of 10, 40 or
100 μM ThT, the increase of the lag-phase period observed with 12.5 μM of compound
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(99l) was very similar, strongly suggesting that this molecule was, indeed, slowing the
amyloidogenic process.
The mechanism by which this 2,5-diaryl substituted thiophene decelerates and
partially inhibits IAPP amyloid formation warrants more investigation based on these
interesting preliminary results.
6.3.3 Mono- and Di-Carboxylic Acid Substituted Aryl Thio-
phenes
IAPP is a charged peptide that displays three positive charges at physiological pH,
thus favoring electrostatic interactions with negatively charged molecules (Figure 6.8).
As a consequence, we designed several mono- and di-carboxylic acid substituted aryl
thiophenes to target one side of the transient IAPP helix that exhibits a hydrophobic
region (Phe15) surrounded by polar and/or charged residues (Arg11 and His18; Table
3). In this way, the potential interaction of positively charged Arg and partially
positively charged His side chains at i and i+7 positions of IAPP with the negatively
charged side chains of the ligands could be probed (Figure 6.8).
i
i + 4
i + 7
Arg
Phe
His
(a) (b)
S
C
R2
C
O
O
O
O
Figure 6.8: Modiﬁcations of the side chain functional groups to carboxylic acids towards
improved interaction (a): Ribbon representation of IAPP α-helix (PDB ID: 2KB8);311 (b): Di-carboxylic
acid substituted aryl thiophene template
2,5-Diaryl substituted thiophenes encompassing one or two diethyl esters on the
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aryl groups were hydrolyzed to provide the mono- or di-carboxylic acid substituted
aryl thiophenes, respectively. Scheme 6.9 exempliﬁes the reaction conditions for the
generation of a dicarboxylic acid substituted aryl thiophene (103a).
NaOH
THF, MeOH
S
CO2Et
CO2Et
99g
S
COOH
COOH
103a
94%
reflux, 1 h
Scheme 6.9: Hydrolysis of diester substituted aryl thiophenes
Subsequently, other monoester aryl substituted thiophenes were hydrolyzed using
the above conditions (Table 6.4).
S
R2
R3
COOH
103b - e
Entry R3 R2 Product
31 CN Me 103b
32 CF3 Me 103c
33 CHO Me 103d
34 CF3 N -MeMs 103e
Table 6.4: Monoacid aryl substituted thiophenes
The mono- and di-carboxylic acid substituted aryl thiophenes were then evaluated
for any eﬀects of electrostatic interactions with the positively charged residues of IAPP
at physiological pH.
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As suspected, carboxylic acid-functionalized thiophenes showed profound eﬀects
on IAPP amyloidogenesis at a 1:1 molar ratio. Interestingly, monocarboxylic acid
substituted thiophenes with a methyl group at position R2 (compounds 103b, 103c
and 103d) virtually abolished the lag phase without signiﬁcantly aﬀecting the ﬁnal
ThT ﬂuorescence. This type of aggregation kinetics suggests that these compounds
induce the formation of IAPP aggregates with lower ThT-binding capacities, indicative
of non-ﬁbrillar structure (Figure 6.9).
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Figure 6.9: Eﬀects of mono- and di-carboxylic acid aryl substituted thiophenes on
IAPP kinetics of amyloid ﬁbril formation monitored by ThT ﬂuorescence. IAPP (12.5
μM) was incubated in 20 mM Tris, pH 7.4, at 25 °C without agitation in the absence (circle, blue) or in the presence
of 12.5 μM of compound 103a (square, red) or 12.5 μM of compound 103c (triangle, green). ThT ﬂuorescence (40
μM) was measured every 10 min over the course of 25 h, with excitation at 440 nm and emission at 485 nm.
In sharp contrast, the dicarboxylic acid analogue (compound 103a) reduced the
lag phase and led to a signiﬁcant increase of the ﬁnal ThT ﬂuorescence (Figure 6.9).
This suggests that a larger amount of amyloids was formed in the presence of one
equivalent of compound (103a) and/or that these amyloid ﬁbrils exhibit a better-
deﬁned cross-β-sheet quaternary structure. These possibilities should be investigated
more to better understand the mechanism by which these molecules interact with
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IAPP.
To probe if the accelerating eﬀects of the mono- and di-carboxylic acid aryl
substituted thiophenes on IAPP amyloidogenesis were simply a result of non-speciﬁc
charge neutralization eﬀects, benzoic acid was used as a control compound. The
kinetic data for amyloid formation obtained in the presence of 12.5 μM (1 equivalent)
and 125 μM (10 equivalents) of benzoic acid are very similar to the control (Figure
6.10). Together, these data indicated that the negative charge(s) on the thiophene
scaﬀold are crucial for the modulating activity and that the nature and/or the position
of other substituents also play a key role, suggesting speciﬁc interactions. Again,
further investigation would be necessary to determine the exact mechanism by which
these derivatives modulate the formation of amyloid ﬁbrils.
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Figure 6.10: Eﬀects of benzoic acid on kinetics of IAPP amyloid ﬁbril formation
monitored by ThT ﬂuorescence. IAPP (12.5 μM) was incubated in 20 mM Tris, pH 7.4, at 25 °C without
agitation in the absence (circle, blue) or in the presence of 1 equivalent and 10 equivalents of benzoic acid (square,
red). ThT ﬂuorescence (40 μM) was measured every 10 min over the course of 25 h, with excitation at 440 nm and
emission at 485 nm.
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6.3.4 Cell Viability Assays
The cytotoxicity of IAPP species that had been pre-incubated for 20 h in the absence
or presence of selected 2,5-diarylthiophene derivatives were analyzed using rat INS-1
(β-pancreatic cell line) cells (Appendix). Cell viability was measured by the resazurin
reduction assay. Resazurin can measure the viability of bacterial and mammalian cells.
Resazurin is a non-ﬂuorescent dye that can form highly ﬂuorescent resoruﬁn when
reduced by living cells (Scheme 6.10). The cell viability was calculated from the ratio
of the ﬂuorescence of the treated sample to the control cells (non-treated).
N
O OO
O
Na+
Resazurin
N
O OONa+
Reduction
Resorufin
non-fluorescent highly-fluorescent
Scheme 6.10: Reduction of Resazurin to Resoruﬁn.
Other groups have previously reported that IAPP induces death of pancreatic cells
when the amyloidogenic peptide is directly added to the cell culture medium.202,308 In
fact, IAPP pre-incubated for 20 h without compounds decreased pancreatic β-cells
viability in a concentration-dependent manner (Figure 6.11, A). When IAPP was
pre-incubated with 1 molar equivalent of either compound (99d), (99l) or (103c),
no changes in the proteotoxic eﬀects induced by 50 μM IAPP were observed (Figure
6.11, B). However, pre-incubation of IAPP with the dicarboxylic acid substituted aryl
thiophene (compound 103a) before cell treatment abolished the cytotoxic eﬀects of
IAPP. This result suggests that this compound stimulates the formation of poorly
toxic IAPP quaternary species, mostly ﬁbrillar, according to the high ThT ﬂuorescence
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observed (Figure 6.11, B). It is noteworthy that all tested compounds were not toxic
on β-pancreatic cells when used at a concentration of 50 μM.
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Figure 6.11: Eﬀects of 2,5-diaryl substituted thiophenes on IAPP-induced toxicity
on pancreatic β-cells. (A): INS-1 cells were treated with concentrations of IAPP ranging from 0 to 100 μM
for 24 h and cell viability was measured by the resazurin reduction assay and compared to cells treated with vehicle
only (100% cell viability). (B): INS-1 cells were treated with 50 μM IAPP that had been pre-incubated for 20 h in
20 mM Tris, pH 7.4, 25 °C, in the absence or presence of one molar equivalent of the thiophene derivatives. After 24
h incubation, cell viability was measured.
It is worthwhile to perform biophysical investigations to delineate the mechanisms
by which these molecules interfere with IAPP amyloidogenic process. This study
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demonstrates that we can modulate not only the kinetics of amyloid ﬁbril formation
of an amyloidogenic peptide, but also its cytotoxicity with small molecules that were
designed to mimic/target the transient helical motif.
6.4 Future Directions
The modular and short synthetic pathway for the synthesis of 2,5-diaryl substituted
thiophenes allows for rapid installation of the aryl substituted groups on the thiophene.
Some of these side chain substituents can also be easily converted to other functional
groups. This modular synthesis is particularly advantageous in structure-activity
relationship (SAR) studies where compound modiﬁcations can lead to improved
biological activity. With this small library of 2,5-diaryl substituted thiophenes, further
diversiﬁcation of the side chain substituents will be investigated for improving the
ligand-IAPP interactions based on the biological assays. For instance, transformations
of the nitriles to amides, aldehydes to amines and methoxy groups to alcohols can
be used to access side chain functionalities that are not compatible with our chosen
conditions of palladium-catalyzed cross-coupling reactions.
S
R2
CN
CN
S
RCONH2
CONH2
S
R2
CHO
R1
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R2
R1
S
R2
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OCH3
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R2
R3
OH
N
R'
R''
Scheme 6.11: Diversiﬁcation of the side chain substituents of the aryl groups
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Despite developing a successful methodology for the arylation of thiophenes, the
current conditions are unable to eﬃciently eﬀect a C–H arylation reaction between
thiophene and electron-rich aryl bromides, which places some limitations on the
generation of various aryl substituted thiophenes. Therefore, the development of
catalytic systems capable of tolerating both electron-deﬁcient and -rich aryl halides
would be beneﬁcial.
6.5 Conclusion
There is a great interest in designing non-peptidic small molecules to interact with
proteins. Due to their essential roles in mediating protein-protein interactions, α-
helices have become attractive targets. Several classes of compounds have been
developed to mimic these ordered secondary structures and subsequently stabilize
their conformation. These developed molecules were mainly used to disrupt protein-
protein interactions. Inspired by this, we targeted IAPP, which is a peptidic hormone
that forms amyloid ﬁbrils. We have developed a modular approach using palladium-
mediated cross-coupling reactions for the synthesis of highly functionalized small
molecules based on a 2,5-diaryl substituted thiophene scaﬀold. This strategy allows us
to quickly construct ligands to screen for interaction with and stabilization of α-helices
in an eﬃcient manner. In this eﬀort, the ligands were assessed for their capacity to
modulate IAPP amyloidogenesis and inﬂuence the cytotoxicity of the species generated
from this process on β-pancreatic cells. The results demonstrated that some of the
molecules could act as modulators of IAPP amyloidogenesis by increasing or decreasing
the lag-phase period of IAPP amyloid ﬁbril formation. This would be a potential
research area to better understand the mechanism by which these molecules interact
with IAPP. As several amyloidogenic natively disordered (poly)peptides, including the
amyloid-b peptide, calcitonin and α-synuclein, populate helical intermediates during
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the initial phase of ﬁbril formation, these 2,5-diaryl substituted thiophenes could
ultimately lead to the development of novel therapeutics for protein amyloid-related
diseases.
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Supporting Information
Synthesis of 2,5-Diaryl Substituted Thiophenes as Helical Mimet-
ics: Towards the Modulation of Islet Amyloid Polypeptide (IAPP)
Amyloid Fibril Formation and Cytotoxicity
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 General Conditions and Instrumentation 
 
Reactions were carried out in flame-dried glassware under an argon atmosphere unless 
otherwise noted. Commercially available chemicals were purchased from Aldrich and 
Alfa Aesar and used without further purification. Bis(tri-tert-butylphosphine)palladium 
(0) and palladium (II) acetate were stored under inert gas. All solvents were purchased 
from Fisher Scientific or JT Baker as ACS grade. Unless stated otherwise, solvents were 
dried using and stored over activated 3 Å molecular sieves in a flame-dried Schlenk flask. 
Distilled water was obtained from an in-house distillery. Compounds were purified using 
column chromatography on silica-gel (Zeoprep 60 Eco, 40 – 63 µm, Zeochem AG).  
Microwave assisted reactions were carried out using the Biotage Initiator™ 2.3 build 
6250 microwave system with a 400 W magnetron. 1H and 13C NMR data were measured 
on a Varian VNMRS-500 (500 MHz 1H NMR and 125 MHz 13C NMR) in chloroform-d 
or dimethyl sulfoxide-d6. 1H and 13C NMR spectra were referred to residual solvent peaks. 
The chemical shifts are reported in parts per million (ppm), followed in parentheses by 
the multiplicity of the signals (s = singlet, d = doublet, dd = doublet of doublets, ddd = 
doublet of doublet of doublets, t = triplet, q = quartet and m = multiplet), followed by the 
number of protons and coupling constants J (Hz). High-resolution mass spectral data 
(HRMS) were collected using a LC-TOF ESI mass spectrometer operated in positive ion 
mode (unless stated otherwise).

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Experimental Procedures 
 
Procedure for the synthesis of methyl 3-(methylsulfonamido) thiophene-2-
carboxylate (compound 87) 
 
The procedure employed by Tondi and co-workers was used with some modifications.[1] 
Methyl 3-amino-thiophene-2-carboxylate (1 equiv) was dissolved in pyridine (0.8M of 
heterocycle solution) and methanesulfonyl chloride (1.5 equiv) was added to the stirred 
solution. The reaction was heated for 1 hour at 50 °C. The reaction mixture was then 
diluted with EtOAc and washed with water. The aqueous phase was extracted with 
EtOAc and the combined organic phases were washed 5 times with water. The organic 
phase was dried over anhydrous sodium sulphate, filtered and concentrated.  The crude 
solid was recrystallized from EtOAc and hexanes to provide the title compound as light 
brown crystals in 90% yield. 
 
Procedure for the synthesis of methyl 3-(N-methylmethylsulfonamido) thiophene-2-
carboxylate (compound 88)  
 
The procedure employed by Cardullo and co-workers was used for the methylation of the 
secondary amine with some modifications.[2] The sulfonamide prepared above (1 equiv) 
was dissolved in anhydrous DMF (0.4 M of sulfonamide solution) and Cs2CO3 (1 equiv) 
and MeI (2.5 equiv) were added to the solution. The mixture was stirred for 24 hours at 
40 °C. Subsequent to filtering the solution, the solvent was evaporated under reduced 
pressure. The crude material was dissolved in anhydrous chloroform and stirred for 1 
hour at room temperature. The mixture was filtered and the solvent was evaporated to 
give the title compound as a white solid in 95% yield. The compound was used without 
further purification. 

General procedure for saponification  
 
The methyl ester (1 equiv) was dissolved in a 1:1:2 mixture of 2 M NaOH(aq.) (5 
equiv):MeOH:THF, and the mixture was refluxed for 1 hour at 80 °C. The solution was 
diluted with EtOAc and acidified with HCl (1M) to bring the pH to 3 or 4. The aqueous 
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phase was extracted with additional EtOAc and the combined organic phases were 
washed with water (3x). The solution was dried over anhydrous sodium sulphate, filtered, 
and the solvent was evaporated.  The compound was used without further purification.  
 
General procedure for decarboxylative cross-coupling  
 
The procedure employed by Forgione and co-workers was used with slight 
modifications.[3] In a 2-5 mL, open to air, oven dried microwave vial were added the 
heterocyclic carboxylic acid (2 equiv), aryl bromide (1 equiv), tetra-n-butylammonium 
chloride (1 equiv), cesium carbonate (1.5 equiv), Bis(tri-tert-butylphosphine)palladium 
(0) (0.05 equiv) and anhydrous DMF (0.1 M of the aryl bromide solution). The vial was 
capped with a septum and the mixture was pre-stirred for 30 seconds at 23 °C and 
submitted to microwave heating at 170 °C for 8 min with stirring and the high absorption 
setting. The crude mixture was cooled to 23 °C and was filtered over Celite®. The 
solution was then diluted with EtOAc and the organic layer was washed with a saturated 
NaCl aqueous solution (3x), saturated NaHCO3 aqueous solution (2x), water (1x), and 
saturated NaCl aqueous solution (1x). The aqueous phases were combined and extracted 
with EtOAc. The combined organic phases were dried over sodium sulfate, and after 
filtration the solvent was evaporated to provide the crude compound.  

General procedure for C-H activation  
 
A procedure employed by Fagnou and co-workers was used with slight modifications.[4] 
An oven dried vial equipped with a magnetic stir bar was charged with heterocycle (1 
equiv), aryl bromide (2 equiv), PCy3.HBF4 (0.1 equiv), PivOH (0.3 equiv), K2CO3 (1.5 
equiv), and palladium (II) acetate (0.05 equiv). Anhydrous DMA (0.08 M of the 
heterocycle solution) was added. Liquid aryl bromides were added after the addition of 
solvent. The mixture was heated for 16 hours at 100 °C. After cooling to 23 °C, the 
reaction mixture was diluted with EtOAc and filtered through a pad of Celite®. The 
filtrate was washed with a saturated NaCl aqueous solution (3x), saturated NaHCO3 
aqueous solution (2x) (unless otherwise stated), water (1x), and saturated NaCl aqueous 
solution (1x). The aqueous phases were combined and extracted with EtOAc. The 
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combined organic phases were dried over sodium sulfate, and after filtration the solvent 
was evaporated to provide the crude compound. 
 
X-ray crystallography of compound  99n 
A colorless rhomb-like specimen of C20H18N2O3S2, approximate dimensions 0.356 mm 
x 0.371 mm x 0.438 mm, was used for the X-ray crystallographic analysis. The X-ray 
intensity data were measured. 
 
A total of 1464 frames were collected. The total exposure time was 4.07 hours. The 
frames were integrated with the Bruker SAINT software package using a narrow-frame 
algorithm. The integration of the data using an orthorhombic unit cell yielded a total 
of 18642 reflections to a maximum θ angle of 28.97° (0.73 Å resolution), of 
which 4493 were independent (average redundancy 4.149, completeness = 93.3%, 
Rint = 4.56%) and 3794 (84.44%) were greater than 2σ(F2). The final cell constants 
of a = 10.862(3) Å, b = 9.289(3) Å, c = 18.357(5) Å, volume = 1852.2(9) Å3, are based 
upon the refinement of the XYZ-centroids of 5458 reflections above 20 σ(I) with 4.437° 
< 2θ < 52.96°. Data were corrected for absorption effects using the multi-scan method 
(SADABS). The ratio of minimum to maximum apparent transmission was 0.802. The 
calculated minimum and maximum transmission coefficients (based on crystal size) 
are 0.8760 and 0.8970.  
 
The structure was solved and refined using the Bruker SHELXTL Software Package, 
using the space group P n a 21, with Z = 4 for the formula unit, C20H18N2O3S2. The final 
anisotropic full-matrix least-squares refinement on F2 with 247 variables converged at R1 
= 3.67%, for the observed data and wR2 = 8.54% for all data. The goodness-of-fit 
was 1.043. The largest peak in the final difference electron density synthesis was 0.201 e-
/Å3 and the largest hole was -0.315 e-/Å3 with an RMS deviation of 0.048 e-/Å3. On the 
basis of the final model, the calculated density was 1.429g/cm3 and F(000), 832 e-.  
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Preparation and Characterization of Compounds 
 
 N-(2-(3-cyanophenyl)thiophen-3-yl)-N-methylmethanesulfonamide (98a; Table 6.1, 
Entry 1)  
General procedure 2 was followed using 3-bromobenzonitrile (38.5 mg, 0.21 mmol) and 
compound 97 to yield the title compound as a yellow solid (36 mg, 58%).  
1H NMR (500 MHz, CDCl3) δ 7.94 (ddd, J = 7.8, 1.9, 1.2 Hz, 1H), 7.87 - 8.86 (m, 1H), 
7.64 (ddd, J = 7.8, 1.4, 1.2 Hz, 1H), 7.54 (dd, J = 7.8, 7.8 Hz, 1H), 7.39 (d, J = 5.4 Hz, 
1H), 7.12 (d, J = 5.4 Hz, 1H), 3.21 (s, 3H), 2.87 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 138.1, 135.2, 133.8, 132.7, 131.8, 131.6, 129.7, 125.5, 
125.3, 118.4, 113.1, 38.8, 36.8. 
HRMS (EI): calculated for C13H12N2O2S2 [M + H]+: 293.0413, found: 293.0414. 


N-(2-(3-methoxyphenyl) thiophen-3-yl)-N-methylmethanesulfonamide (98b; Table 
6.1, Entry 2)  
General procedure 2 was followed using 1-bromo-3-methoxybenzene (26.5 μL, 0.21 
mmol) and compound 97 to yield the title compound as a light yellow solid (43 mg, 68%). 
1H NMR (500 MHz, CDCl3) δ 7.32 (dd, J = 8.0, 8.0 Hz, 1H), 7.27 (d, J = 5.4 Hz, 1H), 
7.22 (dd, J = 2.6, 1.7 Hz, 1H), 7.17 (ddd, J = 8.0, 1.7, 0.9 Hz, 1H), 7.08 (d, J = 5.4 Hz, 
1H), 6.90 (ddd, J = 8.0, 2.6, 0.9 Hz, 1H), 3.85 (s, 3H), 3.19 (s, 3H), 2.81 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 159.8, 140.1, 134.2, 133.5, 129.8, 126.4, 123.9, 120.8, 
114.2, 113.8, 55.4, 38.5, 38.1. 
HRMS (EI): calculated for C13H15NO3S2 [M + H]+: 298.0566, found: 298.0561.   
 
 
Ethyl 3-(3-(N-methylmethylsulfonamido)thiophen-2-yl)benzoate (98c; Table 6.1, 
Entry 3)  
General procedure 2 was followed using ethyl 3-bromobenzoate (33.6 μL, 0.21 mmol) 
and compound 97 to yield the title compound as a brown solid (47 mg, 66%). 
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1H NMR (500 MHz, CDCl3) δ 8.27 (dd, J = 2.2, 1.6 Hz, 1H), 8.04 - 8.02 (m, 1H), 7.84 
(ddd, J = 7.8, 1.8, 1.1 Hz, 1H), 7.51 (dd, J = 7.8, 7.8 Hz, 1H), 7.33 (d, J = 5.5 Hz, 1H), 
7.12 (d, J = 5.5 Hz, 1H), 4.40 (q, J = 7.1 Hz, 2H), 3.20 (s, 3H), 2.84 (s, 3H), 1.41 (t, J = 
7.1 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ 166.1, 139.1, 134.7, 132.7, 132.6, 131.1, 129.4, 129.3, 
129.0, 126.4, 124.4, 61.2, 38.6, 37.8, 14.3. 
HRMS (EI): calculated for C15H17NO4S2 [M + H]+: 340.0672, found: 340.0664.  
 
 
3-(3-methylthiophen-2-yl)benzonitrile (98d; Table 6.1, Entry 4)  
General procedure 2 was followed using 2-bromobenzonitrile (63.7 mg, 0.35 mmol) and 
3-methylthiophene-2-carboxylic acid to yield the title compound as a light yellow oil (48 
mg, 69%).  
1H NMR (500 MHz, CDCl3) δ 7.74 - 7.73 (m, 1H), 7.69 (ddd, J = 7.8, 1.9, 1.2 Hz, 1H), 
7.59 (ddd, J = 8.0, 1.4, 1.4 Hz, 1H), 7.51 (ddd, J = 8.0, 7.5, 0.5 Hz, 1H), 7.27 (d, J = 5.2 
Hz, 1H), 6.95 (d, J = 5.2 Hz, 1H), 2.33 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 136.2, 135.1, 134.5, 133.2, 132.2, 131.4, 130.5, 129.4, 
124.7, 118.6, 112.8, 14.9.  
HRMS (EI): calculated for C12H9NS [M + H]+: 200.0528, found: 200.0525.   
 
 
2-(3-methoxyphenyl)-3-methylthiophene (98e; Table 6.1, Entry 5) 
General procedure 2 was followed using 1-bromo-3-methoxybenzene (44.2 μL, 0.35 
mmol) and 3-methylthiophene-2-carboxylic acid to yield the title compound as a 
colorless oil (54 mg, 75%). 
1H NMR (500 MHz, CDCl3) δ 7.34 - 7.30 (m, 1H), 7.20 (d, J = 5.1 Hz, 1H), 7.07 - 7.04 
(m, 1H), 7.02 - 7.00 (m, 1H), 6.92 (d, J = 5.1 Hz, 1H), 6.88 - 6.86 (m, 1H), 3.84 (s, 3H), 
2.34 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 159.6, 137.7, 136.1, 133.3, 131.1, 129.5, 123.4, 121.5, 
114.6, 112.7, 55.3, 15.0. 
HRMS (EI): calculated for C12H12OS [M + H]+: 205.0682, found: 205.0682. 
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Ethyl 3-(3-methylthiophen-2-yl) benzoate (98f; Table 6.1, Entry 6)  
General procedure 2 was followed using 1-bromo-3-methoxybenzene (56.1 μL, 0.35 
mmol) and 3-methylthiophene-2-carboxylic acid to yield the title compound as a 
colorless oil (53 mg, 61%).  
1H NMR (500 MHz, CDCl3) δ 8.15 - 8.14 (m, 1H), 8.01 - 7.98 (dm, J =7.8 Hz, 1H), 7.64 
(ddd, J = 7.8, 1.9, 1.3 Hz, 1H), 7.48 (dd, J = 7.8, 7.8 Hz, 1H), 7.24 (d, J = 5.1 Hz, 1H), 
6.94 (d, J = 5.1 Hz, 1H), 4.40 (q, J = 7.1 Hz, 2H), 2.33 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ 166.4, 136.7, 135.1, 133.8, 133.2, 131.1, 130.8, 130.0, 
128.5, 128.2, 123.9, 61.1, 14.9, 14.3. 
HRMS (EI): calculated for C14H14O2S [M + H]+: 247.0787, found: 247.0785. 
 
 
2-(5-(3-methoxyphenyl)-4-methylthiophen-2-yl)benzonitrile (99c; Table 6.2, Entry 7)  
General procedure 3 was followed using compound 98e (120 mg, 0.58 mmol) and 2-
bromobenzonitrile to yield the title compound as a yellow oil (41 mg, 23%). 
1H NMR (500 MHz, CDCl3) δ 7.74 - 7.74 (m, 1H), 7.64 - 7.62 (m, 1H), 7.58 (ddd, J = 
8.0, 7.4, 1.5 Hz, 1H), 7.50 (s, 1H), 7.38 - 7.33 (m, 2H), 7.10 (ddd, J = 8.0, 1.5, 0.9 Hz, 
1H), 7.04 (dd, J = 2.5, 1.5 Hz, 1H), 6.90 (ddd, J = 8.0, 2.5, 0.9 Hz, 1H), 3.86 (s, 3H), 2.38 
(s, 3H). 
13C NMR (125 MHz, CDCl3) δ 159.7, 140.0, 137.5, 136.9, 135.3, 134.6, 134.4, 133.0, 
131.4, 129.6, 129.3, 127.3, 121.5, 119.0, 114.6, 113.3, 109.5, 55.3, 15.2. 
HRMS (EI): calculated for C19H15NOS [M + H]+: 306.0947, found: 306.0948.   
 
 
2-(5-(3-methoxyphenyl)-4-methylthiophen-2-yl)benzaldehyde (99d; Table 6.2, Entry 
8)  
General procedure 3 was followed using compound 98e (40 mg, 0.2 mmol) and 2-
bromobenzaldehyde to yield the title compound as an orange solid (49 mg, 79%). 
1H NMR (500 MHz, CDCl3) δ 10.31 (s, 1H), 8.01 (ddd, J = 7.5, 1.5, 0.6 Hz, 1H), 7.64 -
7.60 (m, 1H), 7.59 -7.57 (m, 1H), 7.49 - 7.46 (m, 1H), 7.35 (dd, J = 8.0, 8.0 Hz, 1H), 7.10 
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(ddd, J = 7.8, 1.6, 0.9 Hz, 1H), 7.05 (dd, J = 2.5, 1.6 Hz, 1H), 6.91 (ddd, J = 7.8, 2.5, 0.9 
Hz, 1H), 6.89 (s, 1H), 3.86 (s, 3H), 2.38 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 192.2, 159.7, 140.1, 138.0, 136.5, 135.3, 134.1, 134.0, 
133.7, 133.6, 131.0, 129.7, 128.0, 127.9, 121.4, 114.5, 113.2, 55.3, 15.1. 
HRMS (EI): calculated for C19H16O2S [M + H]+: 309.0944, found: 309. 0937.   
 
 
2-(3-methoxyphenyl)-3-methyl-5-(2-(trifluoromethyl)phenyl)thiophene (99e; Table 
6.2, Entry 9)  
General procedure 3 was followed using compound 98e (40 mg, 0.2 mmol) and 1-bromo-
2-(trifluoromethyl)benzene to yield the title compound as a colorless oil (57 mg, 81%). 
1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 7.5 Hz, 1H), 7.55 - 7.54 (m, 2H), 7.47 - 7.54 
(m, 1H), 7.33 (dd, J = 8.0, 8.0 Hz, 1H), 7.10 (ddd, J = 7.5, 1.6, 0.9 Hz, 1H), 7.05 (dd, J = 
2.5, 1.6 Hz, 1H), 6.95 (s, 1H), 6.88 (ddd, J = 8.0, 2.5, 0.9 Hz, 1H), 3.86 (s, 3H), 2.36 (s, 
3H). 
13C NMR (125 MHz, CDCl3) δ 159.6, 138.7, 137.5, 135.6, 133.7, 133.2, 133.0, 132.8, 
131.8, 131.4, 129.8 (q, JCF = 30.0 Hz), 127.8, 126.5 (q, JCF = 5.0 Hz), 124.0 (q, JCF = 
274.0 Hz), 121.5, 114.5, 113.0, 55.3, 15.2. 
HRMS (EI): calculated for C19H15F3OS [M + H]+: 349.0868, found: 349.0875.  
 
 
Ethyl 2-(5-(3-methoxyphenyl)-4-methylthiophen-2-yl)benzoate (99f; Table 6.2, 
Entry 10)  
General procedure 3 was followed using compound 98e (11 mg, 0.05 mmol) and ethyl 2-
bromobenzoate to yield the title compound as a yellow oil (13.6 mg, 73%). 
1H NMR (500 MHz, CDCl3) δ 7.71 (d, J = 7.5 Hz, 1H), 7.52 - 7.46 (m, 2H), 7.40 - 7.36 
(m, 1H), 7.33 (dd, J = 8.0, 8.0 Hz, 1H), 7.08 (ddd, J = 7.6, 1.5, 0.9 Hz, 1H), 7.03 (dd, J = 
2.6, 1.5 Hz, 1H), 6.89 - 6.86 (m, 2H), 4.25 (q, J = 7.0 Hz, 2H), 3.85 (s, 3H), 2.34 (s, 3H), 
1.20 (t, J = 7.0 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ 168.9, 159.6, 139.9, 138.3, 135.8, 134.0, 133.4, 132.1, 
130.9, 130.8, 130.5, 129.5, 129.4, 127.6, 121.4, 114.5, 112.8, 61.3, 55.3, 15.1, 13.9. 
HRMS (EI): calculated for C21H20O3S [M + H]+: 353.1206, found: 353.1207. 
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Ethyl 2-(5-(3-(ethoxycarbonyl)phenyl)-4-methylthiophen-2-yl)benzoate (99g; Table 
6.2, Entry 11)  
General procedure 3 was followed using compound 98f (38 mg, 0.15 mmol) and ethyl 2-
bromobenzoate to yield the title compound as a colorless oil (55 mg, 94%). 
1H NMR (500 MHz, CDCl3) δ 8.17 (dd, J = 1.6, 1.6 Hz, 1H), 8.00 (ddd, J = 7.8, 1.4, 1.3 
Hz, 1H), 7.73 (d, J = 7.5 Hz, 1H), 7.66 (ddd, J = 7.8, 1.5, 1.4 Hz, 1H), 7.52 - 7.47 (m, 
3H), 7.41 - 7.38 (m, 1H), 6.88 (s, 1H), 4.40 (q, J = 7.1, 2H), 4.27 (q, J = 7.1, 2H), 2.34 (s, 
3H), 1.41 (t, J = 7.1, 3H), 1.22 (t, J = 7.1, 3H). 
13C NMR (125 MHz, CDCl3) δ 168.8, 166.4, 140.4, 137.3, 134.8, 133.9, 133.8, 133.1, 
132.0, 130.92, 130.89 (2C), 130.5, 129.9, 129.4, 128.6, 128.2, 127.8, 61.3, 61.1, 15.0, 
14.3, 13.9. 
HRMS (EI): calculated for C23H22O4S [M + H]+: 395.1311, found: 395.1307.   
 
 
Ethyl 3-(5-(2-cyanophenyl)-3-methylthiophen-2-yl)benzoate (99h; Table 6.2, Entry 
12)  
General procedure 3 was followed using compound 98f (45 mg, 0.18 mmol) and 2-
bromobenzonitrile to yield the title compound as a white solid (52 mg, 81%). 
1H NMR (500 MHz, CDCl3) δ 8.19 - 8.18 (m, 1H), 8.03 (ddd, J = 7.8, 1.2, 0.5 Hz, 1H), 
7.74 (ddd, J = 7.8, 1.6, 0.5 Hz, 1H), 7.69 (ddd, J = 7.5, 2.0, 1.0 Hz, 1H), 7.64 (ddd, J = 
7.5, 2.0, 0.5 Hz, 1H), 7.61 - 7.58 (m, 1H), 7.53 - 7.49 (m, 2H), 7.40 - 7.36 (ddd, J = 7.6, 
7.6, 1.4 Hz, 1H), 4.41 (q, J = 7.0 Hz, 2H), 2.38 (s, 3H), 1.42 (t, J = 7.0 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ 166.2, 138.9, 137.4, 137.3, 135.1, 134.4, 134.3, 133.2, 
133.0, 131.5, 131.0, 130.0, 129.3, 128.72, 128.69, 127.5, 118.9, 109.6, 61.2, 15.1, 14.4. 
HRMS (EI): calculated for C21H17NO2S [M + H]+: 348.1053, found: 348.1049.   
 
 
Ethyl 3-(3-methyl-5-(2-(trifluoromethyl)phenyl)thiophen-2-yl)benzoate (99i; Table 
6.2, Entry 13)  
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General procedure 3 was followed using compound 98f (44 mg, 0.18 mmol) and 1-
bromo-2-(trifluoromethyl)benzene to yield the title compound as a colorless oil  (50 mg, 
72%). 
1H NMR (500 MHz, CDCl3) δ 8.19 (dd, J = 1.6, 1.6 Hz, 1H), 8.01 (ddd, J = 7.8, 1.4, 1.4 
Hz, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.69 (ddd, J = 7.8, 1.8, 1.2 Hz, 1H), 7.56 - 7.54 (m, 
2H), 7.51 - 7.45 (m, 2H), 6.97 (s, 1H), 4.41 (q, J = 7.1 Hz, 2H), 2.36 (s, 3H), 1.41 (t, J = 
7.1 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ 166.4, 138.0, 137.7, 134.6, 133.8, 133.5, 133.2, 133.0, 
131.9, 131.4, 130.9, 129.7 (q, JCF = 30.0 Hz), 128.6, 128.3, 128.0, 126.5 (q, JCF = 5.0 
Hz), 125.1, 124.0 (q, JCF = 274.0 Hz), 61.1, 15.1, 14.4. 
HRMS (EI): calculated for C21H17F3O2S [M + H]+: 391.0974, found: 391.0963. 
 
 
Ethyl 3-(5-(2-formylphenyl)-3-methylthiophen-2-yl)benzoate (99j; Table 6.2, Entry 
14) 
General procedure 3 was followed using compound 98f (75 mg, 0.3 mmol) and 2-
bromobenzaldehyde to yield the title compound as a yellow solid (68 mg, 65%). 
1H NMR (500 MHz, CDCl3) δ 10.26 (s, 1H), 8.15 (dd, J = 1.6, 1.6 Hz, 1H), 7.98 (m, 2H), 
7.66 - 7.64 (m, 1H), 7.61 - 7.53 (m, 2H), 7.50 - 7.43 (m, 2H), 6.88 (s, 1H), 4.40 (q, J = 
7.0 Hz, 2H), 2.36 (s, 3H), 1.41 (t, J = 7.0 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ 192.1, 166.2, 139.0, 137.8, 137.0, 134.6, 134.3, 134.1, 
133.7, 133.6, 133.1, 131.06, 131.05, 129.9, 128.7, 128.6, 128.2, 127.9, 61.2, 15.0, 14.4. 
HRMS (EI): calculated for C21H18O3S [M + H]+: 351.1049, found: 351.1049. 
 
 
 3-(3-methyl-5-(2-(trifluoromethyl)phenyl)thiophen-2-yl)benzonitrile (99k; Table 6.2, 
Entry 15) 
General procedure 3 was followed using compound 98d (40 mg, 0.2 mmol) and 1-bromo-
2-(trifluoromethyl)benzene to yield the title compound as a white solid (32 mg, 47%). 
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1H NMR (500 MHz, CDCl3) δ 7.80 - 7.77 (m, 2H), 7.75 - 7.72 (dm, J = 7.8 Hz, 1H), 7.62 
- 7.60 (dm, J = 7.8 Hz, 1H), 7.57 (dd, J = 7.2, 7.2 Hz, 1H), 7.55 - 7.52 (m, 2H), 7.49 (dd, 
J = 7.8, 7.2 Hz, 1H), 6.97 (s, 1H), 2.35 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 138.9, 136.0, 135.7, 134.4, 133.15, 133.12, 133.0, 132.2, 
132.1, 131.5, 130.6, 129.5, 128.9 (q, JCF = 30.0 Hz), 128.2, 126.5 (q, JCF = 5.0 Hz), 123.9 
(q, JCF = 274.0 Hz), 118.6, 112.9, 15.1. 
HRMS (EI): calculated for C19H12F3NS [M + H]+: 344.0715, found: 344.0710. 
 
 
2-(5-(3-cyanophenyl)-4-methylthiophen-2-yl)benzonitrile (99l; Table 6.2, Entry 16) 
 
General procedure 3 was followed using compound 98d (80 mg, 0.4 mmol) and 2-
bromobenzonitrile to yield the title compound as a yellow solid (60 mg, 50%). 
1H NMR (500 MHz, CDCl3) δ 7.80 - 7.73 (m, 3H), 7.65 - 7.61 (m, 3H), 7.55 (dd, J = 7.8, 
7.8 Hz, 1H), 7.50 (s, 1H), 7.43 - 7.39 (m, 1H), 2.37 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 138.3, 137.2, 137.0, 135.7, 135.4, 134.5, 133.2, 133.1, 
132.2, 131.6, 131.0, 129.6, 129.4, 127.8, 118.8, 118.5, 113.0, 109.8, 15.2. 
HRMS (EI): calculated for C19H12N2S [M + H]+: 301.0794, found: 301.0778. 
 
 
3-(3-methyl-5-phenylthiophen-2-yl)benzonitrile (98m; Table 6.2, Entry 17) 
General procedure 3 was followed using compound 98d (40 mg, 0.2 mmol) and 
bromobenzene to yield the title compound as a yellow solid (38 mg, 69%). 
1H NMR (500 MHz, CDCl3) δ 7.78 - 7.77 (m, 1H), 7.73 (ddd, J = 7.8, 1.9, 1.2 Hz, 1H), 
7.61 - 7.59 (m, 3H), 7.53 (ddd, J = 8.0, 7.8, 0.6 Hz, 1H), 7.41 - 7.38 (m, 2H), 7.32 - 7.29 
(m, 1H), 7.17 (s, 1H), 3.35 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 143.3, 136.0, 135.5, 134.4, 133.8, 133.0, 132.9, 132.0, 
130.5, 130.3, 129.5, 129.0, 127.8, 127.4, 125.6, 118.6, 112.9, 15.2. 
HRMS (EI): calculated for C18H13NS [M + H]+: 276.0841, found: 276.0835. 
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N-(5-(2-formylphenyl)-2-(3-methoxyphenyl)thiophen-3-yl)-N 
methylmethanesulfonamide (99b; Table 6.2, Entry 19) 
General procedure 3 was followed using compound 98b (32 mg, 0.11 mmol) and 2-
bromobenzaldehyde to yield the title compound as a light yellow oil (37 mg, 87%). 
1H NMR (500 MHz, CDCl3) δ 10.30 (s, 1H), 8.04 - 8.02 (m, 1H), 7.65 (ddd, 7.5, 7.3, 1.5 
Hz, 1H), 7.59 - 7.57 (m, 1H), 7.55 - 7.51 (m, 1H), 7.38 - 7.35 (dd, J = 8.0, 7.5 Hz, 1H), 
7.29 - 7.27 (m, 1H), 7.23 (m, 1H), 7.08 (s, 1H), 6.95 (ddd, J = 8.0, 2.5, 1.0 Hz, 1H), 3.87 
(s, 3H), 3.23 (s, 3H), 2.87 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 191.5, 159.9, 142.1, 137.0, 136.5, 134.3, 134.1, 133.8, 
132.8, 131.0, 130.0, 128.8, 128.6, 128.3, 120.7, 114.8, 113.7, 55.4, 38.6, 38.3. 
HRMS (EI): calculated for C20H19NO4S2 [M + H]+: 402.0828, found: 402.0833. 
 
 
N-(5-(2-cyanophenyl)-2-(3-methoxyphenyl)thiophen-3-yl)-N-
methylmethanesulfonamide (99n; Table 6.3, Entry 20) 
General procedure 3 was followed using compound 98b (26 mg, 0.08 mmol) and 2-
bromobenzonitrile to yield the title compound as a colorless oil (26 mg, 75%). 
1H NMR (500 MHz, CDCl3) δ 7.77 - 7.75 (m, 1H), 7.68 (s, 1H), 7.65 - 7.63 (m, 2H), 7.45 
- 7.41 (m, 1H), 7.37 - 7.33 (m, 2H), 7.28 - 7.25 (m, 1H), 6.94 (ddd, J = 8.0, 2.5, 0.7 Hz, 
1H), 3.86 (s, 3H), 3.24 (s, 3H), 3.96 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 159.8, 142.6, 136.8, 136.5, 134.6, 134.4, 133.3, 132.8, 
129.9, 128.9, 128.1, 126.3, 120.8, 118.8, 114.9, 113.6, 109.6, 55.4, 38.7, 37.5. 
HRMS (EI): calculated for C20H18N2O3S2 [M + H]+: 399.0832, found: 399.0831. 
 
 
N-(2-(3-methoxyphenyl)-5-(2-(trifluoromethyl)phenyl)thiophen-3-yl)-N-
methylmethanesulfonamide (99o; Table 6.3, Entry 21) 
General procedure 3 was followed using compound 98b (32 mg, 0.11 mmol) and 1-
bromo-2-(trifluoromethyl)benzene to yield the title compound as a colorless oil (37 mg, 
78%). 
188
1H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 8.0 Hz, 1H), 7.62 - 7.55 (m, 2H), 7.52 - 7.49 
(m, 1H), 7.34 (d, J = 7.5 Hz, 1H), 7.32 - 7.31 (m, 1H), 7.26 - 7.24 (m, 1H), 7.14 (s, 1H), 
6.92 (ddd, J = 8.2, 2.5, 1.0 Hz, 1H), 3.86 (s, 3H), 3.23 (s, 3H), 2.87 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 159.8, 141.3, 137.5, 133.6, 133.1, 132.8, 132.7, 131.7, 
129.8, 128.9 (q, JCF = 30.0 Hz), 128.5, 126.8, 126.7 (q, JCF = 5.0 Hz), 123.9 (q, JCF = 
274.0 Hz), 120.7, 114.6, 113.6, 55.4, 38.6, 37.5. 
HRMS (EI): calculated for C20H18F3NO3S2 [M + H]+: 442.0753, found: 442.0752. 
 
 
Ethyl 2-(5-(3-cyanophenyl)-4-(N-methylmethylsulfonamido)thiophen-2-yl)benzoate 
(99p; Table 6.2, Entry 22)  
 
General procedure 3 was followed using compound 98a (17.5 mg, 0.06 mmol) and ethyl 
2-bromobenzoate to yield the title compound as a colorless oil (20 mg, 77%). 
1H NMR (500 MHz, CDCl3) δ 7.99 (ddd, J = 8.0, 2.0, 1.5 Hz, 1H), 7.92 - 7.89 (m, 1H), 
7.82 (ddd, J = 8.0, 1.5, 0.5 Hz, 1H), 7.64 (ddd, J = 8.0, 1.5, 1.5 Hz, 1H), 7.57 - 7.74 (m, 
2H), 7.51 - 7.45 (m, 2H), 7.08 (s, 1H), 4.25 (q, J = 7.1 Hz, 2H), 3.23 (s, 3H), 2.91 (s, 3H), 
1.24 (t, J = 7.1 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ 168.0, 141.5, 138.3, 134.6, 133.7, 132.9, 132.5, 131.9, 
131.65, 131.61, 131.3, 131.0, 129.9, 129.8, 128.7, 124.9, 118.4, 113.1, 61.5, 38.8, 36.7, 
14.0. 
HRMS (EI): calculated for C22H20N2O4S2 [M + H]+: 441.0937, found: 441.0937. 
 
 
N-(2-(3-cyanophenyl)-5-(2-formylphenyl)thiophen-3-yl)-N-
methylmethanesulfonamide (99q; Table 6.3, Entry 23)  
General procedure 3 was followed using compound 98a (46 mg, 0.16 mmol) and 2-
bromobenzaldehyde to yield the title compound as a yellow solid (40 mg, 64%). 
1H NMR (500 MHz, CDCl3) δ 10.22 (s, 1H), 8.02 - 7.98 (m, 1H), 7.95 (ddd, J = 8.0, 2.5, 
1.0 Hz, 1H), 7.89 - 7.88 (m, 1H), 7.67 - 7.63 (m, 2H), 7.57 - 7.52 (m, 3H), 7.07 (s, 1H), 
3.24 (s, 3H), 2.90 (s, 3H). 
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13C NMR (125 MHz, CDCl3) δ 191.1, 139.8, 138.2, 136.2, 135.2, 134.1, 133.9, 133.2, 
132.6, 132.0, 131.7, 131.1, 129.9, 129.2, 128.8, 127.7, 118.2, 113.3, 38.8, 37.1. 
HRMS (EI): calculated for C20H16N2O3S2 [M + H]+: 397.0675, found: 397.0665. 
 
 
N-(2-(3-cyanophenyl)-5-(2-(trifluoromethyl)phenyl)thiophen-3-yl)-N-
methylmethanesulfonamide (99r; Table 6.3, Entry 24)  
General procedure 3 was followed using compound 98a (30 mg, 0.1 mmol) and 1-bromo-
2-(trifluoromethyl)benzene to yield the title compound as a yellow oil (42 mg, 95%). 
 
1H NMR (500 MHz, CDCl3) δ 8.01 (ddd, J = 8.0, 2.0, 1.5 Hz, 1H), 7.93 - 9.92 (m, 1H), 
7.81 (d, J = 7.5 Hz, 1H), 7.66 - 7.64 (m, 1H), 7.63 - 7.61 (m, 1H), 7.58 - 7.54 (m, 3H), 
7.15 (s, 1H), 3.27 (s, 3H), 2.90 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 139.1, 139.0, 134.5, 133.5, 132.7, 132.6, 132.1, 131.9, 
131.8, 131.7, 129.8, 129.0, 128.9 (q, JCF = 30.0 Hz), 126.8 (q, JCF = 5.0 Hz), 125.9, 121.7 
(q, JCF = 274.0 Hz), 118.4, 113.1, 38.8, 36.3. 
HRMS (EI): calculated for C20H15F3N2O2S2 [M + H]+: 437.0600, found: 437.0606. 
 
 
N-(5-(2-cyanophenyl)-2-(3-cyanophenyl)thiophen-3-yl)-N-
methylmethanesulfonamide (99a; Table 6.3, Entry 25)  
General procedure 3 was followed using compound 98a (22 mg, 0.08 mmol) and 2-
bromobenzonitrile to yield the title compound as a white solid (21 mg, 72%). 
1H NMR (500 MHz, CDCl3) δ 8.05 (ddd, J = 7.9, 1.8, 1.2 Hz, 1H), 7.94 - 7.93 (m, 1H), 
7.80 (ddd, J = 7.9, 1.2, 0.6 Hz, 1H), 7.70 (s, 1H), 7.69 - 7.68 (m, 1H), 7.67 - 7.64 (m, 
2H), 7.58 (ddd, J = 7.9, 7.9, 0.6 Hz, 1H), 7.48 (ddd, J = 7.8, 7.0, 1.7 Hz, 1H), 3.28 (s, 
3H), 2.99 (s, 3H).  
13C NMR (125 MHz, CDCl3) δ 140.2, 138.2, 136.0, 135.6, 134.5, 133.5, 133.2, 132.7, 
132.0, 131.8, 129.9, 129.0, 128.6, 125.6, 118.7, 118.3, 113.2, 109.9, 38.9, 36.4. 
HRMS (EI): calculated for C20H15N3O2S2 [M + H]+: 394.0678, found: 394.0676. 
 
190
 Ethyl 3-(5-(2-formylphenyl)-3-(N-methylmethylsulfonamido)thiophen-2-yl)benzoate 
(99s; Table 6.3, Entry 26)  
General procedure 3 was followed using compound 98c (34 mg, 0.1 mmol) and 2-
bromobenzaldehyde to yield the title compound as a yellow solid (29 mg, 65%). 
1H NMR (500 MHz, CDCl3) δ 10.31 (s, 1H), 8.33 - 8.32 (m, 1H), 8.09 - 8.03 (dm, J = 8 
Hz, 1H), 8.05 - 8.03 (dm, J = 8 Hz, 1H), 7.91 - 7.89 (m, 1H), 7.69 - 7.65 (m, 1H), 7.60 - 
7.58 (m, 1H), 7.57 - 7.53 (m, 2H), 7.12 (s, 1H), 4.42 (q, J = 7.5, Hz, 2H), 3.25 (s, 3H), 
2.89 (s, 3H), 1.42 (t, J = 7.5 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ 191.3, 166.0, 141.0, 137.1, 136.8, 134.8, 134.1, 133.9, 
132.5, 132.0, 131.3, 131.0, 129.7, 129.4, 129.2, 128.9, 128.6, 128.4, 61.3, 38.7, 38.0, 
14.3.  
HRMS (EI): calculated for C22H21NO5S2 [M + H]+: 444.0934, found: 444.0936. 
 
 
Ethyl 3-(3-(N-methylmethylsulfonamido)-5-(2-(trifluoromethyl)phenyl)thiophen-2-
yl)benzoate (99t; Table 6.2, Entry 27)  
General procedure 3 was followed using compound 98c (30 mg, 0.09 mmol) and 1-
bromo-2-(trifluoromethyl)benzene to yield the title compound as a colorless oil (32 mg, 
75%). 
1H NMR (500 MHz, CDCl3) δ 8.32 (dd, J = 1.8, 1.6 Hz, 1H), 8.06 - 8.04 (m, 1H), 7.93 
(ddd, J = 7.8, 1.9, 1.2 Hz, 1H), 7.79 (d, J = 7.5 Hz, 1H), 7.63 - 7.56 (m, 2H), 7.55 - 7.50 
(m, 2H), 7.17 (s, 1H), 4.41 (q, J = 7.13 Hz, 2H), 3.25 (s, 3H), 2.28 (s, 3H), 1.42 (t, J = 
7.13 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ 166.1, 140.3, 138.0, 134.0, 132.8, 132.53, 132.50, 132.3, 
131.7, 131.1, 129.5, 129.4, 129.0, 128.9 (q, JCF = 30.0 Hz), 128.7, 126.72 (q, JCF = 5.0 
Hz), 126.67, 123.9 (q, JCF = 274.0 Hz), 61.2, 38.7, 37.3, 14.3. 
HRMS (EI): calculated for C22H20F3NO4S2 [M + H]+: 484.0859, found: 484.0854. 
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Ethyl 3-(5-(2-cyanophenyl)-3-(N-methylmethylsulfonamido)thiophen-2-yl)benzoate 
(99u; Table 6.3, Entry 28)  
General procedure 3 was followed using compound 98c (40 mg, 0.12 mmol) and 2-
bromobenzonitrile to yield the title compound as a yellow oil (49 mg, 93%). 
1H NMR (500 MHz, CDCl3) δ 8.34 - 8.33 (m, 1H), 8.08 - 8.059 (m, 1H), 7.98 - 7.96 (m, 
1H), 7.79 - 7.77 (m, 1H), 7.71 (s, 1H), 7.67 - 7.65 (m, 2H), 7.56 - 7.52 (m, 1H), 7.47 - 
7.44 (m, 1H), 4.41 (q, J = 7.0 Hz, 2H), 3.27 (s, 3H), 2.96 (s, 3H), 1.42 (t, J = 7.0 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ 166.0, 141.6, 137.3, 136.4, 135.1, 134.4, 133.3, 132.5, 
132.0, 131.2, 129.8, 129.5, 129.1, 129.0, 128.3, 126.2, 118.7, 109.8, 61.3, 38.8, 37.2, 
14.3. 
HRMS (EI): calculated for C22H20N2O4S2 [M + H]+: 441.0937, found: 441.0930. 
 
 
2-(5-(3-carboxyphenyl)-4-methylthiophen-2-yl)benzoic acid (103a)  
General procedure 1 was followed using compound 99g (41 mg, 0.1 mmol) to yield the 
title compound as a white solid (35 mg, 94%). 
1H NMR (500 MHz, d6-DMSO) δ 8.02 (dd, J = 1.7, 1.6 Hz, 1H), 7.92 (ddd, J = 8.0, 1.4, 
1.4 Hz, 1H), 7.77 (ddd, J = 7.7, 1.1, 0.7 Hz, 1H), 7.64 - 7.59 (m, 2H), 7.56 - 7.53 (m, 
2H), 7.47- 7.44 (m, 1H), 7.06 (s, 1H), 2.32 (s, 3H).  
13C NMR (125 MHz, d6-DMSO) δ 170.3, 167.4, 140.2, 136.8, 134.6, 134.5, 133.4, 132.9, 
132.3, 131.9, 131.2, 131.1, 130.6, 129.8, 129.2, 129.1, 128.6, 128.5, 15.4. 
HRMS (EI): calculated for C19H14O4S [M + H]+: 339.0686, found: 339.0686. 
 
 
3-(5-(2-cyanophenyl)-3-methylthiophen-2-yl)benzoic acid (103b; Table 6.4, Entry 
31)  
General procedure 1 was followed using compound 99h (17 mg, 0.05 mmol) to yield the 
title compound as a white solid in quantitative yield. 
1H NMR (500 MHz, CDCl3) δ 8.27 (dd, J = 2.0, 1.7 Hz, 1H), 8.10 (ddd, J = 7.8, 1.4, 1.2 
Hz, 1H), 7.77 - 7.74 (m, 2H), 7.67 - 7.64 (m, 1H), 7.61 (ddd, J = 7.4, 7.4, 1.4 Hz, 1H), 
192
7.56 (dd, J = 7.7, 7.7 Hz, 1H), 7.52 (s, 1H), 7.39 (ddd, J = 7.5, 7.5, 1.4 Hz, 1H), 2.40, (s, 
3H). 
13C NMR (125 MHz, CDCl3) δ 170.4, 138.6, 137.6, 137.3, 135.3, 134.6, 134.5 134.1, 
133.0, 131.5, 130.5, 129.7, 129.4, 129.3, 128.9, 127.6, 118.9, 109.6, 15.17. 
HRMS (EI): calculated for C19H13NO2S [M - H]-: 318.0594, found: 318.0600. 
 
 
3-(3-methyl-5-(2-(trifluoromethyl)phenyl)thiophen-2-yl)benzoic acid (103c; Table 
6.4, Entry 32)  
General procedure 1 was followed using compound 99i (33 mg, 0.08 mmol) to yield the 
title compound as a white solid in quantitative yield.  
1H NMR (500 MHz, d6-DMSO) δ 8.03 (dd, J = 1.7, 1.6 Hz, 1H), 7.95 - 7.93 (ddd, J = 8.0, 
1.4, 1.4 Hz, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.79 (ddd, J = 7.7, 1.5, 1.0 Hz, 1H), 7.74 (dd, J 
= 7.6, 7.5 Hz, 1H), 7.66 - 7.60 (m, 3H), 7.07 (s, 1H), 2.34 (s, 3H). 
13C NMR (125 MHz, d6-DMSO) δ 167.4, 137.6, 137.5, 134.3, 134.2, 133.6, 133.04, 
133.02, 132.9, 132.8, 131.9, 129.9, 129.45, 129.42 (q, JCF = 30.0 Hz), 129.3, 128.8, 127.0 
(q, JCF = 5.0 Hz), 124.4 (q, JCF = 274.0 Hz), 15.3. 
HRMS (EI): calculated for C19H13F3O2S [M - H]-: 361.0516, found: 361.0521. 
 
 
3-(5-(2-formylphenyl)-3-methylthiophen-2-yl)benzoic acid (103d; Table 6.4, Entry 
33)  
General procedure 1 was followed using compound 99j (38 mg, 0.11 mmol) to yield the 
title compound as a white solid in quantitative yield.  
1H NMR (500 MHz, d6-DMSO) δ 10.17 (s, 1H), 8.01 (s, 1H), 7.89 (d, J = 7.7 Hz, 1H), 
7.85 (d, J = 7.6 Hz, 1H), 7.75 (d, J = 7.7 Hz, 1H), 7.70 (dd, J = 7.2, 7.2 Hz, 1H), 7.61 - 
7.51 (m, 3H), 7.14 (s, 1H), 2.3 (s, 3H). 
13C NMR (125 MHz, d6-DMSO) δ 192.0, 167.4, 138.4, 137.2, 136.8, 135.3, 134.7, 134.6, 
134.2, 133.90, 133.1, 131.9, 131.4, 129.9, 129.3, 129.0, 128.9, 128.2, 15.3. 
HRMS (EI): calculated for C19H14O3S [M - H]-: 321.0591, found: 321.0597. 
 
193
 3-(3-(N-methylmethylsulfonamido)-5-(2-(trifluoromethyl)phenyl)thiophen-2-
yl)benzoic acid (103e; Table 6.4, Entry 34)  
General procedure 1 was followed using compound 99t (16 mg, 0.03 mmol) to yield the 
title compound as a white solid in quantitative yield.  
1H NMR (500 MHz, CDCl3) δ 8.39 (s, 1H), 8.12 (d, J = 7.8 Hz, 1H), 8.01 (d, J = 7.9 Hz, 
1H), 7.80 (d, J = 7.9 Hz, 1H), 7.63 - 7.56 (m, 3H), 7.53 (dd, J = 7.9, 7.3 Hz, 1H), 7.18 (s, 
1H), 3.27 (s, 3H), 2.89 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 170.6, 140.1, 138.2, 134.1, 133.5, 132.8 (2C), 132.6, 
132.5, 131.8, 130.1, 130.0, 129.2, 129.0 (q, JCF = 30.0 Hz), 128.7, 126.7, 126.6 (q, JCF = 
5.0 Hz), 123.9 (q, JCF = 274.0 Hz), 38.8, 37.2.  
HRMS (EI): calculated for C20H16F3NO4S2 [M - H]-: 454.0400, found: 454.0404. 
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N-(2-(3-cyanophenyl)thiophen-3-yl)-N-methylmethanesulfonamide (98a; Table 6.1, 
Entry 1)  

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N-(2-(3-cyanophenyl)thiophen-3-yl)-N-methylmethanesulfonamide (98a; Table 6.1, 
Entry 1) 13C:  
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N-(2-(3-methoxyphenyl) thiophen-3-yl)-N-methylmethanesulfonamide (98b; Table 
6.1, Entry 2)  
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N-(2-(3-methoxyphenyl) thiophen-3-yl)-N-methylmethanesulfonamide (98b; Table 
6.1, Entry 2) 13C: 
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Ethyl 3-(3-(N-methylmethylsulfonamido)thiophen-2-yl)benzoate (98c; Table 6.1, 
Entry 3)  
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Ethyl 3-(3-(N-methylmethylsulfonamido)thiophen-2-yl)benzoate (98c; Table 6.1, 
Entry 3) 13C: 
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3-(3-methylthiophen-2-yl)benzonitrile (98d; Table 6.1, Entry 4)  
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3-(3-methylthiophen-2-yl)benzonitrile (98d; Table 6.1, Entry 4) 13C: 
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2-(3-methoxyphenyl)-3-methylthiophene (98e; Table 6.1, Entry 5) 1H: 
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2-(3-methoxyphenyl)-3-methylthiophene (98e; Table 6.1, Entry 5) 13C: 
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Ethyl 3-(3-methylthiophen-2-yl) benzoate (98f; Table 6.1, Entry 6) 1H: 
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Ethyl 3-(3-methylthiophen-2-yl) benzoate (98f; Table 6.1, Entry 6) 13C: 
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2-(5-(3-methoxyphenyl)-4-methylthiophen-2-yl)benzonitrile (99c; Table 6.2, Entry 7) 
1H: 
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2-(5-(3-methoxyphenyl)-4-methylthiophen-2-yl)benzonitrile (99c; Table 6.2, Entry 7) 
13C: 
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2-(5-(3-methoxyphenyl)-4-methylthiophen-2-yl)benzaldehyde (99d; Table 6.2, Entry 
8) 1H: 
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2-(5-(3-methoxyphenyl)-4-methylthiophen-2-yl)benzaldehyde (99d; Table 6.2, Entry 
8) 13C: 
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2-(3-methoxyphenyl)-3-methyl-5-(2-(trifluoromethyl)phenyl)thiophene (99e; Table 
6.2, Entry 9) 1H: 
 
 
 
211
SO
M
e
C
F 3
2-(3-methoxyphenyl)-3-methyl-5-(2-(trifluoromethyl)phenyl)thiophene (99e; Table 
6.2, Entry 9)  13C: 
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Ethyl 2-(5-(3-methoxyphenyl)-4-methylthiophen-2-yl)benzoate (99f; Table 6.2, Entry 
10) 1H: 
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Ethyl 2-(5-(3-methoxyphenyl)-4-methylthiophen-2-yl)benzoate (99f; Table 6.2, Entry 
10) 13C:  
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Ethyl 2-(5-(3-(ethoxycarbonyl)phenyl)-4-methylthiophen-2-yl)benzoate (99g; Table 
6.2, Entry 11) 1H: 
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Ethyl 2-(5-(3-(ethoxycarbonyl)phenyl)-4-methylthiophen-2-yl)benzoate (99g; Table 
6.2, Entry 11) 13C: 
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Ethyl 3-(5-(2-cyanophenyl)-3-methylthiophen-2-yl)benzoate (99h; Table 6.2, Entry 
12) 1H: 
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Ethyl 3-(5-(2-cyanophenyl)-3-methylthiophen-2-yl)benzoate (99h; Table 6.2, Entry 
12) 13C: 
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Ethyl 3-(3-methyl-5-(2-(trifluoromethyl)phenyl)thiophen-2-yl)benzoate (99i; Table 
6.2, Entry 13) 1H: 
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Ethyl 3-(3-methyl-5-(2-(trifluoromethyl)phenyl)thiophen-2-yl)benzoate (99i; Table 
6.2, Entry 13) 13C: 
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Ethyl 3-(5-(2-formylphenyl)-3-methylthiophen-2-yl)benzoate (99j; Table 6.2, Entry 
14) 1H: 
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Ethyl 3-(5-(2-formylphenyl)-3-methylthiophen-2-yl)benzoate (99j; Table 6.2, Entry 
14) 13C: 
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3-(3-methyl-5-(2-(trifluoromethyl)phenyl)thiophen-2-yl)benzonitrile (99k; Table 6.2, 
Entry 15) 1H: 
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3-(3-methyl-5-(2-(trifluoromethyl)phenyl)thiophen-2-yl)benzonitrile (99k; Table 6.2, 
Entry 15) 13C: 
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2-(5-(3-cyanophenyl)-4-methylthiophen-2-yl)benzonitrile (99l; Table 6.2, Entry 16) 
1H: 
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2-(5-(3-cyanophenyl)-4-methylthiophen-2-yl)benzonitrile (99l; Table 6.2, Entry 16)  
13C: 
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3-(3-methyl-5-phenylthiophen-2-yl)benzonitrile (99m; Table 6.2, Entry 17) 1H: 
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3-(3-methyl-5-phenylthiophen-2-yl)benzonitrile (99m; Table 6.2, Entry 17) 13C: 
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N-(5-(2-formylphenyl)-2-(3-methoxyphenyl)thiophen-3-yl)-N 
methylmethanesulfonamide (99b; Table 6.3, Entry 19) 1H: 
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N-(5-(2-formylphenyl)-2-(3-methoxyphenyl)thiophen-3-yl)-N 
methylmethanesulfonamide (99b; Table 6.3, Entry 19) 13C: 
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N-(5-(2-cyanophenyl)-2-(3-methoxyphenyl)thiophen-3-yl)-N-
methylmethanesulfonamide (99n; Table 6.3, Entry 20) 1H: 
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N-(5-(2-cyanophenyl)-2-(3-methoxyphenyl)thiophen-3-yl)-N-
methylmethanesulfonamide (99n; Table 6.3, Entry 20) 13C: 
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N-(2-(3-methoxyphenyl)-5-(2-(trifluoromethyl)phenyl)thiophen-3-yl)-N-
methylmethanesulfonamide (99o; Table 6.3, Entry 21) 1H: 
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N-(2-(3-methoxyphenyl)-5-(2-(trifluoromethyl)phenyl)thiophen-3-yl)-N-
methylmethanesulfonamide (99o; Table 6.3, Entry 21) 13C: 
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Ethyl 2-(5-(3-cyanophenyl)-4-(N-methylmethylsulfonamido)thiophen-2-yl)benzoate 
(99p; Table 6.3, Entry 22) 1H: 
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Ethyl 2-(5-(3-cyanophenyl)-4-(N-methylmethylsulfonamido)thiophen-2-yl)benzoate 
(99p; Table 6.3, Entry 22) 13C: 
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N-(2-(3-cyanophenyl)-5-(2-formylphenyl)thiophen-3-yl)-N-
methylmethanesulfonamide (99q; Table 6.3, Entry 23) 1H: 
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N-(2-(3-cyanophenyl)-5-(2-formylphenyl)thiophen-3-yl)-N-
methylmethanesulfonamide (99q; Table 6.3, Entry 23) 13C: 
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N-(2-(3-cyanophenyl)-5-(2-(trifluoromethyl)phenyl)thiophen-3-yl)-N-
methylmethanesulfonamide (99r; Table 6.3, Entry 24) 1H: 
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N-(2-(3-cyanophenyl)-5-(2-(trifluoromethyl)phenyl)thiophen-3-yl)-N-
methylmethanesulfonamide (99r; Table 6.3, Entry 24) 13C: 
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N-(5-(2-cyanophenyl)-2-(3-cyanophenyl)thiophen-3-yl)-N-
methylmethanesulfonamide (99a; Table 6.3, Entry 25) 1H: 
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N-(5-(2-cyanophenyl)-2-(3-cyanophenyl)thiophen-3-yl)-N-
methylmethanesulfonamide (99a; Table 6.3, Entry 25) 13C: 
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Ethyl 3-(5-(2-formylphenyl)-3-(N-methylmethylsulfonamido)thiophen-2-yl)benzoate 
(99s; Table 6.3, Entry 26) 1H: 
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Ethyl 3-(5-(2-formylphenyl)-3-(N-methylmethylsulfonamido)thiophen-2-yl)benzoate 
(99s; Table 6.3, Entry 26) 13C: 
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Ethyl 3-(3-(N-methylmethylsulfonamido)-5-(2-(trifluoromethyl)phenyl)thiophen-2-
yl)benzoate (99t; Table 6.3, Entry 27) 1H: 
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Ethyl 3-(3-(N-methylmethylsulfonamido)-5-(2-(trifluoromethyl)phenyl)thiophen-2-
yl)benzoate (99t; Table 6.3, Entry 27) 13C: 
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Ethyl 3-(5-(2-cyanophenyl)-3-(N-methylmethylsulfonamido)thiophen-2-yl)benzoate 
(99u; Table 6.3, Entry 28) 1H: 
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Ethyl 3-(5-(2-cyanophenyl)-3-(N-methylmethylsulfonamido)thiophen-2-yl)benzoate 
(99u; Table 6.3, Entry 28) 13C: 
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2-(5-(3-carboxyphenyl)-4-methylthiophen-2-yl)benzoic acid 	
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2-(5-(3-carboxyphenyl)-4-methylthiophen-2-yl)benzoic acid 	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3-(5-(2-cyanophenyl)-3-methylthiophen-2-yl)benzoic acid (103b; Table 6.4, Entry 31) 
1H: 
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3-(5-(2-cyanophenyl)-3-methylthiophen-2-yl)benzoic acid (103b; Table 6.4, Entry 31) 
13C: 
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3-(3-methyl-5-(2-(trifluoromethyl)phenyl)thiophen-2-yl)benzoic acid (103c; Table 
6.4, Entry 32) 1H:  
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3-(3-methyl-5-(2-(trifluoromethyl)phenyl)thiophen-2-yl)benzoic acid (103c; Table 
6.4, Entry 32) 13C:  
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3-(5-(2-formylphenyl)-3-methylthiophen-2-yl)benzoic acid (103d; Table 6.4, Entry 
33) 1H: 
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3-(5-(2-formylphenyl)-3-methylthiophen-2-yl)benzoic acid (103d; Table 6.4, Entry 
33) 13C: 
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3-(3-(N-methylmethylsulfonamido)-5-(2-(trifluoromethyl)phenyl)thiophen-2-
yl)benzoic acid (103e; Table 6.4, Entry 34) 1H: 
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3-(3-(N-methylmethylsulfonamido)-5-(2-(trifluoromethyl)phenyl)thiophen-2-
yl)benzoic acid (103e; Table 6.4, Entry 34) 13C: 
 
S
N
C
O
O
H
C
F 3
M
s
258
Materials and Methods 
 
IAPP synthesis, purification and characterization 
IAPP was synthesised by solid phase peptide synthesis on a Rink amide polystyrene resin 
based on Fmoc chemistry and 2-(6-chloro-1-H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium haxafluorophosphate (HCTU) coupling as previously described.[5] 
Cleavage from the resin was achieved with a mixture of TFA/ethanedithiol/phenol/water 
(92/2.5/3/2.5). Crude IAPP was purified by preparative scale reversed-phase high 
performance liquid chromatography (RP-HPLC) using a linear gradient of ACN in 
H2O/TFA (0.06% v/v). Collected fractions were analyzed by analytical RP-HPLC using a 
C18 (3.6 μm) column (250 mm x 4.6 mm) and a linear gradient of ACN in H2O/TFA 
(0.06% v/v). Fractions were also analysed by LC/MS-TOF to confirm the identity of the 
peptide. Disulfide bond formation between Cys-2 and Cys-7 was achieved by dimethyl 
sulfoxide (DMSO) oxidation according to the method developed by Abedini.[6] IAPP was 
re-purified by RP-HPLC as described above. Fractions corresponding to the desired 
product, as revealed by MS-TOF analysis, and with purity higher than 95%, confirmed by 
analytical RP-HPLC, were finally pooled and lyophilized. 
 
Amyloid formation measured by thioflavin T fluorescence 
Aliquots of monomerized IAPP were prepared by dissolving the lyophilized peptide in 
100% hexafluoro-2-propanol (HFIP), and the solution was sonicated for 30 minutes and 
filtered through a 0.22 μm hydrophilic polypropylene filter before lyophilisation. 
Lyophilized IAPP was resolubilized in HFIP, sonicated for 30 minutes and the solution 
was aliquoted and lyophilized again to remove HFIP. Samples were kept dried at -80 °C 
until used. IAPP solutions were prepared by dissolving IAPP at a concentration of 25 μM 
(2x of final concentration) in 20 mM Tris, pH 7, 4, 40 μM ThT, immediately before final 
dilution and measurement. Substituted thiophene solutions were prepared at 100x (1.25 
mM; final concentration of 12.5 μM, unless otherwise specified) in DMSO before being 
incorporated in the assay mixture. Assays were performed at room temperature (RT) 
without stirring in sealed black-wall, clear-bottom 96-well non-binding surface plates 
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with a volume of 100 μL per well. ThT fluorescence was measured from the bottom of 
the well every 10 min over the course of 25 h with excitation at 440 nm and emission at 
485 nm. Data obtained from triplicate runs were averaged and corrected by subtracting 
the corresponding control reaction. 
 
Cell toxicity assay    
Rat INS-1 (β-pancreatic cell line) cells were seeded in black wall clear bottom 96-well 
plates at a density of 35 000 cells/well (100 μl/well) in RPMI-1640 complete medium.[5] 
After 24 h incubation at 37 °C in a 5% CO2 incubator, cells were treated by directly 
adding 50 μl of IAPP solutions at 3x final concentrations in 20 mM Tris, pH 7,4 that had 
been pre-incubated for 20 h at room temperature in presence or in absence of 1 equivalent 
of substituted thiophene derivatives. These solutions were then incubated for an 
additional 24h, and cell viability was measured by the resazurin reduction assay. Control 
conditions were performed in presence of 50 μM of compounds. Cell viability (in %) was 
calculated from the ratio of the fluorescence of the treated sample to the control cells 
(non-treated).  
 
 
 
 
 
 
 
 
 
 
 
 
 


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Figures 
 
Figure S.1: Effects of 2,5-diaryl substituted thiophenes on IAPP kinetics of amyloid 
fibril formation monitored by ThT fluorescence. IAPP (12.5 μM) was incubated in 20 
mM Tris, pH 7.4, at 25 °C without agitation in the absence (♦, blue) or in the presence of 
12.5 μM of compound  (■, red). ThT fluorescence (40 μM) was measured every 10 min 
over the course of 25 h, with excitation at 440 nm and emission at 485 nm. 
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Figure S.2: Effects of 2,5-diaryl substituted thiophenes on IAPP kinetics of amyloid 
fibril formation monitored by ThT fluorescence. IAPP (12.5 μM) was incubated in 20 
mM Tris, pH 7.4, at 25 °C without agitation in the absence (♦, blue) or in the presence of 
12.5 μM of compound  (■, red). ThT fluorescence (40 μM) was measured every 10 min 
over the course of 25 h, with excitation at 440 nm and emission at 485 nm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
  


 	


	

	

	
	

	

262
Figure S.3: Effects of 2,5-diaryl substituted thiophenes on IAPP kinetics of amyloid 
fibril formation monitored by ThT fluorescence. IAPP (12.5 μM) was incubated in 20 
mM Tris, pH 7.4, at 25 °C without agitation in the absence (♦, blue) or in the presence of 
12.5 μM of compound  (■, red). ThT fluorescence (40 μM) was measured every 10 min 
over the course of 25 h, with excitation at 440 nm and emission at 485 nm.  
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Figure S.4: Effects of 2,5-diaryl substituted thiophenes and benzoic acid on IAPP 
kinetics of amyloid fibril formation monitored by ThT fluorescence. IAPP (12.5 μM) was 
incubated in 20 mM Tris, pH 7.4, at 25 °C without agitation in the absence (♦, blue) or in 
the presence of 12.5 μM of compound  (■, red). 12.5 μM (1 equiv) and 125 μM of 
benzoic acid was used (10 equiv). ThT fluorescence (40 μM) was measured every 10 min 
over the course of 25 h, with excitation at 440 nm and emission at 485 nm.  
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